



Office de la Propriété

Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2583690 C 2016/04/05

(11)(21) **2 583 690**

(12) **BREVET CANADIEN**
CANADIAN PATENT

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2005/10/12
(87) Date publication PCT/PCT Publication Date: 2006/04/27
(45) Date de délivrance/Issue Date: 2016/04/05
(85) Entrée phase nationale/National Entry: 2007/04/10
(86) N° demande PCT/PCT Application No.: US 2005/036373
(87) N° publication PCT/PCT Publication No.: 2006/044322
(30) Priorités/Priorities: 2004/10/12 (USPCT/US2004/033379);
2005/04/14 (US60/671,089)

(51) Cl.Int./Int.Cl. *C12N 15/63*(2006.01),
C12N 15/82(2006.01), *C12N 15/85*(2006.01),
C12N 5/10(2006.01), *C12N 5/14*(2006.01),
C12N 5/16(2006.01)

(72) Inventeurs/Inventors:
TOBODA, JOSE REYES, MX;
ZHANG, XIUREN, US;
SOYANO, TAKASHI, US;
CHUA, NAM-HAI, US;
NIU, QI-WEN, US;
LIN, SHIH-SHUN, US


(73) Propriétaire/Owner:
THE ROCKEFELLER UNIVERSITY, US

(74) Agent: OSLER, HOSKIN & HARCOURT LLP

(54) Titre : CONSTRUITS DE MICRO-ARN POUR LA SUPPRESSION DE L'EXPRESSION DE GENES CIBLES OU LA
DEGRADATION DE GENES CIBLES ET METHODES CONNEXES
(54) Title: MICRORNA CONSTRUCTS FOR THE SUPPRESSION OF THE EXPRESSION OF TARGETED GENES OR
THE DOWN REGULATION OF TARGETED GENES AND METHODS THEREFORE

(57) Abrégé/Abstract:

The invention provides methods and compositions useful in target sequence suppression, target sequence validation and target sequence down regulation. The invention provides polynucleotide constructs useful for gene silencing or RNA down regulation, as well as cells, plants and seeds comprising the polynucleotides. The invention also provides a method for using microRNA to silence a target sequence or to down regulate RNA.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 April 2006 (27.04.2006)

PCT

(10) International Publication Number
WO 2006/044322 A3

(51) International Patent Classification:

<i>C12N 15/63</i> (2006.01)	<i>C12N 5/10</i> (2006.01)
<i>C12N 15/82</i> (2006.01)	<i>C12N 5/14</i> (2006.01)
<i>C12N 15/85</i> (2006.01)	<i>C12N 5/16</i> (2006.01)

LIN, Shih-Shun [CN/US]; 500 East 63rd Street, Apt. 21F, New York, New York 10021 (US).

(21) International Application Number:

PCT/US2005/036373

(74) Agents: IHNEN, Jeffrey, L. et al.; 1425 K Street, N.W., Suite 800, Washington, District of Columbia 20005 (US).

(22) International Filing Date: 12 October 2005 (12.10.2005)

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:

PCT/US2004/033379

12 October 2004 (12.10.2004)	US	
60/671,089	14 April 2005 (14.04.2005)	US

Published:

— with international search report

(71) Applicant (for all designated States except US): THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, New York 10021-6399 (US).

(88) Date of publication of the international search report: 4 January 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MICRORNAs

(57) Abstract: The invention provides methods and compositions useful in target sequence suppression, target sequence validation and target sequence down regulation. The invention provides polynucleotide constructs useful for gene silencing or RNA down regulation, as well as cells, plants and seeds comprising the polynucleotides. The invention also provides a method for using microRNA to silence a target sequence or to down regulate RNA.

WO 2006/044322 A3

MicroRNA Constructs for the Suppression of the Expression of Targeted Genes or the
Down Regulation of Targeted Genes and Methods Therefore

FIELD OF THE INVENTION

5 [0001] The field of the present invention relates generally to plant molecular biology and plant biotechnology. More specifically it relates to constructs and methods to suppress the expression of targeted genes or to down regulate targeted genes.

BACKGROUND OF THE INVENTION

10 [0002] RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire *et al.* (1998) *Nature* 391:806-811). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing (PTGS) or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-15 conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla (Fire (1999) *Trends Genet.* 15:358-363). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys 20 homologous single-stranded RNA of viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized.

[0003] A new class of small RNA molecules is involved in regulating gene expression in a number of eukaryotic organisms ranging from animals to plants. These short RNAs or microRNAs (miRNAs; miRs) are 20-22 nucleotide-long molecules that specifically base-pair to 25 target messenger-RNAs to repress their translation or to induce their degradation. Recent reports have identified numerous miRNAs from vertebrates, *Caenorhabditis elegans*, *Drosophila* and *Arabidopsis thaliana* (Bartel (2004) *Cell* 116:281-297; He and Hannon (2004) *Nature Reviews Genetics* 5:522-531).

[0004] Viruses such as *Turnip Mosaic Virus* (TuMV) and *Turnip Yellow Mosaic Virus* 30 (TYMV) cause considerable crop loss world-wide and have serious economic impact on agriculture (Morch *et al.* (1998) *Nucleic Acids Res* 16:6157-6173; Skotnicki *et al.* (1992) *Arch Virol* 127:25-35; Tomlinson (1987) *Ann Appl Biol* 110:661-681). Most if not all plant viruses encode one or more proteins that are able to suppress the host's post-transcriptional gene silencing (PTGS) mechanism so as to ensure their successful replication in host cells. The

PTGS is a mechanism that a plant host uses to defend against viruses by triggering breakdown of double stranded RNAs which are produced as intermediates in viral genome replication (Bernstein *et al.* (2001) *Nature* 409:363-366; Hamilton and Baulcombe (1999) *Science* 286:950-952; Zamore *et al.* (2000) *Cell* 31:25-33).

5 [0005] Reduction of the activity of specific genes (also known as gene silencing, or gene suppression), including virus genes, is desirable for several aspects of genetic engineering in plants. There is still a need for methods and constructs that induce gene suppression against a wide selection of target genes, and that result in effective silencing of the target gene at high efficiency.

10

SUMMARY OF THE INVENTION

[0006] According to one aspect, the present invention provides a method of down regulating a target sequence in a cell and a nucleic acid construct for use in this method, as well as a polynucleotide for use in the nucleic acid construct. The method comprises introducing into the 15 cell a nucleic acid construct capable of producing miRNA and expressing the nucleic acid construct for a time sufficient to produce the miRNA, wherein the miRNA inhibits expression of the target sequence. The nucleic acid construct comprises a polynucleotide encoding a modified miRNA precursor capable of forming a double-stranded RNA or a hairpin, wherein the modified miRNA precursor comprises a modified miRNA and a sequence complementary to the modified 20 miRNA, wherein the modified miRNA is a miRNA modified to be (i) fully complementary to the target sequence or (ii) fully complementary to the target sequence except for GU base pairing. As is well known in the art, the pre-miRNA forms a hairpin which in some cases the double-stranded region may be very short, e.g., not exceeding 21-25 bp in length. The nucleic acid construct may further comprise a promoter operably linked to the polynucleotide. The cell 25 may be a plant cell, either monocot or dicot, including, but not limited to, corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco. The promoter may be a pathogen-inducible promoter or other inducible promoters. The binding of the modified miRNA to the target RNA leads to cleavage of the target RNA. The target sequence of a target RNA may be a coding sequence, an intron or a splice site.

30 [0007] According to another aspect, the present invention provides an isolated polynucleotide encoding a modified plant miRNA precursor, the modified precursor is capable of forming a double-stranded RNA or a hairpin and comprises a modified miRNA and a sequence complementary to the modified miRNA, wherein the modified miRNA is a miRNA modified to

be (i) fully complementary to the target sequence or (ii) fully complementary to the target sequence except for GU base pairing. Expression of the polynucleotide produces a miRNA precursor which is processed in a host cell to provide a mature miRNA which inhibits expression of the target sequence. The polynucleotide may be a nucleic acid construct or may 5 be the modified plant miRNA precursor. The nucleic acid construct may further comprise a promoter operably linked to the polynucleotide. The promoter may be a pathogen-inducible promoter or other inducible promoter. The binding of the modified miRNA to the target RNA leads to cleavage of the target RNA. The target sequence of a target RNA may be a coding sequence, a non-coding sequence or a splice site.

10 [0008] According to another aspect, the present invention provides a nucleic acid construct for suppressing a multiple number of target sequences. The nucleic acid construct comprises at least two and up to 45 or more polynucleotides, each of which encodes a miRNA precursor capable of forming a double-stranded RNA or a hairpin. Each miRNA is substantially complementary to a target or is modified to be complementary to a target as described herein. In 15 some embodiments, each of the polynucleotides encoding precursor miRNAs in the construct is individually placed under control of a single promoter. In some embodiments, the multiple polynucleotides encoding precursor miRNAs are operably linked together such that they can be placed under the control of a single promoter. The promoter may be operably linked to the construct of multiple miRNAs or the construct of multiple miRNAs may be inserted into a host 20 genome such that it is operably linked to a single promoter. The promoter may be a pathogen-inducible promoter or other inducible promoter. In some embodiments, the multiple polynucleotides are linked one to another so as to form a single transcript when expressed. Expression of the polynucleotides in the nucleic acid construct produces multiple miRNA precursors which are processed in a host cell to provide multiple mature miRNAs, each of which 25 inhibits expression of a target sequence. In one embodiment, the binding of each of the mature miRNA to each of the target RNA leads to cleavage of each of the target RNA. The target sequence of a target RNA may be a coding sequence, a non-coding sequence or a splice site.

30 [0009] According to another aspect, the present invention provides a method of down regulating a multiple number of target sequences in a cell. The method comprises introducing into the cell a nucleic acid construct capable of producing multiple miRNAs and expressing the nucleic acid construct for a time sufficient to produce the multiple miRNAs, wherein each of the miRNAs inhibits expression of a target sequence. The nucleic acid construct comprises at least two and up to 45 or more polynucleotides, each of which encodes a miRNA precursor capable of

forming a double-stranded RNA or a hairpin. Each miRNA is substantially complementary to a target or is modified to be complementary to a target as described herein. In some embodiments, each of the polynucleotides encoding precursor miRNAs in the construct is individually placed under control of a single promoter. In some embodiments, the multiple 5 polynucleotides encoding precursor miRNAs are linked together such that they can be under the control of a single promoter as described herein. In some embodiments, the multiple polynucleotides are linked one to another so as to form a single transcript when expressed. In some embodiments, the construct may be a hetero-polymeric pre-miRNA or a homo-polymeric pre-miRNA. Expression of the polynucleotides in the nucleic acid construct produces multiple 10 miRNA precursors which are processed in a host cell to provide multiple mature miRNAs, each of which inhibits expression of a target sequence. In one embodiment, the binding of each of the mature miRNA to each of the target RNA leads to cleavage of each of the target RNA. The target sequence of a target RNA may be a coding sequence, a non-coding sequence or a splice site.

15 [0010] According to a further aspect, the present invention provides a cell comprising the isolated polynucleotide or nucleic acid construct of the present invention. In some embodiments, the isolated polynucleotide or nucleic acid construct of the present invention may be inserted into an intron of a gene or a transgene of the cell. The cell may be a plant cell, either a monocot or a dicot, including, but not limited to, corn, wheat, rice, barley, oats, sorghum, 20 millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.

[0011] According to another aspect, the present invention provides a transgenic plant comprising the isolated polynucleotide or nucleic acid construct. In some embodiments, the isolated polynucleotide or nucleic acid construct of the present invention may be inserted into an intron of a gene or a transgene of the transgenic plant. The transgenic plant may be either a 25 monocot or a dicot, including, but not limited to, corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.

[0012] According to a further aspect, the present invention provides a method of inhibiting expression of a target sequence in a cell comprising: (a) introducing into the cell a nucleic acid construct comprising a modified plant miRNA precursor comprising a first and a second 30 oligonucleotide, wherein at least one of the first or the second oligonucleotides is heterologous to the precursor, wherein the first oligonucleotide encodes an RNA sequence substantially identical to the target sequence, and the second oligonucleotide encodes a miRNA substantially complementary to the target sequence, whereby the precursor encodes a miRNA; and

(b) expressing the nucleic acid construct for a time sufficient to produce the miRNA, wherein the miRNA inhibits expression of the target sequence.

[0013] According to another aspect, the present invention provides an isolated polynucleotide comprising a modified plant miRNA precursor, the modified precursor comprising a first and a second oligonucleotide, wherein at least one of the first or the second oligonucleotides is heterologous to the precursor, wherein the first oligonucleotide encodes an RNA sequence substantially identical to a target sequence, and the second oligonucleotide comprises a miRNA substantially complementary to the target sequence, wherein expression of the polynucleotide produces the miRNA which inhibits expression of the target sequence. The present invention 10 also relates to a cell comprising this isolated polynucleotide. The cell may be a plant cell, either monocot or dicot, including, but not limited to, corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.

[0014] According to a further aspect, the present invention provides for a method of inhibiting expression of a target sequence in a cell, such as any of those herein described that 15 further comprises producing a transformed plant, wherein the plant comprises the nucleic acid construct which encodes the miRNA. The present invention also relates to a plant produced by such methods. The plant may a monocot or a dicot, including, but not limited to, corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.

20

BRIEF DESCRIPTION OF THE FIGURES

[0015] Figure 1 shows the predicted hairpin structure formed by the sequence surrounding miR172a-2. The mature microRNA is indicated by a grey box.

[0016] Figure 2 shows the miR172a-2 overexpression phenotype. a, Wild type (Columbia 25 ecotype) plant, 3.5 weeks old. b, EAT-D plant, 3.5 weeks old. c, Wild type flower. d, EAT-D flower. Note absence of second whorl organs (petals). Arrow indicates sepal with ovules along the margins and stigmatic papillae at the tip. e, Cauline leaf margin from a 35S-EAT plant. Arrows indicate bundles of stigmatic papillae projecting from the margin. f, Solitary gynoecium (arrow) emerging from the axil of a cauline leaf of a 35S-EAT plant.

[0017] Figure 3 shows the EAT gene contains a miRNA that is complementary to APETALA2 (AP2). a, Location of the EAT gene on chromosome 5. The T-DNA insertion and orientation of the 35S enhancers is indicated. The 21-nt sequence corresponding to miR172a-2 is shown below the EAT gene (SEQ ID NO:86). b, Putative 21-nt miR172a-2/AP2 RNA duplex 30

is shown below the gene structure of AP2. The GU wobble in the duplex is underlined. c, Alignment of AP2 21-nt region (black bar) and surrounding sequence with three other Arabidopsis AP2 family members, and with two maize AP2 genes (IDS1 and GL15). d, Alignment of miR172a-2 miRNA (black bar) and surrounding sequence with miR172-like 5 sequences from *Arabidopsis*, tomato, soybean, potato and rice.

[0018] Figure 4 shows the miR172a-2 miRNA expression. a, Northern blot of total RNA from wild type (lanes 3 and 7) and EAT-D (lanes 4 and 8). Blots were probed with sense (lanes 1-4) or antisense (lanes 5-8) oligo to miR172a-2 miRNA. 100 pg of sense oligo (lanes 2 and 6) and antisense oligo (lanes 1 and 5) were loaded as hybridization controls. Nucleotide size 10 markers are indicated on the left. b, S1 nuclease mapping of miR172a-2 miRNA. A 5'-end-labeled probe undigested (lane 1) or digested after hybridization to total RNA from wild-type (lane 2), EAT-D (lane 3), or tRNA (lane 4).

[0019] Figure 5 shows the developmental expression pattern of miR172 family members. a, RT-PCR of total RNA from wild type seedlings harvested at 2, 5, 12, and 21 days after 15 germination (lanes 1-4, respectively), or from mature leaves (lane 5) and floral buds (lane 6). Primers for PCR are indicated on the left. b, Northern analysis of miR172 expression in the indicated mutants, relative to wild type (Col). Blot was probed with an oligo to miR172a-2; however, all miR172 members should cross hybridize.

[0020] Figure 6 shows the expression analysis of putative EAT target genes. a, Northern blot 20 analysis of polyA+ RNA isolated from wild type (Col) or EAT-D floral buds. Probes for hybridization are indicated on the right. b, Western blot of proteins from wild type or EAT-D floral buds, probed with AP2 antibody. RbcL, large subunit of ribulose 1,5-bisphosphate carboxylase as loading control.

[0021] Figure 7 shows the identification of LAT-D. a, Location of the T-DNA insert in 25 LAT-D, in between At2g28550 and At2g28560. The 4X 35S enhancers are approximately 5 kb from At2g28550. b, RT-PCR analysis of At2g28550 expression in wild type versus LAT-D plants.

[0022] Figure 8 shows that EAT-D is epistatic to LAT-D. Genetic cross between EAT-D and 30 LAT-D plants, with the resultant F1 plants shown, along with their flowering time (measured as rosette leaf number).

[0023] Figure 9 shows the loss-of-function At2g28550 (2-28550) and At5g60120 (6-60120) mutants. Location of T-DNA in each line is indicated, along with intron/exon structure.

[0024] Figure 10 shows the potential function of the miR172 miRNA family. a, Temporal expression of miR172a-2 and its relatives may cause temporal downregulation of AP2 targets (e.g. At2g28550 and At5g60120), which may trigger flowering once the target proteins drop below a critical threshold (dotted line). b, Dicer cleavage at various positions may generate at least four distinct miRNAs from the miR172 family (indicated as a single hairpin with a miRNA consensus sequence). Sequences at the 5' and 3' ends of each miRNA are indicated, with the invariant middle 15 nt shown as ellipses. The putative targets recognized by the individual miRNAs are in parentheses below each.

[0025] Figures 11A-11C show an artificial microRNA (miRNA) designed to cleave the phytoene desaturase (*PDS*) mRNAs of *Nicotiana benthamiana*. Fig. 11A shows the structure of the pre-miR159a sequence construct under the control of the CaMV 35S promoter (35S) and *NOS* terminator (T_{nos}). The orientation and position of the mature miRNA is indicated by an arrow. Fig. 11B shows that point mutations in miR159a (SEQ ID NO:141) (indicated by arrows) turn it into miR-*PDS*^{159a} (SEQ ID NO:142) to become fully complementary to a region in *N. benthamiana PDS* mRNA. Fig. 11C shows that Northern blot analysis of *Agrobacterium* infiltrated *N. benthamiana* leaves shows expression of miR-*PDS*^{159a}, miR-*PDS*^{159a*} and miR159 in samples infiltrated with an empty vector (vector) or the artificial miRNA (miR-*PDS*^{159a}) 1, 2, 3 days post infiltration (d.p.i.).

[0026] Figures 12A-12B show that *miR-PDS*^{159a} (SEQ ID NO:142) causes *PDS* mRNA (SEQ ID NO:143) cleavage. Fig. 12 A shows Northern blot analysis of *PDS* mRNA from samples infiltrated with empty vector or *miR-PDS*^{159a} after 1 or 2 days post infiltration (d.p.i.) (upper panel). The bottom panel shows the EtBr-stained agarose gel from the same samples. Fig. 12B shows the site of cleavage of the miRNA. 5'RACE analysis was conducted on samples infiltrated with *miR-PDS*^{159a} constructs and the 5'-end sequence of 5 out of 6 clones indicated the site of cleavage of the miRNA as indicated by an arrow.

[0027] Figures 13A-13E show that the expression of *miR-PDS*^{169g} results in cleavage of the *PDS* mRNA. Fig. 13A shows the point mutations (underlined nucleotides) in miR169g that turn it into *miR-PDSa*^{169g} (SEQ ID NO:145) or *miR-PDSb*^{169g} (SEQ ID NO:146) to become fully complementary to two different regions in *N. benthamiana PDS* mRNA. Fig. 13B shows Northern blot analysis of two different miR169g expression constructs. Total RNA was extracted from non-infiltrated leaves (C) or from leaves infiltrated with *Agrobacterium* containing the pre-miR169g sequence in the context of a 0.3kb (0.3kb) or 2.0kb (2.0kb) fragment, or from control *Arabidopsis* leaves (+). The arrow indicates the position of the

miR169 signal. Fig. 13C shows Northern blot showing the expression of *miR-PDSa*^{169g} (a) and *miR-PDSb*^{169g} (b) in infiltrated leaves containing the 0.3kb construct but not in control using the empty plasmid (vector). Fig. 13D shows the sites of cleavage of the miRNA. 5'RACE analysis was conducted on samples infiltrated with *miR-PDS*^{169g} a (SEQ ID NO:145) and b (SEQ ID NO:146) constructs and the 5'-end sequence identified from independent clones is indicated by an arrow together with the number of clones analyzed. The *PDS* mRNAs are SEQ ID NO:147 and SEQ ID NO:148. Fig. 13E shows a Northern blot analysis to detect *PDS* mRNA levels in plants infiltrated with *Agrobacterium* strains carrying the empty vector (C) or constructs expressing *miR-PDSa*^{169g} (a) or *miR-PDSb*^{169g} (b).

[0028] Figures 14A-14C show the microRNA-directed cleavage of *Nicotiana benthamiana* *rbcS* mRNAs. Fig. 14A shows that point mutations in miR159a (SEQ ID NO:141) (indicated by arrows) turn it into *miR-rbcS*^{159a}-A (SEQ ID NO:149) to become complementary to a region common to all *N. benthamiana* *rbcS* mRNAs (shown as *rbcS* mRNA; SEQ ID NO:150). miRNA:mRNA base-pairs are indicated by vertical lines and G:U wobble base-pairs by colons. Fig. 14B shows that Northern blot analysis of *Agrobacterium* infiltrated *N. benthamiana* leaves shows expression of *miR-rbcS*^{159a}-A in samples infiltrated with an empty vector (C) or the artificial miRNA (A) 2 days post infiltration (d.p.i). Fig. 14C shows that RT-PCR analysis was used to detect *rbcS* mRNA abundance for all six genes in the same samples shown in B. Amplification of EF1 α mRNA served as a loading control.

[0029] Figures 15A-15B show the schematic representation of the genes and relevant sequences used in the work shown in Figures 11-14. Fig. 15A shows the *PDS* gene from *Lycopersicum esculentum* that was used as reference sequence since the complete *PDS* gene from *N. benthamiana* is not known (segments missing are shown as a dashed line). Large grey arrows indicate positions targeted by the miR-*PDS* constructs described in the text. Small arrowheads indicate primers used for 5'RACE analysis. Known *N. benthamiana* *PDS* fragments are indicated along with the origin of the sequences. Fig. 15B shows the different reported sequences that were used to assemble the *rbcS* gene sequence schematized here. The grey arrow indicates the position of the sequence targeted by *miR-rbcS*^{159a}-A, the arrowheads indicate the position of primers used in RT-PCR experiments shown in Figures 14A-14C.

[0030] Figures 16A-16B show a summary of changes introduced to *Arabidopsis* miR159a and miR169g. Fig. 16A shows sequences of *miR-PDS*^{159a} (SEQ ID NO:142) and *miR-rbcS*^{159a}-A (SEQ ID NO:149) as compared to miR159a (SEQ ID NO:141). The base-changes in each case are underlined while unmodified positions are marked with an asterisk. Fig. 16B shows

sequences of *miR-PDSa*^{169g} (SEQ ID NO:145) and *miR-PDSb*^{169g} (SEQ ID NO:146) as compared to miR169g (SEQ ID NO:144). The base-changes in each case are underlined while unmodified positions are marked with an asterisk.

[0031] Figure 17 shows development of *Arabidopsis* root hairs in wildtype, mutant and transgenic plants. Panel A: Wild type root shows many root hair structures. Panel B: Very few root hair in *cpc* mutant. Panel C: 35S::*CPC* plants show more root hairs. Panel D: More root hair in *gl2* mutant. This figure is taken from Wada *et al.* ((2002) *Development* 129:5409-5419).

[0032] Figure 18 shows *Arabidopsis* root hair development in transgenic plants. Panel a: *XVE::pre-miRCPC1*^{159a} without inducer (estradiol). Panel b: *XVE::pre-miRCPC1*^{159a} with inducer (estradiol). Panel c: *XVE::pre-miR159a* without inducer (estradiol). Panel d: *XVE::pre-miR159a* with inducer (estradiol).

[0033] Figure 19 shows *Arabidopsis* root hair development in transgenic plants. Panel a: 35S::*pre-miR159*. Panel b: 35S::*pre-miRCPC1*^{159a}. Panel c: 35S::*pre-miRP69*^{159a}.

[0034] Figure 20 shows *Arabidopsis* root hair development in transgenic plants. Panel a: 35S::*pre-miR159*. Panel b: 35S::*pre-miRCPC1*^{159a}.

[0035] Figures 21A-21E represent a diagram for a process for designing a polymeric pre-miRNA. Fig. 21A: The products of amplification of three different pre-miRNAs (pre-miR A, pre-miR B and pre-miR C) in which AvrII, SpeI and XhoI sites have been added by amplification. Fig. 21B: Pre-miR A is digested with SpeI and XhoI and pre-miR B is digested with AvrII and XhoI. Fig. 21C: The digested pre-miR A and pre-miR B are ligated to form a dimeric pre-miRNA. Fig. 21D: Pre-miR A-B is digested with SpeI and XhoI and pre-miR C is digested with AvrII and XhoI. Fig. 21E: The digested pre-miR A-B and pre-miR C are ligated to form a trimeric pre-miRNA.

[0036] Figure 22 is a diagram of a dimeric construct containing *pre-miRPDS1*^{169g} and *pre-miRCPC3*^{159a}.

[0037] Figures 23A and 23B show that mature *miRPDS1*^{169g} (Fig. 23A) and *miRCPC3*^{159a} (Fig. 23B) was successfully produced from the dimeric construct. Lane 1 is 35S::*pre-miRPDS1*^{169g}, lane 2 is 35S::*CPC3*^{159a} and lane 3 is 35S::*pre-miRPDS1*^{169g}-*CPC3*^{159a}.

[0038] Figure 24 shows the structure of the *miR159a* precursor (SEQ ID NO:161).

[0039] Figure 25 shows Northern blot analysis of *miR-HC-Pro*^{159a} were performed with three different treatments: (1) *Agrobacterial* cells with 35S::*pre-miR-HC-Pro*^{159a}, (2) *Agrobacterial* cells with 35S::*HC-Pro*, and (3) *Agrobacterial* cells with 35S::*pre-miR-HC-Pro*^{159a} and 35S::*HC-Pro*.

[0040] Figure 26 shows Northern blot analysis of *miR-P69*, 4 different treatments were performed : (1) *Agrobacterial* cells carrying *35S::pre-miR-P69^{159a}*, (2) *Agrobacterial* cells *XVE::pre-miR-P69^{159a}*, (3) *Agrobacterial* cells carrying *35S::P69*, and (4) *Agrobacterial* cells carrying *35S::pre-miR-P69^{159a}* and *35S::P-69*.

5 [0041] Figure 27 shows Northern blot analysis of mature artificial miRNA levels for randomly picked T₂ *35S::pre-miRHC-Pro^{159a}* transgenic lines (plants). The T₂ plants are known to be transgenic because they were first selected on Kan-containing medium to remove WT. The T₂ plants are either heterozygous (one copy) or homozygous (two copies), and the ratio should be about 2:1.

10 [0042] Figure 28 shows Northern blot analysis of mature artificial miRNA levels for randomly picked T₂ *35S::pre-miR-P69^{159a}* transgenic lines (plants).

[0043] Figure 29 shows that T₂ transgenic plants expressing *miR-HC-Pro^{159a}* artificial miRNA are resistant to TuMV infection. Photographs were taken 2 weeks (14 days after infection) after inoculation. T₂ transgenic plants expressing *miR-HC-Pro^{159a}* (line #11; Fig. 15 33B) developed normal inflorescences whereas WT plants and T₂ transgenic plants expressing *miR-P69^{159a}* (line #1; Fig 33B) showed viral infection symptoms. The bar represents 3 cm.

[0044] Figure 30 shows symptoms of inflorescences caused by TuMV infection. (Top panel) Forteen days after TuMV infection, T₂ transgenic *miR-P69^{159a}* plants (line #1) and col-0 plants showed shorter internodes between flowers in inflorescences, whereas T₂ *miR-HC-Pro^{159a}* 20 transgenic plant (line #11) displayed normal inflorescences development. The bar represents 1 cm. (Bottom panel) Close-up views of inflorescences on TuMV-infected *Arabidopsis* plants. T₂ transgenic *miR-P69^{159a}* plants (line #1) and col-0 plants showed senescence and pollination defects whereas T₂ transgenic *miR-HC-Pro^{159a}* plants (line #11) showed normal flower and siliques development. For mock-infection, plants were inoculated with buffer only. The bar 25 represents 0.2 cm.

[0045] Figure 31 shows symptoms of siliques caused by TuMV infection. In TuMV-infected T₂ transgenic *miR-P69^{159a}* plants (line #1) and WT (col-0) plants, siliques were small and mal-developed. T₂ transgenic *miR-HC-Pro^{159a}* plants (line #11) were resistant to TuMV infection and showed normal siliques development. Buffer-inoculated plants (mock-inculated) 30 were used as controls. The bar represents 0.5 cm.

[0046] Figure 32 shows Western blot analysis of TuMV coat protein (CP) levels in leaves of different transgenic and WT plants.

[0047] Figure 33 shows (A) Western blot analysis of representative plants of 35S:: *miR-HC-Pro*^{159a}, 35S:: *miR-P69*^{159a}, and WT (Col-0) and (B) Northern blot analysis of miRNAs produced by the transgenic plants.

[0048] Figure 34 shows ELISA detection of TuMV in different transgenic and non-transgenic *Arabidopsis*.

[0049] Figure 35 shows Northern blot analysis of pre-*miR-P69*^{159a}, pre-*miR-HC-Pro*^{159a} and pre-*miR-P69*^{159a}-*HC-Pro*^{159a} demonstrating that homo-dimeric miRNA precursor, pre-*miR-P69*^{159a}-*HC-Pro*^{159a}, can produce mature *miR-P69*^{159a} and *miR-HC-Pro*^{159a}.

[0050] Figure 36 shows constructs in which *miR-HC-Pro*^{159a} is placed in either intron 1 or intron 2 of the *CPC* gene.

[0051] Figure 37 shows Northern blot analysis of the constructs of Figure 36 and demonstrates that intron 1 and intron 2 of the *CPC* transcript can be used to produce artificial miRNAs.

[0052] Figure 38 shows constructs in which pre-*miR-HC-Pro*^{159a} is placed in either intron 1 or intron 2 and pre-*miR-P69*^{159a} is placed in either intron 2 or intron 1 of the *CPC* gene.

[0053] Figure 39 shows Northern blot analysis of the constructs of Figure 38 and demonstrates that it is possible to use *CPC* introns to produce two different artificial miRNAs simultaneously in one transcript.

20 DETAILED DESCRIPTION

[0054] Recently discovered small RNAs play an important role in controlling gene expression. Regulation of many developmental processes including flowering is controlled by small RNAs. It is now possible to engineer changes in gene expression of plant genes by using transgenic constructs which produce small RNAs in the plant.

[0055] The invention provides methods and compositions useful for suppressing targeted sequences. The compositions can be employed in any type of plant cell, and in other cells which comprise the appropriate processing components (e.g., RNA interference components), including invertebrate and vertebrate animal cells. The compositions and methods are based on an endogenous miRNA silencing process discovered in *Arabidopsis*, a similar strategy can be used to extend the number of compositions and the organisms in which the methods are used. The methods can be adapted to work in any eukaryotic cell system. Additionally, the compositions and methods described herein can be used in individual cells, cells or tissue in culture, or *in vivo* in organisms, or in organs or other portions of organisms.

[0056] The compositions selectively suppress the target sequence by encoding a miRNA having substantial complementarity to a region of the target sequence. The miRNA is provided in a nucleic acid construct which, when transcribed into RNA, is predicted to form a hairpin structure which is processed by the cell to generate the miRNA, which then suppresses 5 expression of the target sequence.

[0057] A nucleic acid construct is provided to encode the miRNA for any specific target sequence. Any miRNA can be inserted into the construct, such that the encoded miRNA selectively targets and suppresses the target sequence.

[0058] A method for suppressing a target sequence is provided. The method employs the 10 constructs above, in which a miRNA is designed to a region of the target sequence, and inserted into the construct. Upon introduction into a cell, the miRNA produced suppresses expression of the targeted sequence. The target sequence can be an endogenous plant sequence, or a heterologous transgene in the plant. The target gene may also be a gene from a plant pathogen, such as a pathogenic virus, nematode, insect, or mold or fungus.

[0059] A plant, cell, and seed comprising the construct and/or the miRNA is provided. 15 Typically, the cell will be a cell from a plant, but other eukaryotic cells are also contemplated, including but not limited to yeast, insect, nematode, or animal cells. Plant cells include cells from monocots and dicots. The invention also provides plants and seeds comprising the construct and/or the miRNA. Viruses and prokaryotic cells comprising the construct are also 20 provided.

[0060] Units, prefixes, and symbols may be denoted in their SI accepted form. Unless 25 otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxyl orientation, respectively. Numeric ranges recited within the specification are inclusive of the numbers defining the range and include each integer within the defined range. Amino acids may be referred to herein by either commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes. Unless otherwise provided for, software, electrical, and electronics terms as used herein are as defined in The New IEEE Standard 30 Dictionary of Electrical and Electronics Terms (5th edition, 1993). The terms defined below are more fully defined by reference to the specification as a whole.

[0061] As used herein, "nucleic acid construct" or "construct" refers to an isolated polynucleotide which is introduced into a host cell. This construct may comprise any

combination of deoxyribonucleotides, ribonucleotides, and/or modified nucleotides. The construct may be transcribed to form an RNA, wherein the RNA may be capable of forming a double-stranded RNA and/or hairpin structure. This construct may be expressed in the cell, or isolated or synthetically produced. The construct may further comprise a promoter, or other sequences which facilitate manipulation or expression of the construct.

5 [0062] As used here "suppression" or "silencing" or "inhibition" are used interchangeably to denote the down-regulation of the expression of the product of a target sequence relative to its normal expression level in a wild type organism. Suppression includes expression that is decreased by about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,
10 75%, 80%, 85%, 90%, 95%, or 100% relative to the wild type expression level.

[0063] As used herein, "encodes" or "encoding" refers to a DNA sequence which can be processed to generate an RNA and/or polypeptide.

15 [0064] As used herein, "expression" or "expressing" refers to the generation of an RNA transcript from an introduced construct, an endogenous DNA sequence, or a stably incorporated heterologous DNA sequence. The term may also refer to a polypeptide produced from an mRNA generated from any of the above DNA precursors.

20 [0065] As used herein, "heterologous" in reference to a nucleic acid is a nucleic acid that originates from a foreign species, or is synthetically designed, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. A heterologous protein may originate from a foreign species or, if from the same species, is substantially modified from its original form by deliberate human intervention.

25 [0066] By "host cell" is meant a cell which contains an introduced nucleic acid construct and supports the replication and/or expression of the construct. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as fungi, yeast, insect, amphibian, nematode, or mammalian cells. Alternatively, the host cells are monocotyledonous or dicotyledonous plant cells. An example of a monocotyledonous host cell is a maize host cell.

30 [0067] The term "introduced" means providing a nucleic acid or protein into a cell. Introduced includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be incorporated into the genome of the cell, and includes reference to the transient provision of a nucleic acid or protein to the cell. Introduced includes reference to stable or transient transformation methods, as well as sexually crossing.

[0068] The term "isolated" refers to material, such as a nucleic acid or a protein, which is: (1) substantially or essentially free from components which normally accompany or interact with

the material as found in its naturally occurring environment or (2) if the material is in its natural environment, the material has been altered by deliberate human intervention to a composition and/or placed at a locus in the cell other than the locus native to the material.

[0069] As used herein, "miRNA" refers to an oligoribonucleic acid, which suppresses expression of a polynucleotide comprising the target sequence transcript or down regulates a target RNA. A "miRNA precursor" refers to a larger polynucleotide which is processed to produce a mature miRNA, and includes a DNA which encodes an RNA precursor, and an RNA transcript comprising the miRNA. A "mature miRNA" refers to the miRNA generated from the processing of a miRNA precursor. A "miRNA template" is an oligonucleotide region, or regions, in a nucleic acid construct which encodes the miRNA. The "backside" region of a miRNA is a portion of a polynucleotide construct which is substantially complementary to the miRNA template and is predicted to base pair with the miRNA template. The miRNA template and backside may form a double-stranded polynucleotide, including a hairpin structure. As is known for natural miRNAs, the mature miRNA and its complements may contain mismatches and form bulges and thus do not need to be fully complementary.

[0070] As used herein, the phrases "target sequence" and "sequence of interest" are used interchangeably. Target sequence is used to mean the nucleic acid sequence that is selected for suppression of expression, and is not limited to polynucleotides encoding polypeptides. The target sequence comprises a sequence that is substantially or completely complementary to the miRNA. The target sequence can be RNA or DNA, and may also refer to a polynucleotide comprising the target sequence.

[0071] As used herein, "nucleic acid" means a polynucleotide and includes single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Nucleic acids may also include fragments and modified nucleotides.

[0072] By "nucleic acid library" is meant a collection of isolated DNA or RNA molecules which comprise and substantially represent the entire transcribed fraction of a genome of a specified organism or of a tissue from that organism. Construction of exemplary nucleic acid libraries, such as genomic and cDNA libraries, is taught in standard molecular biology references such as Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology*, Vol. 152, Academic Press, Inc., San Diego, CA (Berger); Sambrook et al., *Molecular Cloning - A Laboratory Manual*, 2nd ed., Vol. 1-3 (1989); and *Current Protocols in Molecular Biology*, F.M. Ausubel et al., Eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994).

[0073] As used herein "operably linked" includes reference to a functional linkage of at least two sequences. Operably linked includes linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence.

5 [0074] As used herein, "plant" includes plants and plant parts including but not limited to plant cells, plant tissue such as leaves, stems, roots, flowers, and seeds.

[0075] As used herein, "polypeptide" means proteins, protein fragments, modified proteins, amino acid sequences and synthetic amino acid sequences. The polypeptide can be glycosylated or not.

10 [0076] As used herein, "promoter" includes reference to a region of DNA that is involved in recognition and binding of an RNA polymerase and other proteins to initiate transcription.

[0077] The term "selectively hybridizes" includes reference to hybridization, under stringent hybridization conditions, of a nucleic acid sequence to a specified nucleic acid target sequence to a detectably greater degree (e.g., at least 2-fold over background) than its hybridization to 15 non-target nucleic acid sequences and to the substantial exclusion of non-target nucleic acids. Selectively hybridizing sequences typically have about at least 80% sequence identity, or 90% sequence identity, up to and including 100% sequence identity (*i.e.*, fully complementary) with each other.

20 [0078] The term "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which a probe will selectively hybridize to its target sequence. Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are 100% complementary to the probe (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so 25 that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, optionally less than 500 nucleotides in length.

[0079] Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in

1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 5 0.1X SSC at 60 to 65°C.

[0080] Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl ((1984) *Anal Biochem* 138:267-284): $T_m = 81.5^{\circ}\text{C} + 16.6(\log M) + 0.41(\%GC) - 0.61(\% \text{ form}) - 500/L$; where M is 10 the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1°C for each 1% of mismatching; thus, T_m , 15 hybridization and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with $\geq 90\%$ identity are sought, the T_m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 20 4 °C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10 °C lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20 °C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m , those of ordinary skill will understand that variations in the 25 stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45 °C (aqueous solution) or 32 °C (formamide solution) it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes*, 30 Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York (1993); and *Current Protocols in Molecular Biology*, Chapter 2, Ausubel et al., Eds., Greene Publishing and Wiley-Interscience, New York (1995).

Hybridization and/or wash conditions can be applied for at least 10, 30, 60, 90, 120, or 240 minutes.

[0081] As used herein, "transgenic" includes reference to a plant or a cell which comprises a heterologous polynucleotide. Generally, the heterologous polynucleotide is stably integrated within the genome such that the polynucleotide is passed on to successive generations. Transgenic is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acid including those transgenics initially so altered as well as those created by sexual crosses or asexual propagation from the initial transgenic. The term "transgenic" as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation.

[0082] As used herein, "vector" includes reference to a nucleic acid used in introduction of a polynucleotide of the invention into a host cell. Expression vectors permit transcription of a nucleic acid inserted therein.

[0083] Polynucleotide sequences may have substantial identity, substantial homology, or substantial complementarity to the selected region of the target gene. As used herein "substantial identity" and "substantial homology" indicate sequences that have sequence identity or homology to each other. Generally, sequences that are substantially identical or substantially homologous will have about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity wherein the percent sequence identity is based on the entire sequence and is determined by GAP alignment using default parameters (GCG, GAP version 10, Accelrys, San Diego, CA). GAP uses the algorithm of Needleman and Wunsch ((1970) *J Mol Biol* 48:443-453) to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of sequence gaps. Sequences which have 100% identity are identical. "Substantial complementarity" refers to sequences that are complementary to each other, and are able to base pair with each other. In describing complementary sequences, if all the nucleotides in the first sequence will base pair to the second sequence, these sequences are fully complementary.

[0084] Through a forward genetics approach, a microRNA that confers a developmental phenotype in *Arabidopsis* was identified. This miRNA, miR172a-2 (Park *et al.* (2002) *Curr Biol* 12:1484-1495), causes early flowering and defects in floral organ identity when overexpressed.

The predicted target of miR172a-2 is a small subfamily of APETALA2-like transcription factors (Okamuro *et al.* (1997) *Proc Natl Acad Sci USA* 94:7076-7081). Overexpression of miR172a-2 downregulates at least one member of this family. In addition, overexpression of one of the AP2-like target genes, At2g28550, causes late flowering. This result, in conjunction with loss-of-function analyses of At2g28550 and another target gene, At5g60120, indicates that at least some of the AP2-like genes targeted by miR172a-2 normally function as floral repressors. The EAT-D line overexpressing miR172a-2 has a wild-type response to photoperiod. The genomic region encoding the miRNA was also identified (SEQ ID NO:1) and used to produce a cassette into which other miRNAs to target sequences can be inserted (SEQ ID NO:3), and to produce an expression vector (SEQ ID NO:44) useful for cloning the cassettes and expressing the miRNA. The expression vector comprises the 1.4kb region encoding the miRNA. Expression of this region is processed in the cell to produce the miRNA which suppresses expression of the target gene. Alternatively, the miRNA may be synthetically produced and introduced to the cell directly.

[0085] In one embodiment, there is provided a method for the suppression of a target sequence comprising introducing into a cell a nucleic acid construct encoding a miRNA substantially complementary to the target. In some embodiments the miRNA comprises about 10-200 nucleotides, about 10-15, 15-20, 19, 20, 21, 22, 23, 24, 25, 26, 27, 25-30, 30-50, 50-100, 100-150, or about 150-200 nucleotides. In some embodiments the nucleic acid construct encodes the miRNA. In some embodiments the nucleic acid construct encodes a polynucleotide precursor which may form a double-stranded RNA, or hairpin structure comprising the miRNA. In some embodiments, nucleotides 39-59 and 107-127 of SEQ ID NO:3 are replaced by the backside of the miRNA template and the miRNA template respectively. In some embodiments, this new sequence replaces the equivalent region of SEQ ID NO:1. In further embodiments, this new sequence replaces the equivalent region of SEQ ID NO:44.

[0086] In some embodiments, the nucleic acid construct comprises a modified endogenous plant miRNA precursor, wherein the precursor has been modified to replace the endogenous miRNA encoding regions with sequences designed to produce a miRNA directed to the target sequence. In some embodiments the miRNA precursor template is a miR172a miRNA precursor. In some embodiments, the miR172a precursor is from a dicot or a monocot. In some embodiments the miR172a precursor is from *Arabidopsis thaliana*, tomato, soybean, rice, or corn. In some embodiments the miRNA precursor is SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:44.

[0087] In another embodiment the method comprises:

[0088] A method of inhibiting expression of a target sequence in a cell comprising:

(a) introducing into the cell a nucleic acid construct comprising a promoter operably linked to a polynucleotide, wherein the polynucleotide comprises in the following order:

5 (i) at least about 20 and up to 38 contiguous nucleotides in the region of nucleotides 1-38 of SEQ ID NO:3,

(ii) a first oligonucleotide of 10 to about 50 contiguous nucleotides, wherein the first oligonucleotide is substantially complementary to a second oligonucleotide

10 (iii) at least about 20 and up to 47 contiguous nucleotides in the region of nucleotides 60-106 of SEQ ID NO:3,

(iv) the second oligonucleotide of about 10 to about 50 contiguous nucleotides, wherein the second oligonucleotide encodes a miRNA, and the second oligonucleotide is substantially complementary to the target sequence, and

15 (v) at least about 20 and up to 32 contiguous nucleotides in the region of nucleotides 128-159 of SEQ ID NO:3;

wherein the polynucleotide encodes an RNA precursor capable of forming a hairpin, and

(b) expressing the nucleic acid construct for a time sufficient to produce the miRNA, wherein the miRNA inhibits expression of the target sequence.

[0089] In another embodiment, the method comprises selecting a target sequence of a gene, and designing a nucleic acid construct comprising polynucleotide encoding a miRNA substantially complementary to the target sequence. In some embodiments, the target sequence is selected from any region of the gene. In some embodiments, the target sequence is selected from an untranslated region. In some embodiments, the target sequence is selected from a coding region of the gene. In some embodiments, the target sequence is selected from a region about 50 to about 200 nucleotides upstream from the stop codon, including regions from about 50-75, 75-100, 100-125, 125-150, or 150-200 upstream from the stop codon. In further embodiments, the target sequence and/or the miRNA is based on the polynucleotides and process of EAT suppression of *Apetela2*-like genes in *Arabidopsis thaliana*. In some embodiments, nucleotides 39-59 and 107-127 of SEQ ID NO:3 are replaced by the backside of the miRNA template (first oligonucleotide) and the miRNA template (second oligonucleotide) respectively. In some embodiments, this new sequence replaces the equivalent region of SEQ ID NO:1. In further embodiments, this new sequence replaces the equivalent region of SEQ ID NO:44.

[0090] In some embodiments, the miRNA template, (*i.e.* the polynucleotide encoding the miRNA), and thereby the miRNA, may comprise some mismatches relative to the target sequence. In some embodiments the miRNA template has ≥ 1 nucleotide mismatch as compared to the target sequence, for example, the miRNA template can have 1, 2, 3, 4, 5, or more mismatches as compared to the target sequence. This degree of mismatch may also be described by determining the percent identity of the miRNA template to the complement of the target sequence. For example, the miRNA template may have a percent identity including about at least 70%, 75%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% as compared to the complement of the target sequence.

[0091] In some embodiments, the miRNA template, (*i.e.* the polynucleotide encoding the miRNA) and thereby the miRNA, may comprise some mismatches relative to the miRNA backside. In some embodiments the miRNA template has ≥ 1 nucleotide mismatch as compared to the miRNA backside, for example, the miRNA template can have 1, 2, 3, 4, 5, or more mismatches as compared to the miRNA backside. This degree of mismatch may also be described by determining the percent identity of the miRNA template to the complement of the miRNA backside. For example, the miRNA template may have a percent identity including about at least 70%, 75%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% as compared to the complement of the miRNA backside.

[0092] In some embodiments, the target sequence is selected from a plant pathogen. Plants or cells comprising a miRNA directed to the target sequence of the pathogen are expected to have decreased sensitivity and/or increased resistance to the pathogen. In some embodiments, the miRNA is encoded by a nucleic acid construct further comprising an operably linked promoter. In some embodiments, the promoter is a pathogen-inducible promoter.

[0093] In another embodiment, the method comprises replacing the miRNA encoding sequence in the polynucleotide of SEQ ID NO:3 with a sequence encoding a miRNA substantially complementary to the target region of the target gene.

[0094] In another embodiment a method is provided comprising a method of inhibiting expression of a target sequence in a cell comprising:

(a) introducing into the cell a nucleic acid construct comprising a promoter operably linked to a polynucleotide encoding a modified plant miRNA precursor comprising a first and a second oligonucleotide, wherein at least one of the first or the second oligonucleotides is

heterologous to the precursor, wherein the first oligonucleotide is substantially complementary to the second oligonucleotide, and the second oligonucleotide encodes a miRNA substantially complementary to the target sequence, wherein the precursor is capable of forming a hairpin; and

5 (b) expressing the nucleic acid construct for a time sufficient to produce the miRNA, wherein the miRNA inhibits expression of the target sequence.

[0095] In another embodiment a method is provided comprising a method of inhibiting expression of a target sequence in a cell comprising:

10 (a) introducing into the cell a nucleic acid construct comprising a promoter operably linked to a polynucleotide encoding a modified plant miR172 miRNA precursor comprising a first and a second oligonucleotide, wherein at least one of the first or the second oligonucleotides is heterologous to the precursor, wherein the first oligonucleotide is substantially complementary to the second oligonucleotide, and the second oligonucleotide encodes a miRNA substantially complementary to the target sequence, wherein the precursor is capable of forming a hairpin; and

15 (b) expressing the nucleic acid construct for a time sufficient to produce the miRNA, wherein the miRNA inhibits expression of the target sequence.

[0096] In some embodiments, the modified plant miR172 miRNA precursor is a modified *Arabidopsis* miR172 miRNA precursor, or a modified corn miR172 miRNA precursor or the like.

[0097] In another embodiment, there is provided a nucleic acid construct for suppressing a target sequence. The nucleic acid construct encodes a miRNA substantially complementary to the target. In some embodiments, the nucleic acid construct further comprises a promoter operably linked to the polynucleotide encoding the miRNA. In some embodiments, the nucleic acid construct lacking a promoter is designed and introduced in such a way that it becomes operably linked to a promoter upon integration in the host genome. In some embodiments, the nucleic acid construct is integrated using recombination, including site-specific recombination. See, for example, PCT International published application No. WO 99/25821.

30 In some embodiments, the nucleic acid construct is an RNA. In some embodiments, the nucleic acid construct comprises at least one recombination site, including site-specific recombination sites. In some embodiments the nucleic acid construct comprises at least one recombination site in order to facilitate integration, modification, or cloning of the construct. In some embodiments the nucleic acid construct comprises two site-

specific recombination sites flanking the miRNA precursor. In some embodiments the site-specific recombination sites include FRT sites, lox sites, or att sites, including attB, attL, attP or attR sites. See, for example, PCT International published application No. WO 99/25821, and U.S. Patents 5,888,732, 6,143,557, 6,171,861, 6,270,969, and 6,277,608.

5

[0098] In some embodiments, the nucleic acid construct comprises a modified endogenous plant miRNA precursor, wherein the precursor has been modified to replace the miRNA encoding region with a sequence designed to produce a miRNA directed to the target sequence. In some embodiments the miRNA precursor template is a miR172a miRNA precursor. In some 10 embodiments, the miR172a precursor is from a dicot or a monocot. In some embodiments the miR172a precursor is from *Arabidopsis thaliana*, tomato, soybean, rice, or corn. In some embodiments the miRNA precursor is SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:44.

[0099] In another embodiment, the nucleic acid construct comprises an isolated polynucleotide comprising a polynucleotide which encodes a modified plant miRNA precursor, 15 the modified precursor comprising a first and a second oligonucleotide, wherein at least one of the first or the second oligonucleotides is heterologous to the precursor, wherein the first oligonucleotide *i* is substantially complementary to the second oligonucleotide, and the second oligonucleotide comprises a miRNA substantially complementary to the target sequence, wherein the precursor is capable of forming a hairpin.

[0100] In another embodiment, the nucleic acid construct comprises an isolated polynucleotide comprising a polynucleotide which encodes a modified plant miR172 miRNA precursor, the modified precursor comprising a first and a second oligonucleotide, wherein at 20 least one of the first or the second oligonucleotides is heterologous to the precursor, wherein the first oligonucleotide is substantially complementary to the second oligonucleotide, and the second oligonucleotide comprises a miRNA substantially complementary to the target sequence, wherein the precursor is capable of forming a hairpin. In some embodiments, the modified plant miR172 miRNA precursor is a modified *Arabidopsis* miR172 miRNA precursor, or a modified corn miR172 miRNA precursor, or the like.

[0101] In some embodiments the miRNA comprises about 10-200 nucleotides, about 10-15, 30 15-20, 19, 20, 21, 22, 23, 24, 25, 26, 27, 25-30, 30-50, 50-100, 100-150, or about 150-200 nucleotides. In some embodiments the nucleic acid construct encodes the miRNA. In some embodiments the nucleic acid construct encodes a polynucleotide precursor which may form a double-stranded RNA, or hairpin structure comprising the miRNA. In some embodiments,

nucleotides 39-59 and/or 107-127 of SEQ ID NO:3 are replaced by the backside of the miRNA template and the miRNA template respectively. In some embodiments, this new sequence replaces the equivalent region of SEQ ID NO:1. In further embodiments, this new sequence replaces the equivalent region of SEQ ID NO:44. In some embodiments, the target region is selected from any region of the target sequence. In some embodiments, the target region is selected from a untranslated region. In some embodiments, the target region is selected from a coding region of the target sequence. In some embodiments, the target region is selected from a region about 50 to about 200 nucleotides upstream from the stop codon, including regions from about 50-75, 75-100, 100-125, 125-150, or 150-200 upstream from the stop codon. In further embodiments, the target region and/or the miRNA is based on the polynucleotides and process of EAT suppression of *Apetela2*-like sequences in *Arabidopsis thaliana*.

[0102] In another embodiment the nucleic acid construct comprises an isolated polynucleotide comprising in the following order at least 20 and up to 38 contiguous nucleotides in the region from nucleotides 1-38 of SEQ ID NO:3, a first oligonucleotide of about 10 to about 50 contiguous nucleotides, wherein the first oligonucleotide is substantially complementary to a second oligonucleotide, at least about 20 and up to 47 contiguous nucleotides in the region from nucleotides 60-106 of SEQ ID NO:3, a second oligonucleotide of about 10 to about 50 contiguous nucleotides, wherein the second oligonucleotide encodes a miRNA, and the second oligonucleotide is substantially complementary to the target sequence, and at least about 20 and up to 32 contiguous nucleotides in the region from nucleotides 128-159 of SEQ ID NO:3, wherein the polynucleotide encodes an RNA precursor capable of forming a hairpin structure.

[0103] In some embodiments there are provided cells, plants, and seeds comprising the introduced polynucleotides, and/or produced by the methods of the invention. The cells include prokaryotic and eukaryotic cells, including but not limited to bacteria, yeast, fungi, viral, invertebrate, vertebrate, and plant cells. Plants, plant cells, and seeds of the invention include gynosperms, monocots and dicots, including but not limited to, for example, rice, wheat, oats, barley, millet, sorghum, soy, sunflower, safflower, canola, alfalfa, cotton, *Arabidopsis*, and tobacco.

[0104] In some embodiments, the cells, plants, and/or seeds comprise a nucleic acid construct comprising a modified plant miRNA precursor, wherein the precursor has been modified to replace the endogenous miRNA encoding regions with sequences designed to produce a miRNA directed to the target sequence. In some embodiments the miRNA precursor template is a miR172a miRNA precursor. In some embodiments, the miR172a precursor is from a dicot or a

monocot. In some embodiments the miR172a precursor is from *Arabidopsis thaliana*, tomato, soybean, rice, or corn. In some embodiments the miRNA precursor is SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:44. In some embodiments the miRNA precursor is encoded by SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:44. In some embodiments, the nucleic acid construct 5 comprises at least one recombination site, including site-specific recombination sites. In some embodiments the nucleic acid construct comprises at least one recombination site in order to facilitate modification or cloning of the construct. In some embodiments the nucleic acid construct comprises two site-specific recombination sites flanking the miRNA precursor. In some embodiments the site-specific recombination sites include FRT sites, lox sites, or att sites, 10 including attB, attL, attP or attR sites. See, for example, PCT International published application No. WO 99/25821, and U.S. Patents 5,888,732, 6,143,557, 6,171,861, 6,270,969, and 6,277,608.

[0105] In a further embodiment, there is provided a method for down regulating a target RNA comprising introducing into a cell a nucleic acid construct that encodes a miRNA that is 15 complementary to a region of the target RNA. In some embodiments, the miRNA is fully complementary to the region of the target RNA. In some embodiments, the miRNA is complementary and includes the use of G-U base pairing, i.e. the GU wobble, to otherwise be fully complementary. In some embodiments, the first ten nucleotides of the miRNA (counting from the 5' end of the miRNA) are fully complementary to a region of the target RNA and the 20 remaining nucleotides may include mismatches and/or bulges with the target RNA. In some embodiments the miRNA comprises about 10-200 nucleotides, about 10-15, 15-20, 19, 20, 21, 22, 23, 24, 25, 26, 27, 25-30, 30-50, 50-100, 100-150, or about 150-200 nucleotides. The binding of the miRNA to the complementary sequence in the target RNA results in cleavage of the target RNA. In some embodiments, the miRNA is a miRNA that has been modified such 25 that the miRNA is fully complementary to the target sequence of the target RNA. In some embodiments, the miRNA is an endogenous plant miRNA that has been modified such that the miRNA is fully complementary to the target sequence of the target RNA. In some embodiments, the polynucleotide encoding the miRNA is operably linked to a promoter. In some embodiments, the nucleic acid construct comprises a promoter operably linked to the 30 miRNA.

[0106] In some embodiments, the nucleic acid construct encodes the miRNA. In some embodiments, the nucleic acid construct comprises a promoter operably linked to the miRNA. In some embodiments, the nucleic acid construct encodes a polynucleotide which may form a

double-stranded RNA, or hairpin structure comprising the miRNA. In some embodiments, the nucleic acid construct comprises a promoter operably linked to the polynucleotide which may form a double-stranded RNA, or hairpin structure comprising the miRNA. In some embodiments, the nucleic acid construct comprises an endogenous plant miRNA precursor that 5 has been modified such that the miRNA is fully complementary to the target sequence of the target RNA. In some embodiments, the nucleic acid construct comprises a promoter operably linked to the miRNA precursor. In some embodiments, the nucleic acid construct comprises about 50 nucleotides to about 3000 nucleotides, about 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 10 1000-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, 1900-2000, 2000-2100, 2100-2200, 2200-2300, 2300-2400, 2400-2500, 2500-2600, 2600-2700, 2700-2800, 2800-2900 or about 2900-3000 nucleotides.

[0107] In some embodiments, the nucleic acid construct lacking a promoter is designed and introduced in such a way that it becomes operably linked to a promoter upon integration in the 15 host genome. In some embodiments, the nucleic acid construct is integrated using recombination, including site-specific recombination. In some embodiments, the nucleic acid construct is an RNA. In some embodiments, the nucleic acid construct comprises at least one recombination site, including site-specific recombination sites. In some embodiments the nucleic acid construct comprises at least one recombination site in order to facilitate integration, 20 modification, or cloning of the construct. In some embodiments the nucleic acid construct comprises two site-specific recombination sites flanking the miRNA precursor.

[0108] In another embodiment, the method comprises a method for down regulating a target RNA in a cell comprising introducing into the cell a nucleic acid construct that encodes a miRNA that is complementary to a region of the target RNA and expressing the nucleic acid 25 construct for a time sufficient to produce miRNA, wherein the miRNA down regulates the target RNA. In some embodiments, the miRNA is fully complementary to the region of the target RNA. In some embodiments, the miRNA is complementary and includes the use of G-U base pairing, i.e. the GU wobble, to otherwise be fully complementary.

[0109] In another embodiment, the method comprises selecting a target RNA, selecting a 30 miRNA, comparing the sequence of the target RNA (or its DNA) with the sequence of the miRNA, identifying a region of the target RNA (or its DNA) in which the nucleotide sequence is similar to the nucleotide sequence of the miRNA, modifying the nucleotide sequence of the miRNA so that it is complementary to the nucleotide sequence of the identified region of the

target RNA and preparing a nucleic acid construct comprising the modified miRNA. In some embodiments, the miRNA is fully complementary to the identified region of the target RNA. In some embodiments, the miRNA is complementary and includes the use of G-U base pairing, i.e. the GU wobble, to otherwise be fully complementary. In some embodiments, a nucleic acid construct encodes a polynucleotide which may form a double-stranded RNA, or hairpin structure comprising the miRNA. In some embodiments, a nucleic acid construct comprises a precursor of the miRNA, i.e., a pre-miRNA that has been modified in accordance with this embodiment.

[0110] In another embodiment, the method comprises selecting a target RNA, selecting a nucleotide sequence within the target RNA, selecting a miRNA, modifying the sequence of the miRNA so that it is complementary to the nucleotide sequence of the identified region of the target RNA and preparing a nucleic acid construct comprising the modified miRNA. In some embodiments, the miRNA is fully complementary to the identified region of the target RNA. In some embodiments, the miRNA is complementary and includes the use of G-U base pairing, i.e. the GU wobble, to otherwise be fully complementary. In some embodiments, a nucleic acid construct encodes a polynucleotide which may form a double-stranded RNA, or hairpin structure comprising the miRNA. In some embodiments, a nucleic acid construct comprises a precursor of the miRNA, i.e., a pre-miRNA that has been modified in accordance with this embodiment.

[0111] In some embodiments, the miRNA is a miRNA disclosed in the microRNA registry, now also known as the miRBase Sequence Database (Griffiths-Jones (2004) *Nucl Acids Res* 32, Database issue:D109-D111; <http://microrna.sanger.ac.uk/>). In some embodiments, the miRNA is ath-MIR156a, ath-MIR156b, ath-MIR156c, ath-MIR156d, ath-MIR156e, ath-MIR156f, ath-MIR156g, ath-MIR156h, ath-MIR157a, ath-MIR157b, ath-MIR157c, ath-MIR157d, ath-MIR158a, ath-MIR158b, ath-MIR159a, ath-MIR159b, ath-MIR159c, ath-MIR160a, ath-MIR160b, ath-MIR160c, ath-MIR161, ath-MIR162a, ath-MIR162b, ath-MIR163, ath-MIR164a, ath-MIR164b, ath-MIR164c, ath-MIR165a, ath-MIR165b, ath-MIR166a, ath-MIR166b, ath-MIR166c, ath-MIR166d, ath-MIR166e, ath-MIR166f, ath-MIR166g, ath-MIR167a, ath-MIR167b, ath-MIR167c, ath-MIR167d, ath-MIR168a, ath-MIR168b, ath-MIR169a, ath-MIR169b, ath-MIR169c, ath-MIR169d, ath-MIR169e, ath-MIR169f, ath-MIR169g, ath-MIR169h, ath-MIR169i, ath-MIR169j, ath-MIR169k, ath-MIR169l, ath-MIR169m, ath-MIR169n, ath-MIR170, ath-MIR171a, ath-MIR171b, ath-MIR171c, ath-MIR172a, ath-MIR172b, ath-MIR172c, ath-MIR172d, ath-MIR172e, ath-MIR173, ath-MIR319a, ath-MIR319b, ath-MIR319c, ath-MIR390a, ath-MIR390b, ath-MIR393a, ath-MIR393b, ath-MIR394a, ath-MIR394b, ath-MIR395a, ath-MIR395b, ath-MIR395c, ath-MIR395d, ath-

MIR395e, ath-MIR395f, ath-MIR396a, ath-MIR396b, ath-MIR397a, ath-MIR397b, ath-MIR398a, ath-MIR398b, ath-MIR398c, ath-MIR399a, ath-MIR399b, ath-MIR399c, ath-MIR399d, ath-MIR399e, ath-MIR399f, ath-MIR400, ath-MIR401, ath-MIR402, ath-MIR403, ath-MIR404, ath-MIR405a, ath-MIR405b, ath-MIR405d, ath-MIR406, ath-MIR407, ath-5 MIR408, ath-MIR413, ath-MIR414, ath-MIR415, ath-MIR416, ath-MIR417, ath-MIR418, ath-MIR419, ath-MIR420, ath-MIR426, ath-MIR447a, ath-MIR447b, ath-MIR447c, osa-MIR156a, osa-MIR156b, osa-MIR156c, osa-MIR156d, osa-MIR156e, osa-MIR156f, osa-MIR156g, osa-MIR156h, osa-MIR156i, osa-MIR156j, osa-MIR156k, osa-MIR156l, osa-MIR159a, osa-10 MIR159b, osa-MIR159c, osa-MIR159d, osa-MIR159e, osa-MIR159f, osa-MIR160a, osa-MIR160b, osa-MIR160c, osa-MIR160d, osa-MIR160e, osa-MIR160f, osa-MIR162a, osa-MIR162b, osa-MIR164a, osa-MIR164b, osa-MIR164c, osa-MIR164d, osa-MIR164e, osa-MIR166a, osa-MIR166b, osa-MIR166c, osa-MIR166d, osa-MIR166e, osa-MIR166f, osa-MIR166j, osa-MIR166k, osa-MIR166l, osa-MIR166g, osa-MIR166h, osa-MIR166i, osa-MIR166m, osa-MIR166n, osa-MIR167a, osa-MIR167b, osa-MIR167c, osa-MIR167d, osa-15 MIR167e, osa-MIR167f, osa-MIR167g, osa-MIR167h, osa-MIR167i, osa-MIR167j, osa-MIR168a, osa-MIR168b, osa-MIR169a, osa-MIR169b, osa-MIR169c, osa-MIR169d, osa-MIR169e, osa-MIR169f, osa-MIR169g, osa-MIR169h, osa-MIR169i, osa-MIR169j, osa-MIR169k, osa-MIR169l, osa-MIR169m, osa-MIR169n, osa-MIR169o, osa-MIR169p, osa-MIR169q, osa-MIR171a, osa-MIR171b, osa-MIR171c, osa-MIR171d, osa-MIR171e, osa-20 MIR171f, osa-MIR171g, osa-MIR171h, osa-MIR171i, osa-MIR172a, osa-MIR172b, osa-MIR172c, osa-MIR173d, osa-MIR390, osa-MIR39a, osa-MIR39b, osa-MIR393, osa-MIR393b, osa-MIR394, osa-MIR395b, osa-MIR395c, osa-MIR395d, osa-MIR395e, osa-MIR395g, osa-MIR395h, osa-MIR395i, osa-MIR395j, osa-MIR395k, osa-MIR395l, osa-MIR395m, osa-MIR395n, osa-MIR395o, osa-MIR395r, osa-MIR395q, osa-MIR395c, osa-25 MIR395a, osa-MIR395f, osa-MIR395p, osa-MIR396a, osa-MIR396b, osa-MIR396c, osa-MIR397a, osa-MIR397b, osa-MIR398a, osa-MIR398b, osa-MIR399a, osa-MIR399b, osa-MIR399c, osa-MIR399d, osa-MIR399e, osa-MIR399f, osa-MIR399g, osa-MIR399h, osa-MIR399i, osa-MIR399j, osa-MIR399k, osa-MIR408, osa-MIR413, osa-MIR414, osa-MIR415, osa-MIR416, osa-MIR417, osa-MIR418, osa-MIR419, osa-MIR426, osa-MIR437, osa-30 MIR439, osa-MIR439c, osa-MIR439d, osa-MIR438e, osa-MIR439f, osa-MIR439g, osa-MIR439h, osa-MIR440, osa-MIR441a, osa-MIR441c, osa-MIR442, osa-MIR443, osa-MIR445d, osa-MIR446, zma-MIR156a, zma-MIR156b, zma-MIR156c, zma-MIR156d, zma-MIR156e, zma-MIR156f, zma-MIR156g, zma-MIR156h, zma-MIR156i, zma-MIR156j, zma-

MIR156k, zma-MIR159a, zma-MIR159b, zma-MIR159c, zma-MIR159d, zma-MIR160a, zma-MIR160b, zma-MIR160c, zma-MIR160d, zma-MIR160e, zma-MIR160f, zma-MIR1611, zma-MIR162, zma-MIR164a, zma-MIR164b, zma-MIR164c, zma-MIR164d, zma-MIR166a, zma-MIR166b, zma-MIR166c, zma-MIR166d, zma-MIR166e, zma-MIR166e, zma-MIR166f, zma-MIR166g, zma-MIR166h, zma-MIR166i, zma-MIR166j, zma-MIR166k, zma-MIR166m, zma-MIR167a, zma-MIR167b, zma-MIR167c, zma-MIR167d, zma-MIR167e, zma-MIR167f, zma-MIR167g, zma-MIR167h, zma-MIR168a, zma-MIR168b, zma-MIR169a, zma-MIR169b, zma-MIR169c, zma-MIR169d, zma-MIR169e, zma-MIR169f, zma-MIR169g, zma-MIR169i, zma-MIR169j, zma-MIR169k, zma-MIR171a, zma-MIR171b, zma-MIR171c, zma-MIR171d, zma-MIR171e, zma-MIR171f, zma-MIR171g, zma-MIR171h, zma-MIR171i, zma-MIR171j, zma-MIR171k, zma-MIR172a, zma-MIR172b, zma-MIR172c or zma-MIR172d, zma-MIR172e, zma-MIR319a, zma-MIR319b, zma-MIR319d, zma-MIR393, zma-MIR394a, zma-MIR394b, zma-MIR395a, zma-MIR395b, zma-MIR395c, zma-MIR395d, zma-MIR396a, zma-MIR396b, zma-MIR399a, zma-MIR399b, zma-MIR399c, zma-MIR399d, zma-MIR399e, zma-MIR399f, zma-MIR408.

[0112] In some embodiments, the miRNA is a miRNA disclosed in Genbank (USA), EMBL (Europe) or DDBJ (Japan). In some embodiments, the miRNA is selected from one of the following Genbank accession numbers: AJ505003, AJ505002, AJ505001, AJ496805, AJ496804, AJ496803, AJ496802, AJ496801, AJ505004, AJ493656, AJ493655, AJ493654, AJ493653, AJ493652, AJ493651, AJ493650, AJ493649, AJ493648, AJ493647, AJ493646, AJ493645, AJ493644, AJ493643, AJ493642, AJ493641, AJ493640, AJ493639, AJ493638, AJ493637, AJ493636, AJ493635, AJ493634, AJ493633, AJ493632, AJ493631, AJ493630, AJ493629, AJ493628, AJ493627, AJ493626, AJ493625, AJ493624, AJ493623, AJ493622, AJ493621, AJ493620, AY615374, AY615373, AY730704, AY730703, AY730702, AY730701, AY730700, AY730699, AY730698, AY599420, AY551259, AY551258, AY551257, AY551256, AY551255, AY551254, AY551253, AY551252, AY551251, AY551250, AY551249, AY551248, AY551247, AY551246, AY551245, AY551244, AY551243, AY551242, AY551241, AY551240, AY551239, AY551238, AY551237, AY551236, AY551235, AY551234, AY551233, AY551232, AY551231, AY551230, AY551229, AY551228, AY551227, AY551226, AY551225, AY551224, AY551223, AY551222, AY551221, AY551220, AY551219, AY551218, AY551217, AY551216, AY551215, AY551214, AY551213, AY551212, AY551211, AY551210, AY551209, AY551208, AY551207, AY551206, AY551205, AY551204, AY551203, AY551202, AY551201,

AY551200, AY551199, AY551198, AY551197, AY551196, AY551195, AY551194,
 AY551193, AY551192, AY551191, AY551190, AY551189, AY551188, AY50143 4,
 AY501433, AY501432, AY501431, AY498859, AY376459, AY376458 AY88423 3,
 AY884232, AY884231, AY884230, AY884229, AY884228, AY884227, AY884226,
 5 AY884225, AY884224, AY884223, AY884222, AY884221, AY884220, AY88421 9,
 AY884218, AY884217, AY884216, AY728475, AY728474, AY728473, AY728472,
 AY728471, AY728470, AY728469, AY728468, AY728467, AY728466, AY728465,
 AY728464, AY728463, AY728462, AY728461, AY728460, AY728459, AY728458,
 AY728457, AY728456, AY728455, AY728454, AY728453, AY728452, AY728451,
 10 AY728450, AY728449, AY728448, AY728447, AY728446, AY728445, AY728444,
 AY728443, AY728442, AY728441, AY728440, AY728439, AY728438, AY728437,
 AY728436, AY728435 AY728434, AY728433, AY728432, AY728431, AY728430,
 AY728429, AY728428, AY728427, AY728426, AY728425, AY728424, AY728423,
 AY728422, AY728421, AY728420, AY728419, AY728418, AY728417, AY728416,
 15 AY728415, AY728414, AY728413, AY728412, AY728411, AY728410, AY728409,
 AY728408, AY728407, AY728406, AY728405, AY728404, AY728403, AY728402,
 AY728401, AY728400, AY728399, AY728398, AY728397, AY728396, AY728395,
 AY728394, AY728393, AY728392, AY728391, AY728390, AY728389, AY728388,
 AY851149, AY851148, AY851147, AY851146, AY851145, AY851144 or AY599420.

20 [0113] In some embodiments, the miRNA is selected from one of the sequences disclosed in U.S. published patent application No. 2005/0144669 A1.

[0114] In some embodiments, the above miRNAs, as well as those disclosed herein, have been modified to be directed to a specific target as described herein.

[0115] In some embodiments the target RNA is an RNA of a plant pathogen, such as a plant 25 virus or plant viroid. In some embodiments, the miRNA directed against the plant pathogen RNA is operably linked to a pathogen-inducible promoter. In some embodiments, the target RNA is an mRNA. The target sequence in an mRNA may be a non-coding sequence (such as an intron sequence, 5' untranslated region and 3' untranslated region), a coding sequence or a sequence involved in mRNA splicing. Targeting the miRNA to an intron sequence 30 compromises the maturation of the mRNA. Targeting the miRNA to a sequence involved in mRNA splicing influences the maturation of alternative splice forms providing different protein isoforms.

[0116] In some embodiments there are provided cells, plants, and seeds comprising the polynucleotides of the invention, and/or produced by the methods of the invention. In some embodiments, the cells, plants, and/or seeds comprise a nucleic acid construct comprising a modified plant miRNA precursor, as described herein. In some embodiments, the modified 5 plant miRNA precursor in the nucleic acid construct is operably linked to a promoter. The promoter may be any well known promoter, including constitutive promoters, inducible promoters, derepressible promoters, and the like, such as described below. The cells include prokaryotic and eukaryotic cells, including but not limited to bacteria, yeast, fungi, viral, invertebrate, vertebrate, and plant cells. Plants, plant cells, and seeds of the invention include 10 gynosperms, monocots and dicots, including but not limited to, rice, wheat, oats, barley, millet, sorghum, soy, sunflower, safflower, canola, alfalfa, cotton, *Arabidopsis*, and tobacco.

[0117] In another embodiment, there is provided a method for down regulating multiple target RNAs comprising introducing into a cell a nucleic acid construct encoding a multiple 15 number of miRNAs. One miRNA in the multiple miRNAs is complementary to a region of one of the target RNAs. In some embodiments, a miRNA is fully complementary to the region of the target RNA. In some embodiments, a miRNA is complementary and includes the use of G-U base pairing, i.e. the GU wobble, to otherwise be fully complementary. In some 20 embodiments, the first ten nucleotides of the miRNA (counting from the 5' end of the miRNA) are fully complementary to a region of the target RNA and the remaining nucleotides may include mismatches and/or bulges with the target RNA. In some embodiments a miRNA comprises about 10-200 nucleotides, about 10-15, 15-20, 19, 20, 21, 22, 23, 24, 25, 26, 27, 25-30, 30-50, 50-100, 100-150, or about 150-200 nucleotides. The binding of a miRNA to its complementary sequence in the target RNA results in cleavage of the target RNA. In some 25 embodiments, the miRNA is a miRNA that has been modified such that the miRNA is fully complementary to the target sequence of the target RNA. In some embodiments, the miRNA is an endogenous plant miRNA that has been modified such that the miRNA is fully complementary to the target sequence of the target RNA. In some embodiments, the miRNA is operably linked to a promoter. In some embodiments, the multiple miRNAs are linked one to another so as to form a single transcript when expressed. In some embodiments, the nucleic acid 30 construct comprises a promoter operably linked to the miRNA.

[0118] In some embodiments, the nucleic acid construct encodes miRNAs for suppressing a multiple number of target sequences. The nucleic acid construct encodes at least two miRNAs. In some embodiments, each miRNA is substantially complementary to a target or which is

modified to be complementary to a target as described herein. In some embodiments, the nucleic acid construct encodes for 2-30 or more miRNAs, for example 3-40 or more miRNAs, for example 3-45 or more miRNAs, and for further example, multimers of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or more miRNAs. In some embodiments, the multiple miRNAs are linked one to another so as to form a single transcript when expressed.

5 [0119] In some embodiments, polymeric pre-miRNAs that are artificial miRNA precursors consisting of more than one miRNA precursor units are provided. The polymeric pre-miRNAs can either be hetero-polymeric with different miRNA precursors, or homo-polymeric containing 10 several units of the same miRNA precursor. The Examples demonstrate that hetero-polymeric pre-miRNAs are able to produce different mature artificial miRNAs. For example, *pre-miR-PDS1^{169g}-CPC3^{159a}*, which is a dimer comprising of *pre-miR-CPC3^{159a}* and *pre-miR-PDS1^{169g}* can produce mature *miR-PDS1^{169g}* and *miR-CPC3^{159a}* when expressed in plant cells. The Examples also demonstrate that homo-polymeric miRNA precursors are able to produce 15 different mature artificial miRNAs. For example, *pre-miR-P69^{159a}-HC-Pro^{159a}*, which is a dimer comprising *pre-miR-P69^{159a}* and *pre-miR-HC-Pro^{159a}*, can produce mature *miR-P69^{159a}* and *miR-HC-Pro^{159a}*. In a similar manner, hetero- or homo-polymeric pre-miRNAs are produced 20 that contain any number of monomer units, such as described herein. An exemplary method for preparing a nucleic acid construct comprising multiple pre-miRNAs under the control of a single promoter is shown in Examples 21 and 27. Each mature miRNA is properly processed from the nucleic acid construct as demonstrated in Examples 22 and 27.

25 [0120] In some embodiments, the nucleic acid construct comprises multiple polynucleotides, each polynucleotide encoding a separate miRNA precursor, i.e., a separate pre-miRNA. The polynucleotides are operably linked one to another such that they may be placed under the control of a single promoter. In some embodiments, the multiple polynucleotides are linked one to another so as to form a single transcript containing the multiple pre-miRNAs when expressed. The single transcript is processed in the host cells to produce multiple mature miRNAs, each capable of downregulating its target gene. As many polynucleotides encoding the pre-miRNAs as desired can be linked together, with the only limitation being the ultimate size of the transcript. It is well known that transcripts of 8-10 kb can be produced in plants. Thus, it is 30 possible to form a nucleic acid construct comprising multimeric polynucleotides encoding 2-30 or more pre-miRNAs, for example 3-40 or more pre-miRNAs, for example 3-45 or more pre-miRNAs, and for further example, multimers of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,

17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or more pre-miRNAs.

[0121] In some embodiments, the nucleic acid construct further comprises a promoter operably linked to the polynucleotide encoding the multiple number of miRNAs. In some 5 embodiments, the nucleic acid construct lacking a promoter is designed and introduced in such a way that it becomes operably linked to a promoter upon integration in the host genome. In some embodiments, the nucleic acid construct is integrated using recombination, including site-specific recombination. See, for example, PCT International published application No. WO 99/25821. In some embodiments, the nucleic acid construct is 10 an RNA. In some embodiments, the nucleic acid construct comprises at least one recombination site, including site-specific recombination sites. In some embodiments the nucleic acid construct comprises at least one recombination site in order to facilitate integration, modification, or cloning of the construct. In some embodiments the nucleic acid construct comprises two site-specific recombination sites flanking the miRNA precursor. In some 15 embodiments the site-specific recombination sites include FRT sites, lox sites, or att sites, including attB, attL, attP or attR sites. See, for example, PCT International published application No. WO 99/25821, and U.S. Patents 5,888,732, 6,143,557, 6,171,861, 6,270,969, and 6,277,608.

[0122] In some embodiments, the pre-miRNA is inserted into an intron in a gene or a 20 transgene of a cell or plant. If the gene has multiple introns, a pre-miRNA, which can be the same or different, can be inserted into each intron. In some embodiments the pre-miRNA inserted into an intron is a polymeric pre-miRNA, such as described herein. During RNA splicing, introns are released from primary RNA transcripts and therefore, as illustrated herein, 25 can serve as precursors for miRNAs. Most introns contain a splicing donor site at the 5' end, splicing acceptor site at the 3' end and a branch site within the intron. The branch site is important for intron maturation -- without it, an intron can not be excised and released from the primary RNA transcript. A branch site is usually located 20-50 nt upstream of the splicing acceptor site, whereas distances between the splice donor site and the branch site are largely 30 variable among different introns. Thus, in some embodiments, the pre-miRNA is inserted into an intron between the splicing donor site and the branch site.

[0123] In some embodiments the target RNA is an RNA of a plant pathogen, such as a plant virus or plant viroid. In some embodiments, the miRNA directed against the plant pathogen RNA is operably linked to a pathogen-inducible promoter. In some embodiments, the target

RNA is an mRNA. The target sequence in an mRNA may be an intron sequence, a coding sequence or a sequence involved in mRNA splicing. Targeting the miRNA to an intron sequence compromises the maturation of the mRNA. Targeting the miRNA to a sequence involved in mRNA splicing influences the maturation of alternative splice forms providing 5 different protein isoforms. In some embodiments, the target includes genes affecting agronomic traits, insect resistance, disease resistance, herbicide resistance, sterility, grain characteristics, and commercial products.

[0124] In some embodiments there are provided cells, plants, and seeds comprising the nucleic acid construct encoding multiple miRNAs of the invention, and/or produced by the 10 methods of the invention. In some embodiments, the cells, plants, and/or seeds comprise a nucleic acid construct comprising multiple polynucleotides, each encoding a plant miRNA precursor, as described herein. In some embodiments, the multiple polynucleotides are operably linked to a promoter. The promoter may be any well known promoter, including constitutive promoters, inducible promoters, derepressible promoters, and the like, such as described below. 15 The polynucleotides encoding the miRNA precursors are linked together. In some embodiments, the multiple polynucleotides are linked one to another so as to form a single transcript containing the multiple pre-miRNAs when expressed in the cells, plants or seeds. The cells include prokaryotic and eukaryotic cells, including but not limited to bacteria, yeast, fungi, viral, invertebrate, vertebrate, and plant cells. Plants, plant cells, and seeds of the invention 20 include gynosperms, monocots and dicots, including but not limited to, rice, wheat, oats, barley, millet, sorghum, soy, sunflower, safflower, canola, alfalfa, cotton, *Arabidopsis*, and tobacco.

[0125] The present invention concerns methods and compositions useful in suppression of a target sequence and/or validation of function. The invention also relates to a method for using 25 microRNA (miRNA) mediated RNA interference (RNAi) to silence or suppress a target sequence to evaluate function, or to validate a target sequence for phenotypic effect and/or trait development. Specifically, the invention relates to constructs comprising small nucleic acid molecules, miRNAs, capable of inducing silencing, and methods of using these miRNAs to selectively silence target sequences.

[0126] RNA interference refers to the process of sequence-specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire *et al.* (1998) *Nature* 391:806-810). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing (PTGS) or RNA silencing and is also referred to as quelling in 30

fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla (Fire *et al.* (1999) *Trends Genet.* 15:358-363). Such protection from foreign gene expression may have evolved in response to the production of 5 double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA of viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response through a mechanism that has yet to be fully characterized.

[0127] The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III 10 enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Bernstein *et al.* (2001) *Nature* 409:363-366). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes (Elbashir *et al.* (2001) *Genes Dev* 15:188-200). Dicer has also been implicated in the excision of 21- and 22-nucleotide small 15 temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner *et al.* (2001) *Science* 293:834-838). The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence complementarity to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle 20 of the region complementary to the antisense strand of the siRNA duplex (Elbashir *et al.* (2001) *Genes Dev* 15:188-200). In addition, RNA interference can also involve small RNA (e.g., microRNA, or miRNA) mediated gene silencing, presumably through cellular mechanisms that regulate chromatin structure and thereby prevent transcription of target gene sequences (see, e.g., Allshire, *Science* 297:1818-1819 2002; Volpe *et al.* (2002) *Science* 297:1833-1837; 25 Jenuwein (2002) *Science* 297:2215-2218; Hall *et al.* (2002) *Science* 297:2232-2237). As such, miRNA molecules of the invention can be used to mediate gene silencing via interaction with RNA transcripts or alternately by interaction with particular gene sequences, wherein such interaction results in gene silencing either at the transcriptional or post-transcriptional level.

[0128] RNAi has been studied in a variety of systems. Fire *et al.* ((1998) *Nature* 391:806-811) were the first to observe RNAi in *C. elegans*. Wianny and Goetz ((1999) *Nature Cell Biol* 2:70) describe RNAi mediated by dsRNA in mouse embryos. Hammond *et al.* ((2000) *Nature* 404:293-296) describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir *et al.* ((2001) *Nature* 411:494-498) describe RNAi induced by introduction of duplexes of synthetic

21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells.

[0129] Small RNAs play an important role in controlling gene expression. Regulation of many developmental processes, including flowering, is controlled by small RNAs. It is now 5 possible to engineer changes in gene expression of plant genes by using transgenic constructs which produce small RNAs in the plant.

[0130] Small RNAs appear to function by base-pairing to complementary RNA or DNA target sequences. When bound to RNA, small RNAs trigger either RNA cleavage or translational inhibition of the target sequence. When bound to DNA target sequences, it is 10 thought that small RNAs can mediate DNA methylation of the target sequence. The consequence of these events, regardless of the specific mechanism, is that gene expression is inhibited.

[0131] It is thought that sequence complementarity between small RNAs and their RNA targets helps to determine which mechanism, RNA cleavage or translational inhibition, is 15 employed. It is believed that siRNAs, which are perfectly complementary with their targets, work by RNA cleavage. Some miRNAs have perfect or near-perfect complementarity with their targets, and RNA cleavage has been demonstrated for at least a few of these miRNAs. Other miRNAs have several mismatches with their targets, and apparently inhibit their targets at the translational level. Again, without being held to a particular theory on the mechanism of action, 20 a general rule is emerging that perfect or near-perfect complementarity favors RNA cleavage, especially within the first ten nucleotides (counting from the 5' end of the miRNA), whereas translational inhibition is favored when the miRNA/target duplex contains many mismatches. The apparent exception to this is microRNA 172 (miR172) in plants. One of the targets of miR172 is APETALA2 (AP2), and although miR172 shares near-perfect complementarity with 25 AP2 it appears to cause translational inhibition of AP2 rather than RNA cleavage.

[0132] MicroRNAs (miRNAs) are noncoding RNAs of about 19 to about 24 nucleotides (nt) in length that have been identified in both animals and plants (Lagos-Quintana *et al.* (2001) *Science* 294:853-858, Lagos-Quintana *et al.* (2002) *Curr Biol* 12:735-739; Lau *et al.* (2002) *Science* 294:858-862; Lee and Ambros (2001) *Science* 294:862-864; Llave *et al.* (2002) *Plant Cell* 14:1605-1619; Mourelatos *et al.* (2002) *Genes Dev* 16:720-728; Park *et al.* (2002) *Curr Biol* 12:1484-1495; Reinhart *et al.* (2002) *Genes Dev* 16:1616-1626). They are processed from 30 longer precursor transcripts that range in size from approximately 70 to 200 nt, and these precursor transcripts have the ability to form stable hairpin structures. In animals, the enzyme

involved in processing miRNA precursors is called Dicer, an RNase III-like protein (Grishok *et al.* (2001) *Cell* 106:23-34; Hutvagner *et al.* (2001) *Science* 293:834-838; Ketting *et al.* (2001) *Genes Dev* 15:2654-2659). Plants also have a Dicer-like enzyme, DCL1 (previously named CARPEL FACTORY/SHORT INTEGUMENTS1/ SUSPENSOR1), and recent evidence 5 indicates that it, like Dicer, is involved in processing the hairpin precursors to generate mature miRNAs (Park *et al.* (2002) *Curr Biol* 12:1484-1495; Reinhart *et al.* (2002) *Genes Dev* 16:1616-1626). Furthermore, it is becoming clear from recent work that at least some miRNA hairpin 10 precursors originate as longer polyadenylated transcripts, and several different miRNAs and associated hairpins can be present in a single transcript (Lagos-Quintana *et al.* (2001) *Science* 294:853-858; Lee *et al.* (2002) *EMBO J* 21:4663-4670). Recent work has also examined the 15 selection of the miRNA strand from the dsRNA product arising from processing of the hairpin by DICER (Schwartz *et al.* (2003) *Cell* 115:199-208). It appears that the stability (*i.e.* G:C vs. A:U content, and/or mismatches) of the two ends of the processed dsRNA affects the strand selection, with the low stability end being easier to unwind by a helicase activity. The 5' end 20 strand at the low stability end is incorporated into the RISC complex, while the other strand is degraded.

[0133] In animals, there is direct evidence indicating a role for specific miRNAs in development. The lin-4 and let-7 miRNAs in *C. elegans* have been found to control temporal development, based on the phenotypes generated when the genes producing the lin-4 and let-7 25 miRNAs are mutated (Lee *et al.* (1993) *Cell* 75:843-854; Reinhart *et al.* (2000) *Nature* 403:901-906). In addition, both miRNAs display a temporal expression pattern consistent with their roles 30 in developmental timing. Other animal miRNAs display developmentally regulated patterns of expression, both temporal and tissue-specific (Lagos-Quintana *et al.* (2001) *Science* 294:853-853, Lagos-Quintana *et al.* (2002) *Curr Biol* 12:735-739; Lau *et al.* (2001) *Science* 294:858-862; Lee and Ambros (2001) *Science* 294:862-864), leading to the hypothesis that miRNAs may, in many cases, be involved in the regulation of important developmental processes. Likewise, in plants, the differential expression patterns of many miRNAs suggests a role in development (Llave *et al.* (2002) *Plant Cell* 14:1605-1619; Park *et al.* (2002) *Curr Biol* 12:1484-1495; Reinhart *et al.* (2002) *Genes Dev* 16:1616-1626), which has now been shown (*e.g.*, Guo *et al.* (2005) *Plant Cell* 17:1376-1386).

[0134] MicroRNAs appear to regulate target genes by binding to complementary sequences located in the transcripts produced by these genes. In the case of lin-4 and let-7, the target sites are located in the 3' UTRs of the target mRNAs (Lee *et al.* (1993) *Cell* 75:843-854; Wightman

et al. (1993) *Cell* 75:855-862; Reinhart et al. (2000) *Nature* 403:901-906; Slack et al. (2000) *Mol Cell* 5:659-669), and there are several mismatches between the lin-4 and let-7 miRNAs and their target sites. Binding of the lin-4 or let-7 miRNA appears to cause downregulation of steady-state levels of the protein encoded by the target mRNA without affecting the transcript itself (Olsen and Ambros (1999) *Dev Biol* 216:671-680). On the other hand, recent evidence suggests that miRNAs can, in some cases, cause specific RNA cleavage of the target transcript within the target site, and this cleavage step appears to require 100% complementarity between the miRNA and the target transcript (Hutvagner and Zamore (2002) *Science* 297:2056-2060; Llave et al. (2002) *Plant Cell* 14:1605-1619), especially within the first ten nucleotides (counting from the 5' end of the miRNA). It seems likely that miRNAs can enter at least two pathways of target gene regulation. Protein downregulation when target complementarity is <100%, and RNA cleavage when target complementarity is 100%. MicroRNAs entering the RNA cleavage pathway are analogous to the 21-25 nt short interfering RNAs (siRNAs) generated during RNA interference (RNAi) in animals and posttranscriptional gene silencing (PTGS) in plants (Hamilton and Baulcombe (1999) *Science* 286:950-952; Hammond et al., (2000) *Nature* 404:293-296; Zamore et al., (2000) *Cell* 31:25-33; Elbashir et al., (2001) *Nature* 411:494-498), and likely are incorporated into an RNA-induced silencing complex (RISC) that is similar or identical to that seen for RNAi.

[0135] Identifying the targets of miRNAs with bioinformatics has not been successful in animals, and this is probably due to the fact that animal miRNAs have a low degree of complementarity with their targets. On the other hand, bioinformatic approaches have been successfully used to predict targets for plant miRNAs (Llave et al. (2002) *Plant Cell* 14:1605-1619; Park et al. (2002) *Curr Biol* 12:1484-1495; Rhoades et al. (2002) *Cell* 110:513-520), and thus it appears that plant miRNAs have higher overall complementarity with their putative targets than do animal miRNAs. Most of these predicted target transcripts of plant miRNAs encode members of transcription factor families implicated in plant developmental patterning or cell differentiation. Nonetheless, biological function has not been directly demonstrated for any plant miRNA. Although Llave et al. ((2002) *Science* 297:2053-2056) have shown that a transcript for a SCARECROW-like transcription factor is a target of the *Arabidopsis* miRNA mir171, these studies were performed in a heterologous species and no plant phenotype associated with mir171 was reported.

[0136] The methods provided can be practiced in any organism in which a method of transformation is available, and for which there is at least some sequence information for the

target sequence, or for a region flanking the target sequence of interest. It is also understood that two or more sequences could be targeted by sequential transformation, co-transformation with more than one targeting vector, or the construction of a DNA construct comprising more than one miRNA sequence. The methods of the invention may also be implemented by a 5 combinatorial nucleic acid library construction in order to generate a library of miRNAs directed to random target sequences. The library of miRNAs could be used for high-throughput screening for gene function validation.

[0137] General categories of sequences of interest include, for example, those genes involved in regulation or information, such as zinc fingers, transcription factors, homeotic genes, or cell 10 cycle and cell death modulators, those involved in communication, such as kinases, and those involved in housekeeping, such as heat shock proteins.

[0138] Target sequences further include coding regions and non-coding regions such as promoters, enhancers, terminators, introns and the like, which may be modified in order to alter the expression of a gene of interest. For example, an intron sequence can be added to the 5' 15 region to increase the amount of mature message that accumulates (see for example Buchman and Berg (1988) *Mol Cell Biol* 8:4395-4405); and Callis *et al.* (1987) *Genes Dev* 1:1183-1200).

[0139] The target sequence may be an endogenous sequence, or may be an introduced heterologous sequence, or transgene. For example, the methods may be used to alter the regulation or expression of a transgene, or to remove a transgene or other introduced sequence 20 such as an introduced site-specific recombination site. The target sequence may also be a sequence from a pathogen, for example, the target sequence may be from a plant pathogen such as a virus, a mold or fungus, an insect, or a nematode. A miRNA can be expressed in a plant which, upon infection or infestation, would target the pathogen and confer some degree of resistance to the plant. The Examples herein demonstrate the techniques to design artificial 25 miRNAs to confer virus resistance/tolerance to plants. In some embodiments, two or more artificial miRNA sequences directed against different sequences of the virus can be used to prevent the target virus from mutating and thus evading the resistance mechanism. In some embodiments, sequences of artificial miRNAs can be selected so that they target a critical region of the viral RNA (e.g. active site of a silencing gene suppressor). In this case, mutation of the 30 virus in this selected region may render the encoded protein inactive, thus preventing mutation of the virus as a way to escape the resistance mechanism. In some embodiments, an artificial miRNA directed towards a conserved sequence of a family of viruses would confer resistance to members of the entire family. In some embodiments, an artificial miRNA directed towards a

sequence conserved amongst members of would confer resistance to members of the different viral families (e.g, see Table 1).

TABLE 1

5 Conserved Viral Genome Sequence of TuMV for Artificial miRNA Design

TuMV CY5				
No	Region ^a	Gene	Sequence ^b (SEQ ID NO:)	length
1	3207 to 3229	P3	5'-cgatttaggcggcagatacagcg-3' (167)	23
2	9151 to 9185	CP	5'-attctcaatggttaatggtctggcattgagaa-3' (168)	35
3	9222 to 9227	CP	5'-ataaacggaatgtgggtgatgatgga-3' (169)	26
4	9235 to 9255	CP	5'-gatcaggtggaattcccgatc-3' (170)	21
5	9270 to 9302	CP	5'-cacgc当地aaaccacatttaggcaaataatggc-3' (171)	32
6	9319 to 9386	CP	5'-gc当地aagcgtacattgaaaagcgttaaccaagaccgaccatac atgccacgatatggtcttcagcgc当地a-3' (172)	68
7	9430 to 9509	CP	5'-gaaatgacttctagaactccaatacgtgc当地gagaagcacac atccagatgaaaggcagcagcactgc当地ggc当地aaataa-3' (173)	80
8	9541 to 9566	CP	5'-acaacggtagagaacacggagaggca-3' (174)	26

^a The region of genome sequence is according to TuMV CY5 strain (AF530055).

^b The highly conserved of TuMV sequence from 21 different TuMV strains was alignment by Vector NTI Advance 10.0.1 software (Invitrogen Corp).

10 The full-length sequence of 21 different TuMV strains were obtained from the GenBank database under the following accession numbers including AB093596, AB093598, AB093599, AB093600, AB093615, AB093616, AB093617, AB093618, AB093619, AB093611, AB093612, AY227024, AB093609, AF394601, AF169561, AF530055, AF394602, AB093623, AB093624, AY090660, D83184.

15 [0140] In plants, other categories of target sequences include genes affecting agronomic traits, insect resistance, disease resistance, herbicide resistance, sterility, grain characteristics, and commercial products. Genes of interest also include those involved in oil, starch, carbohydrate, or nutrient metabolism as well as those affecting, for example, kernel size, sucrose loading, and the like. The quality of grain is reflected in traits such as levels and types of oils, 20 saturated and unsaturated, quality and quantity of essential amino acids, and levels of cellulose. For example, genes of the phytic acid biosynthetic pathway could be suppressed to generate a high available phosphorous phenotype. See, for example, phytic acid biosynthetic enzymes including inositol polyphosphate kinase-2 polynucleotides, disclosed in WO 02/059324, inositol 1,3,4-trisphosphate 5/6-kinase polynucleotides, disclosed in WO 03/027243, and myo-inositol 1-25 phosphate synthase and other phytate biosynthetic polynucleotides, disclosed in WO 99/05298.

Genes in the lignification pathway could be

suppressed to enhance digestibility or energy availability. Genes affecting cell cycle or cell death could be suppressed to affect growth or stress response. Genes affecting DNA repair and/or recombination could be suppressed to increase genetic variability. Genes affecting flowering time could be suppressed, as well as genes affecting fertility. Any target sequence 5 could be suppressed in order to evaluate or confirm its role in a particular trait or phenotype, or to dissect a molecular, regulatory, biochemical, or proteomic pathway or network.

[0141] A number of promoters can be used, these promoters can be selected based on the desired outcome. It is recognized that different applications will be enhanced by the use of different promoters in plant expression cassettes to modulate the timing, location and/or level of 10 expression of the miRNA. Such plant expression cassettes may also contain, if desired, a promoter regulatory region (e.g., one conferring inducible, constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific/selective expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

15 [0142] Constitutive, tissue-preferred or inducible promoters can be employed. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, the ubiquitin 1 promoter, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Patent No. 5,683,439), the Nos promoter, the pEmu promoter, the rubisco promoter, the GRP1 -8 promoter 20 and other transcription initiation regions from various plant genes known to those of skill. If low level expression is desired, weak promoter(s) may be used. Weak constitutive promoters include, for example, the core promoter of the Rsyn7 promoter (WO 99/43838 and U.S. Patent No. 6,072,050), the core 35S CaMV promoter, and the like. Other constitutive promoters include, for example, U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 25 5,399,680; 5,268,463; and 5,608,142. See also, U.S. Patent No. 6,177,611 .

[0143] Examples of inducible promoters are the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, the PPDK promoter and the PEP (phosphoenol pyruvate) carboxylase promoter which are both inducible by 30 light. Also useful are promoters which are chemically inducible, such as the In2-2 promoter which is safener induced (U.S. Patent No. 5,364,780), the ERE promoter which is estrogen induced, and the Axig1 promoter which is auxin induced and tapetum specific but also active in callus (PCT International published application No. WO 02/04699). Other examples of

inducible promoters include the GVG and XVE promoters, which are induced by glucocorticoids and estrogen, respectively (U.S. Patent No. 6,452,068).

[0144] Examples of promoters under developmental control include promoters that initiate transcription preferentially in certain tissues, such as leaves, roots, fruit, seeds, or flowers. An exemplary promoter is the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051). Examples of seed-preferred promoters include, but are not limited to, 27 kD gamma zein promoter and waxy promoter (Boronat *et al.* (1986) *Plant Sci* 47:95-102; Reina *et al.* (1990) *Nucl Acids Res* 18(21):6426; Kloesgen *et al.* (1986) *Mol. Gen. Genet.* 203:237-244). Promoters that express in the embryo, pericarp, and endosperm are disclosed in U.S. Patent No. 6,225,529 and PCT International published application No. WO 00/12733.

[0145] In some embodiments it will be beneficial to express the gene from an inducible promoter, particularly from a pathogen-inducible promoter. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; *e.g.*, PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See, for example, Redolfi *et al.* (1983) *Neth. J. Plant Pathol.* 89:245-254; Uknnes *et al.* (1992) *Plant Cell* 4:645-656; and Van Loon (1985) *Plant Mol. Virol.* 4:111-116. See also PCT International published application No. WO 99/43819 .

[0146] Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau *et al.* (1987) *Plant Mol Biol* 9:335-342; Matton *et al.* (1989) *Molecular Plant-Microbe Interactions* 2:325-331; Somsisch *et al.* (1986) *Proc Natl Acad Sci USA* 83:2427-2430; Somsisch *et al.* (1988) *Mol Gen Genet* 2:93-98; and Yang (1996) *Proc Natl Acad Sci USA* 93:14972-14977. See also, Chen *et al.* (1996) *Plant J* 10:955-966; Zhang *et al.* (1994) *Proc Natl Acad Sci USA* 91:2507-2511; Warner *et al.* (1993) *Plant J* 3:191-201; Siebertz *et al.* (1989) *Plant Cell* 1:961-968; U.S. Patent No. 5,750,386 (nematode-inducible); and the references cited therein. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen *Fusarium moniliforme* (see, for example, Cordero *et al.* (1992) *Physiol Mol Plant Path* 41:189-200).

[0147] Additionally, as pathogens find entry into plants through wounds or insect damage, a wound-inducible promoter may be used in the constructions of the polynucleotides. Such wound-inducible promoters include potato proteinase inhibitor (pin II) gene (Ryan (1990) *Ann Rev Phytopath* 28:425-449; Duan *et al.* (1996) *Nature Biotech* 14:494-498); wun1 and wun2, U.S. Patent No. 5,428,148; win1 and win2 (Stanford *et al.* (1989) *Mol Gen Genet* 215:200-208);

systemin (McGurl *et al.* (1992) *Science* 225:1570-1573); WIP1 (Rohmeier *et al.* (1993) *Plant Mol Biol* 22:783-792; Eckelkamp *et al.* (1993) *FEBS Lett* 323:73-76); MPI gene (Corderok *et al.* (1994) *Plant J* 6(2):141-150).

[0148] Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-1a promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena *et al.* (1991) *Proc Natl Acad Sci USA* 88:10421-10425 and McElllis *et al.* (1998) *Plant J* 14(2):247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz *et al.* (1991) *Mol Gen Genet* 227:229-237, and U.S. Patent Nos. 5,814,618 and 5,789,156).

[0149] Tissue-preferred promoters can be utilized to target enhanced expression of a sequence of interest within a particular plant tissue. Tissue-preferred promoters include Yamamoto *et al.* (1997) *Plant J* 12(2):255-265; Kawamata *et al.* (1997) *Plant Cell Physiol* 38(7):792-803; Hansen *et al.* (1997) *Mol Gen Genet* 254(3):337-343; Russell *et al.* (1997) *Transgenic Res* 6(2):157-168; Rinehart *et al.* (1996) *Plant Physiol* 112(3):1331-1341; Van Camp *et al.* (1996) *Plant Physiol* 112(2):525-535; Canevascini *et al.* (1996) *Plant Physiol* 112(2):513-524; Yamamoto *et al.* (1994) *Plant Cell Physiol* 35(5):773-778; Lam (1994) *Results Probl Cell Differ* 20:181-196; Orozco *et al.* (1993) *Plant Mol Biol* 23(6):1129-1138; Matsuoka *et al.* (1993) *Proc Natl Acad Sci USA* 90(20):9586-9590; and Guevara-Garcia *et al.* (1993) *Plant J* 4(3):495-505. Such promoters can be modified, if necessary, for weak expression.

[0150] Leaf-preferred promoters are known in the art. See, for example, Yamamoto *et al.* (1997) *Plant J* 12(2):255-265; Kwon *et al.* (1994) *Plant Physiol* 105:357-67; Yamamoto *et al.* (1994) *Plant Cell Physiol* 35(5):773-778; Gotor *et al.* (1993) *Plant J* 3:509-18; Orozco *et al.* (1993) *Plant Mol Biol* 23(6):1129-1138; and Matsuoka *et al.* (1993) *Proc Natl Acad Sci USA* 90(20):9586-9590. In addition, the promoters of cab and RUBISCO can also be used. See, for

example, Simpson *et al.* (1958) *EMBO J* 4:2723-2729 and Timko *et al.* (1988) *Nature* 318:57-58.

[0151] Root-preferred promoters are known and can be selected from the many available from the literature or isolated de novo from various compatible species. See, for example, Hire *et al.* (1992) *Plant Mol Biol* 20(2):207-218 (soybean root-specific glutamine synthetase gene); Keller and Baumgartner (1991) *Plant Cell* 3(10):1051-1061 (root-specific control element in the GRP 1.8 gene of French bean); Sanger *et al.* (1990) *Plant Mol Biol* 14(3):433-443 (root-specific promoter of the mannopine synthase (MAS) gene of *Agrobacterium tumefaciens*); and Miao *et al.* (1991) *Plant Cell* 3(1):11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of soybean). See also Bogusz *et al.* (1990) *Plant Cell* 2(7):633-641, where two root-specific promoters isolated from hemoglobin genes from the nitrogen-fixing nonlegume *Parasponia andersonii* and the related non-nitrogen-fixing nonlegume *Trema tomentosa* are described. The promoters of these genes were linked to a β -glucuronidase reporter gene and introduced into both the nonlegume *Nicotiana tabacum* and the legume *Lotus corniculatus*, and in both instances root-specific promoter activity was preserved. Leach and Aoyagi ((1991) *Plant Science* (Limerick) 79(1):69-76) describe their analysis of the promoters of the highly expressed rolC and rolD root-inducing genes of *Agrobacterium rhizogenes*. They concluded that enhancer and tissue-preferred DNA determinants are dissociated in those promoters. Teeri *et al.* ((1989) *EMBO J* 8(2):343-350) used gene fusion to lacZ to show that the *Agrobacterium* T-DNA gene encoding octopine synthase is especially active in the epidermis of the root tip and that the TR2' gene is root specific in the intact plant and stimulated by wounding in leaf tissue, an especially desirable combination of characteristics for use with an insecticidal or larvicidal gene. The TR1' gene, fused to nptII (neomycin phosphotransferase II) showed similar characteristics. Additional root-preferred promoters include the VfENOD-GRP3 gene promoter (Kuster *et al.* (1995) *Plant Mol Biol* 29(4):759-772); and rolB promoter (Capana *et al.* (1994) *Plant Mol Biol* 25(4):681-691. See also U.S. Patent Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179. The phaseolin gene (Murai *et al.* (1983) *Science* 23:476-482 and Sengupta-Gopalan *et al.* (1988) *Proc Natl Acad Sci USA* 82:3320-3324.

[0152] Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, *i.e.*, monocot or dicot, targeted for transformation. Suitable methods of introducing the DNA construct include microinjection (Crossway *et al.* (1986) *Biotechniques* 4:320-334; and U.S. Patent No. 6,300,543), sexual

crossing, electroporation (Riggs *et al.* (1986) *Proc Natl Acad Sci USA* 83:5602-5606), Agrobacterium-mediated transformation (Townsend *et al.*, U.S. Pat No. 5,563,055; and U.S. Patent No. 5,981,840), direct gene transfer (Paszkowski *et al.* (1984) *EMBO J* 3:2717-2722), and ballistic particle acceleration (see, for example, U.S. Patent No. 4,945,050; U.S. Patent No. 5,879,918; U.S. Patent No. 5,886,244; U.S. Patent No. 5,932,782; Tomes *et al.* (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in *Plant Cell, Tissue, and Organ Culture: Fundamental Methods*, ed. Gamborg and Phillips (Springer-Verlag, Berlin); and McCabe *et al.* (1988) *Biotechnology* 6:923-926). Also see Weissinger *et al.* (1988) *Ann Rev Genet* 22:421-477; Sanford *et al.* (1987) *Particulate Science and Technology* 5:27-37 (onion); Christou *et al.* (1988) *Plant Physiol* 87:671-674 (soybean); Finer and McMullen (1991) *In Vitro Cell Dev Biol* 27P:175-182 (soybean); Singh *et al.* (1998) *Theor Appl Genet* 96:319-324 (soybean); Datta *et al.* (1990) *Biotechnology* 8:736-740 (rice); Klein *et al.* (1988) *Proc Natl Acad Sci USA* 85:4305-4309 (maize); Klein *et al.* (1988) *Biotechnology* 6:559-563 (maize); U.S. Patent No. 5,240,855; U.S. Patent No. 5,322,783; U.S. Patent No. 5,324,646; Klein *et al.* (1988) *Plant Physiol* 91:440-444 (maize); Fromm *et al.* (1990) *Biotechnology* 8:833-839 (maize); Hooykaas-Van Slogteren *et al.* (1984) *Nature* 311:763-764; U.S. Patent No. 5,736,369 (cereals); Bytebier *et al.* (1987) *Proc Natl Acad Sci USA* 84:5345-5349 (Liliaceae); De Wet *et al.* (1985) in *The Experimental Manipulation of Ovule Tissues*, ed. Chapman *et al.* (Longman, New York), pp. 197-209 (pollen); Kaepler *et al.* (1990) *Plant Cell Reports* 9:415-418 and Kaepler *et al.* (1992) *Theor Appl Genet* 84:560-566 (whisker-mediated transformation); D'Halluin *et al.* (1992) *Plant Cell* 4:1495-1505 (electroporation); Li *et al.* (1993) *Plant Cell Reports* 12:250-255 and Christou and Ford (1995) *Annals of Botany* 75:407-413 (rice); Osjoda *et al.* (1996) *Nature Biotechnology* 14:745-750 (maize via *Agrobacterium tumefaciens*); and U.S. Patent No. 5,736,369 (meristem transformation).

[0153] The nucleotide constructs may be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve incorporating a nucleotide construct of the invention within a viral DNA or RNA molecule. Further, it is recognized that useful promoters encompass promoters utilized for transcription by viral RNA polymerases. Methods for introducing nucleotide constructs into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, U.S. Patent Nos. 5,889,191, 5,889,190, 5,866,785, 5,589,367 and 5,316,931.

[0154] In some embodiments, transient expression may be desired. In those cases, standard transient transformation techniques may be used. Such methods include, but are not limited to viral transformation methods, and microinjection of DNA or RNA, as well other methods well known in the art.

5 [0155] The cells from the plants that have stably incorporated the nucleotide sequence may be grown into plants in accordance with conventional ways. See, for example, McCormick *et al.* (1986) *Plant Cell Reports* 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression of the desired phenotypic characteristic imparted by the nucleotide sequence of interest and/or the genetic markers contained within the target site or transfer cassette. Two or 10 more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved.

15 [0156] Initial identification and selection of cells and/or plants comprising the DNA constructs may be facilitated by the use of marker genes. Gene targeting can be performed without selection if there is a sensitive method for identifying recombinants, for example if the targeted gene modification can be easily detected by PCR analysis, or if it results in a certain phenotype. However, in most cases, identification of gene targeting events will be facilitated by the use of markers. Useful markers include positive and negative selectable markers as well as 20 markers that facilitate screening, such as visual markers. Selectable markers include genes carrying resistance to an antibiotic such as spectinomycin (e.g. the aada gene, Svab *et al.* (1990) *Plant Mol Biol* 14:197-205), streptomycin (e.g., aada, or SPT, Svab *et al.* (1990) *Plant Mol Biol* 14:197-205; Jones *et al.* (1987) *Mol Gen Genet* 210:86), kanamycin (e.g., nptII, Fraley *et al.* (1983) *Proc Natl Acad Sci USA* 80:4803-4807), hygromycin (e.g., HPT, Vanden Elzen *et al.* 25 (1985) *Plant Mol Biol* 5:299), gentamycin (Hayford *et al.* (1988) *Plant Physiol* 86:1216), phleomycin, zeocin, or bleomycin (Hille *et al.* (1986) *Plant Mol Biol* 7:171), or resistance to a herbicide such as phosphinothricin (bar gene), or sulfonylurea (acetolactate synthase (ALS)) (Charest *et al.* (1990) *Plant Cell Rep* 8:643), genes that fulfill a growth requirement on an incomplete media such as HIS3, LEU2, URA3, LYS2, and TRP1 genes in yeast, and other such 30 genes known in the art. Negative selectable markers include cytosine deaminase (codA) (Stougaard (1993) *Plant J.* 3:755-761), tms2 (DePicker *et al.* (1988) *Plant Cell Rep* 7:63-66), nitrate reductase (Nussame *et al.* (1991) *Plant J* 1:267-274), SU1 (O'Keefe *et al.* (1994) *Plant Physiol.* 105:473-482), aux-2 from the Ti plasmid of Agrobacterium, and thymidine kinase.

Screenable markers include fluorescent proteins such as green fluorescent protein (GFP) (Chalfie *et al.* (1994) *Science* 263:802; US 6,146,826; US 5,491,084; and WO 97/41228), reporter enzymes such as β -glucuronidase (GUS) (Jefferson (1987) *Plant Mol Biol Rep* 5:387; U.S. Patent No. 5,599,670; U.S. Patent No. 5,432,081), β -galactosidase (lacZ), alkaline phosphatase (AP), glutathione S-transferase (GST) and luciferase (U.S. Patent No. 5,674,713; Ow *et al.* (1986) *Science* 234:856-859), visual markers like anthocyanins such as CRC (Ludwig *et al.* (1990) *Science* 247:449-450) R gene family (e.g. Lc, P, S), A, C, R-nj, body and/or eye color genes in *Drosophila*, coat color genes in mammalian systems, and others known in the art.

5 [0157] One or more markers may be used in order to select and screen for gene targeting events. One common strategy for gene disruption involves using a target modifying polynucleotide in which the target is disrupted by a promoterless selectable marker. Since the selectable marker lacks a promoter, random integration events are unlikely to lead to transcription of the gene. Gene targeting events will put the selectable marker under control of the promoter for the target gene. Gene targeting events are identified by selection for expression 10 of the selectable marker. Another common strategy utilizes a positive-negative selection scheme. This scheme utilizes two selectable markers, one that confers resistance (R+) coupled with one that confers a sensitivity (S+), each with a promoter. When this polynucleotide is randomly inserted, the resulting phenotype is R+/S+. When a gene targeting event is generated, the two markers are uncoupled and the resulting phenotype is R-/S-. Examples of using 15 positive-negative selection are found in Thykjaer *et al.* (1997) *Plant Mol Biol* 35:523-530; and PCT International published application No. WO 01/66717.

20 [0158] The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. See, e.g., Maniatis *et al.* (1982) *Molecular Cloning* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Sambrook *et al.* (1989) *Molecular Cloning*, 2nd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Sambrook and 25 Russell (2001) *Molecular Cloning*, 3rd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Ausubel *et al.* (1992) *Current Protocols in Molecular Biology* (John Wiley & Sons, including periodic updates); Glover (1985) *DNA Cloning* (IRL Press, Oxford); Anand 30 (1992) *Techniques for the Analysis of Complex Genomes* (Academic Press); Guthrie and Fink

(1991) *Guide to Yeast Genetics and Molecular Biology* (Academic Press); Harlow and Lane (1988) *Antibodies*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Jakoby and Pastan, eds. (1979) "Cell Culture" *Methods in Enzymology* Vol. 58 (Academic Press, Inc., Harcourt Brace Jovanovich (NY)); *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Transcription And Translation* (B. D. Hames & S. J. Higgins eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Riott, *Essential Immunology*, 6th Edition, Blackwell Scientific Publications, Oxford, 1988; Hogan et al., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986); Westerfield, M., *The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio)*, (4th Ed., Univ. of Oregon Press, Eugene, 2000); *Methods in Arabidopsis Research* (C. Koncz et al., eds, World Scientific Press, Co., Inc., River Edge, Minnesota, 1992); *Arabidopsis: A Laboratory Manual* (D. Weigel and J. Glazebrook, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2002).

20

EXAMPLES

[0159] The following are non-limiting examples intended to illustrate the invention. Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims. For example, any of the pre-miRNAs and miRNAs described herein can be used in place of the pre-miRNAs and miRNAs used in the examples. Examples 1-15 are derived from PCT International published application Nos. WO 2005/052170 and WO 2005/035769 and from U.S. published application Nos. US 2005/0138689 and US 2005/0120415.

30

EXAMPLE 1

[0160] The example describes the identification of a microRNA

[0161] The following experiments are carried out on the *Arabidopsis thaliana* Col-0 ecotype. Plants are grown in long days (16 h light, 8 h dark) under cool white light at 22° C.

[0162] *Arabidopsis* plants are transformed by a modified version of the floral dip method, in which Agrobacterium cell suspension is applied to plants by direct watering from above. The T-DNA vector used, pHsbarENDs, contained four copies of the CAMV 35S enhancer adjacent to the right border, an arrangement similar to that described by Weigel *et al.* (*Plant Physiol.* 122:1003-1013, 2000). Transformed plants are selected with glufosinate (BASTA) and screened for flowering time, which resulted in the identification of the early-flowering EAT-D mutant. A single T-DNA cosegregating with early flowering is identified in EAT-D, and TAIL-PCR is performed to amplify sequences adjacent to the left and right borders of the T-DNA. To identify transcripts upregulated in the EAT-D mutant, Northern blots containing RNA extracted from wild type (Col-0) and EAT-D plants is probed. Probes for the genes At5g04270 and At5g04280 (GenBank NC_003076) do not detect any difference between wild type and EAT-D, whereas a probe from the intergenic region identifies an ~1.4 kb transcript that is expressed at significantly higher levels in EAT-D than in wild type.

[0163] To isolate the full-length EAT cDNA, 5'- and 3'-RACE-PCR is performed with a GeneRacer kit (Invitrogen) that selects for 5'-capped mRNAs. Reverse transcription is carried out using an oligo-dT primer, and PCR utilized a gene-specific primer (SEQ ID NO:45 5'-CTGTGCTCACGATCTTGTCTTGATC-3') paired with the 5' kit primer, or a second gene-specific primer (SEQ ID NO:46 5'- GTCGGCGGATCCATGGAAGAAAGCTCATC-5') paired with the 3' kit primer.

[0164] The *Arabidopsis* EAT-D (Early Activation Tagged - Dominant) mutant is identified in an activation tagging population (Weigel *et al.* (2000) *Plant Physiol.* 122:1003-1013). As evidenced by visual inspection and by measuring rosette leaf number (Table 2), the EAT-D mutant flowers extremely early. In addition, EAT-D displays floral defects that are virtually identical to those observed for strong *apetala2* (ap2) mutant alleles (Bowman *et al.* (1991) *Development* 112:1-20), including the complete absence of petals and the transformation of sepals to carpels. This ap2-like phenotype is only observed in EAT-D homozygotes, whereas both EAT-D heterozygotes and homozygotes are early flowering, indicating that the flowering time phenotype is more sensitive to EAT-D dosage than the ap2-like floral phenotype.

TABLE 2

Rosette leaf numbers for *Arabidopsis* lines

Genotype	rosette leaf no.	floral phenotype
Col-0	11.4 +/- 1.2	wild type
EAT-D	3.1 +/- 0.8	ap2
EAT-OX	2.0 +/- 0.2	ap2 + additional
eatdel	11.1 +/- 1.1	wild type
miR172a1-OX	2.1 +/- 0.3	ap2 + additional
LAT-D	22.5 +/- 2.1	wild type
At2g28550-OX	28.6 +/- 3.6	wild type
5-60120	10.2 +/- 1.4	wild type
2-28550	8.7 +/- 0.6	wild type
5-60120; 2-28550	6.0 +/- 0.8	wild type

[0165] The activation-tagged T-DNA insert in EAT-D is mapped to chromosome 5, in between the annotated genes At5g04270 and At5g04280. 5'- and 3'-RACE PCR is then used with primers located within this region to identify a 1.4 kb transcript (SEQ ID NO:1), which is named EAT, that is upregulated in EAT-D. When the 1.4 kb EAT cDNA is fused to the constitutive CAMV 35S promoter and the resultant 35S::EAT construct is introduced into wild type (Col-0) plants by Agrobacterium-mediated transformation (Clough and Bent (1998) *Plant J* 16:735-743), the 35S::EAT transformants display the identical early-flowering and ap2-like phenotypes seen for EAT-D (Table 1). Many of the 35S::EAT transformants occasionally display additional defects, including stigmatic papillae on cauline leaf margins and the formation of a complete or partial flower rather than a secondary inflorescence in the axils of cauline leaves. Ectopic expression of the EAT gene in 35S::EAT plants, therefore, affects both flowering time and the specification of floral organ identity.

[0166] The EAT gene produces a 1417-nucleotide noncoding RNA that is predicted to be 5'-capped and polyadenylated, based on the RACE-PCR methodology. BLASTN and BLASTX searches of several databases with the EAT cDNA do not reveal extensive nucleotide or predicted amino acid sequence identity between EAT and any other gene. However, a 21-nucleotide (nt) (SEQ ID NO:4) stretch in the middle of the EAT transcript is identified that is identical to miR172a-2, a recently identified miRNA (Park *et al.* (2002) *Curr Biol* 12:1484-1495). To confirm the functional importance of the miR172a-2 sequence within the EAT cDNA, a mutant form of EAT is generated in which the miR172a-2 sequence is deleted, and a construct consisting of this mutant EAT cDNA, eatdel, is made driven by the 35S promoter.

Transgenic plants carrying this 35S::eatdel construct flower with the same number of leaves as wild-type and had normal flowers (Table 1), indicating that the miR172a-2 sequence is necessary to confer both the flowering time and floral organ identity phenotypes seen in EAT-overexpressing lines.

5 [0167] As noted by Park *et al.* (2002) *Curr Biol* 12:1484-1495), the 21-nt miR172a-2 miRNA has the potential to form an RNA duplex with a sequence near the 3' end of the coding region of AP2 (Table 3).

TABLE 3

10 Putative 21-nt miR172a-2/AP2 RNA duplex

Sequence	Duplex	SEQ ID NO:
AP2 RNA	5'- <u>CUGCAGCAUCAUCAGGAUUCU</u> -3'	47
EAT miRNA	3'- <u>UACGUCGUAGUAGU</u> <u>UCUAAGA</u> -5'	48

The GU wobble in the duplex is underlined.

15 [0168] This particular region of the AP2 gene is poorly conserved at the nucleotide level among the AP2 family; nevertheless, the AP2 sequence (SEQ ID NO:49) that is complementary to miR172a-2 is found in a similar location in three other *Arabidopsis* AP2 family members, At5g60120 (SEQ ID NO:50), At2g28550 (SEQ ID NO:51), At5g67180 (SEQ ID NO:52). In addition, the sequence can be found at the corresponding positions of the maize AP2 genes indeterminate spikelet1 (Chuck *et al.* (1998) *Genes Dev* 12:1145-1154) (IDS1 (SEQ ID NO:53)) and glossy15 (Moose and Sisco (1996) *Genes Dev* 10:3018-3027) (GL15 (SEQ ID NO:54)), and 20 in AP2 family members from many other plant species, including soybean, rice, wheat, tomato and pea (not shown). The alignment of three *Arabidopsis* and two maize AP2 family members is shown in Table 4 below.

TABLE 4

25 Alignment of AP2 21-nt region (black bar) and surrounding sequence (SEQ ID NO:)

AP2	ACCAAGTGGTACAAATGCTGCAGCATCATCAGGATTCTCTCCTCATCATCACAAATCAG	(49)
At5g60120	CACCGCCACTGTTTCAAATGCAGCATCATCAGGATTCTCACTCTCAGCTACACGCCCT	(50)
At2g28550	CACCATTGTTCTCAGTTGCAGCAGCATCATCAGGATTCTCACATTCCGGCCACAACCT	(51)
At5g67180	GAAATCGAGTGGTGGGAATGGCAGCATCATCAGGATTCTCTCCTCAACCTTCCCCTTAC	(52)
IDS1	ACGTGCCGTTGCACCACTCTGCAGCATCATCAGGATTCTACCGCCGCCGGGGCAAC	(53)
GL15	ACGCCAGCAGCGCCGCCGCTGCAGCATCATCAGGATTCCCACGTGGCAGCTGGGTGCG	(54)

[0169] There is an additional copy of the miR172a-2 miRNA in the *Arabidopsis* genome on chromosome 2 (miR172a-1, Fig. 2d), and miR172a-2 is highly similar to three other *Arabidopsis* loci. Like the miR172a-2 miRNA, all four reiterations of the sequence are in intergenic regions, *i.e.* in between the *Arabidopsis* genes currently annotated in GenBank. In addition, the sequence 5 is found in ESTs from tomato, potato and soybean, and four copies were found in the genomic sequence of rice.

EXAMPLE 2

[0170] This example describes the construction of expression vectors
10 [0171] To overexpress the EAT gene, primers containing XhoI sites (SEQ ID NO:55 5'-GACTACTCGAGCACCTCTCACTCCCTTCTCTAAC-3' and SEQ ID NO:56 5'-GACTACTCGAGGTTCTCAAGTTGAGCAGTTGAAAAC-3') are designed to amplify the entire EAT gene from Col-0 DNA. The PCR product is digested with XhoI and inserted into a modified pBluescriptSK+ vector (Stratagene, La Jolla, CA) that lacked BamHI and HindIII sites, 15 to generate EATX4 (SEQ ID NO:44). To generate the 35S::EAT transformants, the XhoI-cut EAT gene is inserted into the binary vector pBE851 in between a CAMV 35S promoter and b-phaseolin terminator, and Col-0 was transformed by floral dip. To generate the eatdel construct, two oligonucleotides are synthesized (SEQ ID NO:57 5'-GATCCATGGAAGAAAGCTCAT 20 CTGTCGTTGTTGTAGGCGCAGCACCATTAGATTACATGGAAATTGATAAAATAC-3' and SEQ ID NO:58 5'-CCTAAATTAGGGTTTGATATGTATATTCAACAAATCGACG GCTACAAATACCTAA-3') that completely recreated the BamHI/HindIII fragment of the EAT cDNA except that it lacked the 21 nt miR172a-2 sequence located within the fragment. These 25 two oligos are annealed to their synthesized complementary strands (SEQ ID NO:59 5'-TAG GGTATTATCAATTCCATGTGAATCTTAATGGTGCTGCGCCTACAAACAAACGACAG ATGAGCTTCTTCCATG-3' and SEQ ID NO:60 5'-AGCTTGTAGGTATTGTAGCCGTC GATTGTTGAATATACATATCAAAACCCCTAATT-3') and ligated to EATX4 that had been 30 digested with BamHI and HindIII, in a trimolecular ligation reaction. This resulted in the replacement of 159 bp of wild-type EAT sequence with the 138 bp mutant sequence. The eatdel cDNA is then subcloned into pBE851 and transformed as described above. BASTA is used to select in plants for both the EAT and eatdel overexpression constructs.

[0172] To test whether another member of the miR172 family, miR172a-1, would confer a phenotype similar to that of miR172a-2, a construct containing the 35S promoter fused to the genomic region surrounding miR172a-1 is generated. Plants containing the 35S::miR172a-1

construct flower early and display an *ap2* phenotype (Table 1), indicating that miR172a-1 behaves in an identical manner to miR172a-2 when overexpressed.

[0173] All of the miR172 miRNA family members are located within a sequence context that allows an RNA hairpin to form (Figure 1). Presumably this hairpin is the substrate which is subsequently cleaved by a plant Dicer homolog to generate the mature miRNA. The location of the miRNA within the hairpin, *i.e.* on the 3' side of the stem, is conserved amongst all the members of the miR172 family, and this may reflect a structural requirement for processing of this particular miRNA family. The 21-nt miR172a-2 miRNA, therefore, is predicted to be a member of a family of miRNAs that have the capacity to regulate a subset of AP2 genes by forming an RNA duplex with a 21-nt cognate sequence in these genes.

EXAMPLE 3

[0174] The example describes the analysis of microRNA expression and AP2 expression

[0175] Total RNA is isolated from wild type and EAT-D whole plants that had already flowered, using TRIZOL reagent (Sigma). 50 mg of each RNA is subjected to electrophoresis on a 15% TBE-Urea Criterion gel (BioRad), electroblotted onto Hybond-N+ filter paper (Amersham) using a TransBlot-SD apparatus (BioRad). The filter is then hybridized at 37° C overnight in UltraHyb-Oligo buffer (Ambion) with 32P-labeled oligos. The oligos are 30-mers that corresponded to either the sense or antisense strands of the miR172a-2 miRNA, with 4-5 nt of flanking sequence on each side. The filter is washed twice at 37°C, in buffer containing 2X SSC and 0.5% SDS. For S1 analysis, probe is made by end-labeling an oligo (SEQ ID NO:61) (5'-ATGCAGCATCATCAAGATTCTCATATACAT-3') with T4 polynucleotide kinase and 32P. Hybridization and processing of S1 reactions are carried out using standard protocols. For developmental analysis of miR172a-2 and miR172a-1, total RNA is isolated from plants at the various stages and tissues indicated in Example 4, using an Rneasy kit (Qiagen). RT-PCR is carried out using standard protocols, and utilized oligos specific for sequences adjacent to miR172a-2 (SEQ ID NO:62) (5'-GTCGGCGGATCCATGG AAGAAAGCTCATC-3' and (SEQ ID NO:63) 5'-CAAAGATCGATCCAGACTTCAATCAA TATC-3') or sequences adjacent to miR172a-1 (SEQ ID NO:64) (5'-TAATTCCGGAGCCAC GGTCGTTGTTG-3' and (SEQ ID NO:65) 5'-AATAGTCGTTGATTGCCGATGCAGCATT-3'). Oligos used to amplify the ACT11 (Actin) transcript were: (SEQ ID NO:66) 5'-ATGGCAGATGGTGAAGACATTCAAG-3', and (SEQ ID NO:67) 5'-GAAGCACTTCCTGTG GACTATTGATG-3'. RT-PCR analysis of AP2 is performed on RNA from floral buds, and

utilized the following oligos: (SEQ ID NO:68) 5'-TTTCCGGGCAGCAGAACATTGGTAG-3', and (SEQ ID NO:69) 5'-GTTCGCCTAACAGTTAACAAAGAGGGATTAGG-3'. Oligos used to amplify the ANT transcript are: (SEQ ID NO:70) 5'-GATCAACTCAATGACTAACTCTG GTTTTC-3', and (SEQ ID NO:71) 5'-GTTATAGAGAGATTCTGTTCACATG-3'.

5 [0176] Immunoblot analysis of AP2 is performed on proteins extracted from floral buds. Following electrophoresis on a 10% SDS-PAGE gel, proteins are transferred to a Hybond-P membrane (Amersham) and incubated with an antibody specific for AP2 protein (aA-20, Santa Cruz Biotechnology). The blot is processed using an ECL-plus kit (Amersham).

10 [0177] Northern analysis using probes both sense and antisense to the miR172a-2 miRNA identifies a small single-stranded RNA of 21-25 nucleotides accumulating to much higher levels in EAT-D mutant plants relative to wild type. The small amount of transcript seen in wild type presumably represents endogenous levels of not only the miR172a-2 miRNA but also its family members, which are similar enough to cross-hybridize with the probe. The predicted miR172a-2 hairpin is 117 nt in length (Fig. 1), a small amount of an ~100 nt transcript accumulating is 15 detected in EAT-D, this likely represents partially processed miR172a-2 hairpin precursor. S1 nuclease mapping of the miR172a-2 miRNA provides independent confirmation of the 5' end of miR172a-2 reported by Park *et al.* ((2002) *Curr Biol* 12:1484-1495).

EXAMPLE 4

20 [0178] The example describes the developmental pattern of EAT miRNA expression.

[0179] To address the wild-type expression pattern of miR172a-2 separate from its other *Arabidopsis* family members, RT-PCR is used to specifically detect a fragment of the 1.4 kb EAT full-length precursor transcript containing miR172a-2. EAT precursor transcript expression is temporally regulated, with little or no transcript detected two days after germination, and progressively more steady-state transcript accumulation seen as the plant approaches flowering. The precursor transcript of miR172a-1 shows a similar temporal pattern of expression. Both miR172a-2 and miR172a-1 precursor transcripts continue to be expressed after flowering has occurred, and accumulate in both leaves and floral buds. Expression of the precursors for the other miR172 family members is not detected, perhaps due to their exclusive expression in tissue types not included in this analysis, or because their precursor transcripts are too transient to detect. The temporal expression pattern seen for miR172a-2 and miR172a-1 is reminiscent of that observed for let-7 and lin-4, two miRNAs that control developmental timing

in *C. elegans* (Feinbaum and Ambros (1999) *Dev Biol* 210:87-95; Reinhart *et al.* (2000) *Nature* 403:901-906).

EXAMPLE 5

5 [0180] The levels of miR172 in various flowering time mutants are assessed, in an attempt to position miR172 within the known flowering time pathways. The levels of miR172 are not altered in any of the mutants tested, and the levels of the EAT transcript are identical in plants grown in long days versus plants grown in short days.

10

EXAMPLE 6

[0181] The example describes evaluation of protein expression
[0182] Immunoblot analysis indicates that AP2 protein is reduced 3.5-fold in the EAT-D mutant relative to wild type, whereas the AP2 transcript is unaffected. This data suggests that the miR172a-2 miRNA negatively regulates AP2 by translational inhibition. The predicted near-perfect complementarity between the miR172a-2 miRNA and the AP2 target site would be predicted to trigger AP2 mRNA cleavage by the RNA interference (RNAi) pathway (Llave *et al.* (2002) *Plant Cell* 14:1605-1619; Hutvagner and Zamore (2002) *Science* 297:2056-2060). Indeed, others have proposed that many plant miRNAs enter the RNAi pathway exclusively due to their near-perfect complementarity to putative targets (Rhoades *et al.* (2002) *Cell* 110:513 - 520). While there is no evidence regarding the GU wobble base pair in the predicted miR172a-2/AP2 RNA duplex, it is conserved in all predicted duplexes between miR172 family members and their AP2 targets. Regardless of the mechanism, it is apparent from the AP2 expression data and the observed phenotype of EAT-D that AP2 is a target of negative regulation by miR172a-2, at least when miR172a-2 is overexpressed.

25

EXAMPLE 7

[0183] In the same genetic screen that identified the early-flowering EAT-D mutant, an activation-tagged late-flowering mutant, called LAT-D, is identified. The LAT-D mutant displays no additional phenotypes besides late flowering (Table 1), and the late-flowering phenotype cosegregates with a single T-DNA insertion. Sequence analysis of the T-DNA insert in LAT-D indicates that the 4X 35S enhancer is located approximately 5 kb upstream of At2g28550, which is one of the AP2-like target genes that are potentially regulated by miR172. RT-PCR analysis using primers specific for At2g28550 indicates that the transcript

corresponding to this gene is indeed expressed at higher levels in the LAT-D mutant relative to wild type. To confirm that overexpression of At2g28550 causes late flowering, a genomic region containing the entire At2g28550 coding region (from start to stop codon) is fused to the 35S promoter, and transgenic plants containing this construct are created. Transgenic 5 35S::At2g28550 plants flower later than wild type plants, and are slightly later than the LAT-D mutant (Table 1). This late flowering phenotype is observed in multiple independent transformants.

[0184] The fact that overexpression of At2g28550 causes late flowering suggests that miR172 promotes flowering in part by downregulating At2g28550. However, because miR172 0 appears to affect protein rather than transcript accumulation of its target genes, and because there is not an antibody to the At2g28550 gene product, this regulation is tested indirectly via a genetic cross. A plant heterozygous for LAT-D is crossed to a plant homozygous for EAT-D, such that all F1 progeny would contain one copy of EAT-D and 50% of the F1 progeny would also have one copy of LAT-D. F1 progeny are scored for the presence or absence of the LAT-D 5 allele by PCR, and also are scored for flowering time. All of the F1 plants are early flowering, regardless of whether or not they contained a copy of the LAT-D allele, indicating that EAT-D is epistatic to LAT-D. This result is consistent with the idea that miR172a-2, which is overexpressed in EAT-D, directly downregulates At2g28550, which is overexpressed in LAT-D.

10

EXAMPLE 8

[0185] To assess the effects of reducing At2g28550 function, plants containing a T-DNA insertion in the At2g28550 gene are identified. In addition, a T-DNA mutant for At2g60120, a closely related AP2-like gene that also contains the miR172 target sequence, is identified. Plants homozygous for either the At2g28550 insert or the At5g60120 insert are slightly early 25 flowering relative to wild type (Table 1). The two mutants are crossed, and the double mutant is isolated by PCR genotyping. The At2g28550/At5g60120 double mutant is earlier flowering than either individual mutant (Table 1), suggesting that the genes have overlapping function. The early flowering phenotype of the At2g28550/At5g60120 double mutant is consistent with the idea that the early flowering phenotype of miR172-overexpressing lines is due to 30 downregulation of several AP2-like genes, including At2g28550 and At5g60120. Interestingly, the At2g28550/At5g60120 double mutant is not as early as miR172-overexpressing lines (c.f. EAT-OX, Table 1), which suggests that other AP2-like targets of miR172, for example AP2 itself or At5g67180, also contribute to flowering time control. Because ap2 mutants are not

early flowering, any potential negative regulation of flowering by AP2 must be normally masked by genetic redundancy.

EXAMPLE 9

5 [0186] This example describes a method of target selection and method to design DNA constructs to generate miRNAs using the constructs of SEQ ID NOS: 3 and 44. Any sequence of interest can be selected for silencing by miRNA generated using the following method:

10 [0187] 1. Choose a region from the coding strand in a gene of interest to be the target sequence. Typically, choose a region of about 10 – 50 nucleotides found in a similar location to the region targeted by EAT in AP2-like genes, which are regions about 100 nt upstream of the stop codon. The exact location of the target, however, does not appear to be critical. It is recommended to choose a region that has ~50% GC and is of high sequence complexity, *i.e.* no repeats or long polynucleotide tracts. It is also recommended that the chosen region ends with a 15 T or A, such that the complementary miRNA will start with an A or U. This is to help ensure a lower stability at the 5' end of the miRNA in its double-stranded Dicer product form (Schwartz, *et al.* (2003) *Cell* 115:199-208). For example, in the miR172a-2 precursor, the miRNA sequence starts with an A, and many other miRNAs start with a U.

20 [0188] 2. To use the construct of SEQ ID NO:3, create a 21 nucleotide sequence complementary to the 21 nt target region (miRNA). Optionally, change a C in the miRNA to a T, which will generate a GU wobble with the target sequence, which mimics the GU wobble seen in EAT.

25 [0189] 3. Create the 21 nucleotide "backside" sequence of the hairpin. This will be substantially complementary to the miRNA from step 2. Note, this backside sequence will also be substantially identical to the target sequence. Typically, introduce a few mismatches to make some bulges in the stem of the hairpin that are similar to the bulges in the original EAT hairpin. Optionally, introduce an A at the 3' end of the backside, to create mismatch at the 5' end of the 30 miRNA. This last step may help ensure lower stability at the 5' end of the miRNA in its double-stranded Dicer product form (Schwartz *et al.* (2003) *Cell* 115:199-208).

[0190] 4. Replace the 21 nucleotide miRNA sequence and the 21 nucleotide "backside" sequence in the EAT BamHI/HindIII DNA construct (SEQ ID NO:3) with the new miRNA and "backside" sequences from steps 2 and 3.

[0191] 5. Use MFOLD (GCG, Accelrys, San Diego, CA), or an equivalent program, to compare the new hairpin from Step 4 with the original hairpin. Generally, the sequence

substantially replicate the structure of the original hairpin (Figure 1). It is predicted that the introduced bulges need not be exactly identical in length, sequence or position to the original. Examine the miRNA sequence in the hairpin for the relative stability of the 5' and 3' ends of the predicted dsRNA product of Dicer.

5 [0192] 6. Generate four synthetic oligonucleotides of 76-77 nucleotides in length to produce two double-stranded fragments which comprise the BamHI and HindIII restriction sites, and a 4 nucleotide overhang to facilitate directional ligation which will recreate the BamHI/HindIII fragment. Design of the overhang can be done by one of skill in the art, the current example uses the 4 nucleotide region of positions 79-82 (CCTA) of SEQ ID NO:3. Hence, for example:

10 [0193] Oligo 1 will have an unpaired BamHI site at the 5' end, and will end with the nucleotide at position 78 of SEQ ID NO:3.

[0194] Oligo 2 will have the nucleotides of position 79-82 (CCTA) unpaired at the 5' end, and will terminate just before the HindIII site (or positions 151-154 in SEQ ID NO:3).

15 [0195] Oligo 3 will be essentially complementary to Oligo 1, (nucleotides 5-78 of SEQ ID NO:3), and will terminate with 4 nucleotides complementary to nucleotides 1-4 (CCTA) of Oligo 2.

[0196] Oligo 4 will be essentially complementary to Oligo 2 beginning at the nucleotide of position 5, and will terminate with the HindIII site at the 3' end.

20 [0197] Anneal the oligonucleotides to generate two fragments to be used in a subsequence ligation reaction with the plasmid sequence.

[0198] Optionally, two synthetic oligonucleotides comprising attB sequences can be synthesized and annealed to create an attB-flanked miRNA precursor that is then integrated into a vector using recombinational cloning (GATEWAY, InVitrogen Corp., Carlsbad, CA).

25 [0199] 7. Ligate the two DNA fragments from Step 6 in a trimolecular ligation reaction with a plasmid cut with BamHI/HindIII. The current example uses the modified pBluescript SK+ plasmid of SEQ ID NO:44, which comprises the 1.4kb EAT sequence of SEQ ID NO:1, digested with BamHI/HindIII and gel purified away from the small fragment using standard molecular biological techniques. The new designed miRNA to the gene of interest has replaced the previous miRNA.

30 [0200] If an attB-flanked sequence is used from Step 6, the BP and LR recombination reactions (GATEWAY, InVitrogen Corp., Carlsbad, CA) can be used to insert the modified hairpin into a destination vector comprising the full-length miR172a-2 precursor.

[0201] 8. The plasmid from Step 7, subject to any other preparations or modifications as needed, is used to transform the target organism using techniques appropriate for the target.

[0202] 9. Silencing of the target gene can be assessed using techniques well-known in the art, for example, Northern blot analysis, immunoblot analysis if the target gene of interest encodes a polypeptide, and any phenotypic screens relevant to the target gene, for example 5 flowering time, or floral morphology.

EXAMPLE 10

[0203] Described in this example are methods one may use for introduction of a 10 polynucleotide or polypeptide into a plant cell.

[0204] A. Maize particle-mediated DNA delivery

[0205] A DNA construct can be introduced into maize cells capable of growth on suitable maize culture medium. Such competent cells can be from maize suspension culture, callus 15 culture on solid medium, freshly isolated immature embryos or meristem cells. Immature embryos of the Hi-II genotype can be used as the target cells. Ears are harvested at approximately 10 days post-pollination, and 1.2-1.5mm immature embryos are isolated from the kernels, and placed scutellum-side down on maize culture medium.

[0206] The immature embryos are bombarded from 18-72 hours after being harvested from 20 the ear. Between 6 and 18 hours prior to bombardment, the immature embryos are placed on medium with additional osmoticum (MS basal medium, Musashige and Skoog (1962) *Physiol Plant* 15:473-497, with 0.25 M sorbitol). The embryos on the high-osmotic medium are used as the bombardment target, and are left on this medium for an additional 18 hours after bombardment.

[0207] For particle bombardment, plasmid DNA (described above) is precipitated onto 1.8 25 mm tungsten particles using standard CaCl₂- spermidine chemistry (see, for example, Klein *et al.* (1987) *Nature* 327:70-73). Each plate is bombarded once at 600 PSI, using a DuPont Helium Gun (Lowe *et al.* (1995) *Bio/Technol* 13:677-682). For typical media formulations used for maize immature embryo isolation, callus initiation, callus proliferation and regeneration of 30 plants, see Armstrong (1994) In *The Maize Handbook*, M. Freeling and V. Walbot, eds. Springer Verlag, NY, pp 663-671.

[0208] Within 1-7 days after particle bombardment, the embryos are moved onto N6-based culture medium containing 3 mg/l of the selective agent bialaphos. Embryos, and later callus,

are transferred to fresh selection plates every 2 weeks. The calli developing from the immature embryos are screened for the desired phenotype. After 6-8 weeks, transformed calli are recovered.

5 [0209] B. Soybean transformation

[0210] Soybean embryogenic suspension cultures are maintained in 35 ml liquid media SB196 or SB172 in 250 ml Erlenmeyer flasks on a rotary shaker, 150 rpm, 26C with cool white fluorescent lights on 16:8 hr day/night photoperiod at light intensity of 30-35 uE/m2s. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 ml of 10 fresh liquid media. Alternatively, cultures are initiated and maintained in 6-well Costar plates.

[0211] SB 172 media is prepared as follows: (per liter), 1 bottle Murashige and Skoog Medium (Duchefa # M 0240), 1 ml B5 vitamins 1000X stock, 1 ml 2,4-D stock (Gibco 11215-019), 60 g sucrose, 2 g MES, 0.667 g L-Asparagine anhydrous (GibcoBRL 11013-026), pH 5.7. SB 196 media is prepared as follows: (per liter) 10ml MS FeEDTA, 10ml MS Sulfate, 10ml FN-Lite Halides, 1 0ml FN-Lite P,B,Mo, 1ml B5 vitamins 1000X stock, 1 ml 2,4-D, (Gibco 11215-019), 2.83g KNO₃, 0.463g (NH₄)₂SO₄, 2g MES, 1g Asparagine Anhydrous, Powder (Gibco 11013-026), 1Og Sucrose, pH 5.8. 2,4-D stock concentration 10 mg/ml is prepared as follows: 2,4-D is solubilized in 0.1 N NaOH, filter-sterilized, and stored at -20°C. B5 vitamins 1000X stock is prepared as follows: (per 100 ml) - store aliquots at -20°C, 10 g myo-inositol, 100 mg 15 nicotinic acid, 100 mg pyridoxine HCl, 1 g thiamin.

[0212] Soybean embryogenic suspension cultures are transformed with various plasmids by the method of particle gun bombardment (Klein *et al.* (1987) *Nature* 327:70). To prepare tissue for bombardment, approximately two flasks of suspension culture tissue that has had approximately 1 to 2 weeks to recover since its most recent subculture is placed in a sterile 60 x 25 20 mm petri dish containing 1 sterile filter paper in the bottom to help absorb moisture. Tissue (*i.e.* suspension clusters approximately 3-5 mm in size) is spread evenly across each petri plate. Residual liquid is removed from the tissue with a pipette, or allowed to evaporate to remove excess moisture prior to bombardment. Per experiment, 4 - 6 plates of tissue are bombarded. Each plate is made from two flasks.

[0213] To prepare gold particles for bombardment, 30 mg gold is washed in ethanol, centrifuged and resuspended in 0.5 ml of sterile water. For each plasmid combination (treatments) to be used for bombardment, a separate micro-centrifuge tube is prepared, starting with 50 μ l of the gold particles prepared above. Into each tube, the following are also added;

5 $5\mu\text{l}$ of plasmid DNA (at $1\mu\text{g}/\mu\text{l}$), $50\mu\text{l}$ CaCl_2 , and $20\mu\text{l}$ 0.1 M spermidine. This mixture is agitated on a vortex shaker for 3 minutes, and then centrifuged using a microcentrifuge set at 14,000 RPM for 10 seconds. The supernatant is decanted and the gold particles with attached, precipitated DNA are washed twice with $400\mu\text{l}$ aliquots of ethanol (with a brief centrifugation as above between each washing). The final volume of 100% ethanol per each tube is adjusted to $40\mu\text{l}$, and this particle/DNA suspension is kept on ice until being used for bombardment.

10 [0214] Immediately before applying the particle/DNA suspension, the tube is briefly dipped into a sonicator bath to disperse the particles, and then $5\mu\text{L}$ of DNA prep is pipetted onto each flying disk and allowed to dry. The flying disk is then placed into the DuPont Biolistics PDS1000/HE. Using the DuPont Biolistic PDS1000/HE instrument for particle-mediated DNA delivery into soybean suspension clusters, the following settings are used. The membrane rupture pressure is 1100 psi. The chamber is evacuated to a vacuum of 27-28 inches of mercury. The tissue is placed approximately 3.5 inches from the retaining/stopping screen (3rd shelf from the bottom). Each plate is bombarded twice, and the tissue clusters are rearranged using a sterile spatula between shots.

15 [0215] Following bombardment, the tissue is re-suspended in liquid culture medium, each plate being divided between 2 flasks with fresh SB196 or SB172 media and cultured as described above. Four to seven days post-bombardment, the medium is replaced with fresh medium containing a selection agent. The selection media is refreshed weekly for 4 weeks and once again at 6 weeks. Weekly replacement after 4 weeks may be necessary if cell density and media turbidity is high.

20 [0216] Four to eight weeks post-bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated, green tissue is removed and inoculated into 6-well microtiter plates with liquid medium to generate clonally-propagated, transformed embryogenic suspension cultures.

25 [0217] Each embryogenic cluster is placed into one well of a Costar 6-well plate with 5mls fresh SB196 media with selection agent. Cultures are maintained for 2-6 weeks with fresh media changes every 2 weeks. When enough tissue is available, a portion of surviving transformed clones are subcultured to a second 6-well plate as a back-up to protect against contamination.

30 [0218] To promote in vitro maturation, transformed embryogenic clusters are removed from liquid SB196 and placed on solid agar media, SB 166, for 2 weeks. Tissue clumps of 2 - 4 mm size are plated at a tissue density of 10 to 15 clusters per plate. Plates are incubated in diffuse,

low light (< 10 μ E) at 26 +/- 1°C. After two weeks, clusters are subcultured to SB 103 media for 3 - 4 weeks.

[0219] SB 166 is prepared as follows: (per liter), 1 pkg. MS salts (Gibco/ BRL - Cat# 11117-017), 1 ml B5 vitamins 1000X stock, 60 g maltose, 750 mg MgCl₂ hexahydrate, 5 g activated charcoal, pH 5.7, 2 g gelrite. SB 103 media is prepared as follows: (per liter), 1 pkg. MS salts (Gibco/BRL - Cat# 11117-017), 1 ml B5 vitamins 1000X stock, 60 g maltose, 750 mg MgCl₂ hexahydrate, pH 5.7, 2 g gelrite. After 5-6 week maturation, individual embryos are desiccated by placing embryos into a 100 X 15 petri dish with a 1cm² portion of the SB103 media to create a chamber with enough humidity to promote partial desiccation, but not death.

[0220] Approximately 25 embryos are desiccated per plate. Plates are sealed with several layers of parafilm and again are placed in a lower light condition. The duration of the desiccation step is best determined empirically, and depends on size and quantity of embryos placed per plate. For example, small embryos or few embryos/plate require a shorter drying period, while large embryos or many embryos/plate require a longer drying period. It is best to check on the embryos after about 3 days, but proper desiccation will most likely take 5 to 7 days. Embryos will decrease in size during this process.

[0221] Desiccated embryos are planted in SB 71-1 or MSO medium where they are left to germinate under the same culture conditions described for the suspension cultures. When the plantlets have two fully-expanded trifoliate leaves, germinated and rooted embryos are transferred to sterile soil and watered with MS fertilizer. Plants are grown to maturity for seed collection and analysis. Healthy, fertile transgenic plants are grown in the greenhouse.

[0222] SB 71-1 is prepared as follows: 1 bottle Gamborg's B5 salts w/ sucrose (Gibco/BRL - Cat# 21153-036), 10 g sucrose, 750 mg MgCl₂ hexahydrate, pH 5.7, 2 g gelrite. MSO media is prepared as follows: 1 pkg Murashige and Skoog salts (Gibco 11117-066), 1 ml B5 vitamins 1000X stock, 30 g sucrose, pH 5.8, 2g Gelrite.

EXAMPLE 11

[0223] This example describes the design and synthesis of miRNA targets and hairpins directed to various gene targets found in maize, soy, and/or *Arabidopsis*, using the method described in Example 9.

[0224] A. Targeting *Arabidopsis* AGAMOUS, At4g18960

[0225] The miRNA sequence of SEQ ID NO:4 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 12-15, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

5 [0226] *Arabidopsis thaliana* Col-0 is transformed and grown as described in Example 1. After transformation with a vector comprising the miRNA of SEQ ID NO:4, 88% of the transformants exhibit a mutant AGAMOUS (*ag*) floral phenotype, characterized by the conversion of stamens to petals in whorl 3, and carpels to another *ag* flower in whorl 4 (Bowman, *et al.* (1991) *The Plant Cell* 3:749-758). The mutant phenotype varies between 10 transformants, with approximately 1/3 exhibiting a strong *ag* phenotype, 1/3 exhibiting an intermediate *ag* phenotype, and 1/3 exhibiting a weak *ag* phenotype. Gel electrophoresis and Northern Blot analysis of small RNAs isolated from the transformants demonstrates that the degree of the mutant *ag* phenotype is directly related to the level of antiAG miRNA, with the strongest phenotype having the highest accumulation of the processed miRNA (~ 21 nt).

15

[0227] B. Targeting *Arabidopsis* Apetala3 (AP3), At3g54340

[0228] Two miRNA targets from AP3 are selected and oligonucleotides designed.

20 [0229] The miRNA sequence of SEQ ID NO:5 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 16-19, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

[0230] The miRNA sequence of SEQ ID NO:6 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 20-23, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

25 [0231] *Arabidopsis thaliana* Col-0 is transformed and grown as described in Example 1. After transformation with a vector comprising the miRNA of SEQ ID NO:5, the transformants have novel leaf and floral phenotypes, but do not exhibit any mutant AP3 phenotype. Gel electrophoresis and Northern analysis of RNA isolated from 2 week old rosette leaf tissue from the transformants demonstrates that the highest accumulation of the processed miRNA (~ 21 nt) corresponds to the “backside” strand of the precursor, which evidently silences a different target 30 sequence to produce the novel leaf and floral phenotypes.

[0232] A new target sequence is selected, with the correct asymmetry in order for the miRNA target strand to be selected during incorporation into RISC (Schwartz *et al.* (2003) *Cell* 115:199-208). The miRNA sequence of SEQ ID NO:6 is selected and designed. The sequence

is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 20-23, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44. Greater than 90% of the transformants show silencing for the AP3 gene, as demonstrated by floral phenotype and electrophoretic analysis. An approximately 21 nt miRNA 5 (antiAP3b) is detected at high levels in the transgenic plants, and not in wild type control plants. RT-PCR analysis confirmed that the amount of AP3 transcript is reduced in the transformants, as compared to wild type control plants.

[0233] C. Targeting Maize Phytoene Desaturase

10 [0234] Two miRNA targets from phytoene desaturase (PDS) are selected and oligonucleotides designed.

[0235] The miRNA sequence of SEQ ID NO:7 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 24-27, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

15 [0236] The miRNA sequence of SEQ ID NO:8 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 28-31, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

[0237] D. Targeting Maize Phytic Acid biosynthetic enzymes

20 [0238] Three maize phytic acid biosynthetic enzyme gene targets are selected and miRNA and oligonucleotides designed. Inositol polyphosphate kinase-2 polynucleotides are disclosed in PCT International published application No. WO 02/059324 . Inositol 1,3,4-trisphosphate 5/6-kinase polynucleotides are disclosed in PCT International published application No. WO 03/027243. Myo-inositol 1- phosphate synthase polynucleotides are disclosed in PCT International published application No. WO 99/05298 .

[0239] Inositol polyphosphate kinase-2 (IPPK2)

[0240] The miRNA sequence of SEQ ID NO:9 is selected and designed. The sequence is put 30 into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 32-35, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

[0241] Inositol 1,3,4-trisphosphate 5/6-kinase-5 (ITPK5)

[0242] The miRNA sequence of SEQ ID NO:10 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 36-39, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

5

[0243] Myo-inositol 1-phosphate synthase (m1ps)

0

[0244] The miRNA sequence of SEQ ID NO:11 is selected and designed. The sequence is put into the BamHI/HindIII hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 40-43, and ligating them into the BamHI/HindIII backbone fragment of SEQ ID NO:44.

[0245] E. Targeting Soy *Apetela2*-like sequences (AP2)

5

[0246] The same EAT (miR172a-2) construct, comprising SEQ ID NO:1, used for *Arabidopsis* transformation is used to transform soybean. This construct has a miRNA template sequence which encodes the miRNA of SEQ ID NO:48. The construct is created using a PCR amplification of miR172a-2 precursor sequence from *Arabidopsis*, restriction digestion, and ligation as described in Example 2.

10

[0247] Soybean tissue is transformed and grown essentially as described in Example 10. After transformation, 42% of the transformants exhibit a mutant phenotype, characterized by the conversion of sepals to leaves. Plants exhibiting the strongest phenotypes are sterile, and produce no seed. Both the homeotic conversion of the organs and the effects on fertility are similar to that seen for *ap2* mutant alleles in *Arabidopsis*. Small RNA gel electrophoresis and Northern analysis, probed with an oligonucleotide probe antisense to miR172, shows accumulation of miR172 in the transgenic lines. A small amount of endogenous soy miR172 is also detected in the soy control line. The degree of the mutant phenotype is directly related to the level of miRNA, with the strongest phenotype having the highest accumulation of the processed miRNA (~ 21 nt).

15

[0248] F. Targeting *Arabidopsis* AP2-like genes

20

[0249] The miRNA sequence of SEQ ID NO:72 is selected and designed. The sequence is put into the attB hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 73-74, and performing the BP recombination reaction (GATEWAY) to generate the attL

intermediate. This intermediate is used in the LR reaction to recombine with the destination vector, generally described in Example 12, comprising the EAT full-length precursor containing attR sites, and negative selection markers in place of the hairpin. The product of this reaction comprises the miR172a-2 precursor hairpin cassette flanked by attR sites (i.e., the hairpin 5 replaces the marker cassette).

[0250] G. Targeting *Arabidopsis* Fatty Acid Desaturase (FAD2)

[0251] The miRNA sequence of SEQ ID NO:75 is selected and designed based on the sequence of NM_112047 (At3g12120). The sequence is put into the attB hairpin cassette by 10 annealing the synthetic oligonucleotides of SEQ ID NOS: 76-77, and performing the BP recombination reaction (GATEWAY) to generate the attL intermediate. This intermediate is used in the LR reaction to recombine with the destination vector, generally described in Example 12, comprising the EAT full-length precursor containing attR sites, and negative selection markers in place of the hairpin. The product of this reaction comprises the FAD2 15 miRNA precursor hairpin cassette flanked by attR sites (i.e., the hairpin replaces the marker cassette). The effect of the anti-FAD2 miRNA can be determined by fatty acid analysis to determine the change in the fatty acid profile, for example, see Wu *et al.* (1997) *Plant Physiol.* 113:347-356 .

20 [0252] H. Targeting *Arabidopsis* Phytoene Desaturase (PDS)

[0253] The miRNA sequence of SEQ ID NO:78 is selected and designed based on the sequence of NM_202816 (At4g14210). The sequence is put into the attB hairpin cassette by annealing the synthetic oligonucleotides of SEQ ID NOS: 79-80, and performing the BP 25 recombination reaction (GATEWAY) to generate the attL intermediate. This intermediate is used in the LR reaction to recombine with the destination vector, generally described in Example 12, comprising the EAT full-length precursor containing attR sites, and negative selection markers in place of the hairpin. The product of this reaction comprises the PDS miRNA precursor hairpin cassette flanked by attR sites (i.e., the hairpin replaces the marker cassette). Transgenic plants containing the antiPDS construct are photobleached upon 30 germination in greater than about 90% of the lines, indicating silencing of PDS.

EXAMPLE 12

[0254] This example describes the construction of expression vectors using recombinational cloning technology.

[0255] The vector described in Example 2 (SEQ ID NO:44) is modified to incorporate att recombination sites to facilitate recombinational cloning using GATEWAY technology (InVitrogen, Carlsbad, CA). The BamHI/HindIII segment is replaced with a sequence comprising in the following order: attR1 – CAM – ccdB – attR2. Upon recombination (BP + LR) with oligos containing attB sites flanking the miRNA hairpin precursor construct, the selectable markers are replaced by the miRNA hairpin precursor.

10

EXAMPLE 13

[0256] This example, particularly Table 5, summarizes the target sequences and oligos used for miRNA silencing constructs as described in the examples.

15

TABLE 5

Organism	Target gene	miRNA name	miRNA template	Precursor oligos SEQ ID NOS
<i>Arabidopsis</i>	AP2-like	miR172-a2	SEQ ID NO:86	55-56 (PCR)
	none	EATdel	none	57-60
	AGAMOUS	antiAG	SEQ ID NO:4	12-15
	APETELA3 (a)	antiAP3a	SEQ ID NO:5	16-19
	APETELA3 (b)	antiAP3b	SEQ ID NO:6	20-23
Corn	PDS1	antiPDS1	SEQ ID NO:7	24-27
	PDS2	antiPDS1	SEQ ID NO:8	28-31
	IPPK2	antiIPPK2	SEQ ID NO:9	32-35
	ITPK5	antiITPK5	SEQ ID NO:10	36-39
	MI1PS	antiMI1PS	SEQ ID NO:11	40-43
Soybean	AP2-like	miR172a-2	SEQ ID NO:86	55-56 (PCR)
<i>Arabidopsis</i>	AP2-like	miR172a-2	SEQ ID NO:72	73-74
	FAD2	antiFAD2	SEQ ID NO:75	76-77
	PDS	antiAtPDS	SEQ ID NO:78	79-80
Corn	miR172b	miR172	SEQ ID NO:92	91
	PDS	antiZmPDS	SEQ ID NO:95	94

EXAMPLE 14

[0257] This example describes the identification and isolation of genomic corn miR172 precursors.

5 [0258] The Genome Survey Sequence (GSS) database of the National Center for Biotechnology Information (NCBI) is searched using the 21nt miR172a-2 sequence in order to identify genomic corn sequences containing miR172 precursor sequence. Several corn miR172 precursors are identified, and named miR172a – miR172e (SEQ ID NOS: 81-85) as summarized in Table 6. Each sequence is imported into Vector NTI (InVitrogen, Carlsbad, CA) and contig 10 analyses done. The analysis identifies four distinct loci, each with a unique consensus sequence. A region of about 200 nucleotides surrounding the miRNA sequence from each locus is examined for secondary structure folding using RNA Structure software (Mathews *et al.* (2004) *Proc Natl Acad Sci USA* 101:7287-7292). The results of this analysis identifies the hairpin precursors of each of the corn sequences miR172a-e.

15

TABLE 6
Corn miR172 precursors and positions of hairpin, & miRNA duplex components

Precursor	NCBI ID	Corn Line	SEQ ID NO:	Length	Hairpin	Backside	miRNA
miR172a	CG090465	B73	81	907	508-598	512-532	574-594
miR172b	BZ401521 and BZ4011525	B73 (both)	82	1128	551-654	567-587	620-640
miR172c	CG247934	B73	83	912	230-400	250-270	364-384
miR172d	CG097860 and BZ972414	B73	84	1063	351-520	361-381	466-486
miR172e	CG065885 and CC334589	B73 (both)	85	1738	913-1072	931-951	1033-1053

[0259] Oligonucleotides are designed in order amplify miR172a or miR172b from a B73 20 genomic corn library, these primers also add restriction enzyme recognition sites in order to facilitate cloning (BamHI or EcoRV). Alternatively, PCR primers designed to create att sites for recombinational cloning could be used. After PCR amplification, the products are isolated, purified, and confirmed by sequence analysis. Once confirmed, these sequences are inserted into a construct comprising the corn ubiquitin (UBI) promoter. This construct can be used for

further transformation vector construction, for example, with the addition of att sites, the GATEWAY system can be used.

[0260] The following PCR primers are used to amplify a sequence comprising the hairpin precursor of corn miR172a

5 Forward primer (SEQ ID NO:87): 5' GGATCCTCTGCACTAGTGGGGTTATT 3'
Reverse primer (SEQ ID NO:88): 5'GATATCTGCAACAGTTACAGGCGTT 3'

[0261] The following PCR primers are used to amplify a sequence comprising the hairpin precursor of corn miR172b

Forward primer (SEQ ID NO:89): 5' GGATCCCATGATATAGATGATGCTTG 3'

10 Reverse primer (SEQ ID NO:90): 5' GATATCAAGAGCTGAGGACAAGTTT 3'

EXAMPLE 15

[0262] This example describes the design and synthesis of miRNA targets and hairpins directed to various gene targets found in maize, for use with the corn miR172b miRNA precursor.

[0263] A. miR172b target in corn

[0264] Similar to the *Arabidopsis* EAT examples, the corn miR172b hairpin precursor will be tested by overexpression in corn. The precursor sequence comprising the miRNA template is shown in SEQ ID NO:91. The miRNA is shown in SEQ ID NO:92, and the backside of the miRNA duplex is shown in SEQ ID NO:93. A double-stranded DNA molecule comprising the miRNA precursor and restriction enzyme overhangs, for BamHI and KpnI, is created by annealing the oligonucleotides of SEQ ID NOS: 97 and 98.

25 [0265] B. Phytoene Desaturase (PDS)

[0266] An oligonucleotide comprising the the miRNA template is shown in SEQ ID NO:94. The miRNA directed to PDS is shown in SEQ ID NO:92, and the backside of the miRNA duplex is shown in SEQ ID NO:93. A double-stranded DNA molecule comprising the miRNA precursor and restriction enzyme overhangs, for BamHI and KpnI, is created by annealing the oligonucleotides of SEQ ID NOS: 99 and 100.

[0267] The oligonucleotides of this example can be inserted into vectors for transformation of corn using standard cloning techniques, including restriction digestion and ligation, and/or recombinational cloning such as GATEWAY.

5

EXAMPLE 16

[0268] This example describes the materials and methods used for Examples 17-19.

[0269] Plasmid constructs

[0270] A fragment of 276 base pairs containing the entire sequence of *Arabidopsis* miR159a (see below) was cloned by PCR amplification using primers CACC-miR159a-prec: 5' CACCACAGTTGCTTATGTCGGATCC 3' (SEQ ID NO:101) and miR159a-Xma: 5' TGACCCGGGATGTAGAGCTCCCTTCAATCC 3' (SEQ ID NO:102). The miR159a-Xma contains 18 of 21 nucleotides of the mature miR159a (bold) and an introduced XmaI site (italic). The PCR fragment was cloned in the pENTR/SD/D-TOPO vector (Invitrogen) according to manufacturers directions to obtain pENTR-miR159a-prec.

[0271] The Gateway recombination system was used to transfer the *pre-miR159a* sequence to the plant binary vector pK2GW7, which contains two copies of the 35S promoter and a *NOS* terminator to generate pK2-*pre-miR159a*.

[0272] Mutagenesis of *pre-miR159a* was performed by PCR with the following oligonucleotides.

[0273] 5'-*miR-PDS*^{159a}: 5' ATAGATCTTGATCTGACGATGGAAGAAGAGATCCTAAC T TTTCAAA 3' (SEQ ID NO:103; This oligonucleotide contains a natural Bgl II site (italic) and the *miR-PDS*^{159a*} sequence (bold)).

[0274] 3'-*miR-PDS*^{159a}: 5' TGACCCGGGATGAAGAGATCCCATATTTCAGAAA 3' SEQ ID NO:104; This oligonucleotide contains point mutations in the miR159a sequence (bold) to increase its complementarity to the *PDS* mRNA sequence, based on available *N. benthamiana* PDS mRNA partial sequence (Genbank AJ571700, see below)).

[0275] PCR amplification of the miR159a precursor using the above primers and pENTR-*miR159a-prec* DNA as template generated a DNA fragment that was digested with BglII and XmaI to be re-inserted into pENTR-*pre-miR159a*, to generate pENTR-*pre-miR-PDS*^{159a}. Gateway system procedures were used again to transfer the *miR-PDS*^{159a} precursor to pK2GW7 and generate pK2-*pre-miR-PDS*^{159a}.

[0276] The *miR-PDS*^{169g} was cloned as follows. An *Arabidopsis* genomic fragment of 222 base pairs containing the miR169g sequence (see below) was amplified using primers miR169g-For 5' CACCAATGATGATTACGATGATGAGAGTC 3' (SEQ ID NO:105), and miR169g-Rev 5' CAAAGTTGATCACGATTCATGA 3' (SEQ ID NO:106). The resulting PCR fragment was introduced into pENTR/D-TOPO vector (Invitrogen) to obtain pENTR-*pre-miR169g*. The *pre-miR169g* sequence was then transferred into binary vectors pBADC and pB2GW7 using the Gateway system to generate pBA-*pre-miR169g* and pB2-*pre-miR169g*.

[0277] Two *miR-PDS*^{169g} precursors were created using pENTR-*pre-miR169g* as template and the Quick-change Mutagenesis kit from Stratagene. pENTR-*pre-miR-PDSa*^{169g} was made by 10 using the following oligonucleotides:

[0278] *miR169*^{PDSa}: 5' GAGAATGAGGTTGAGTTAGTCTGACTTGGCCAGTTTTTA CCAATG 3' (SEQ ID NO:107), and

[0279] *miR169*^{PDSa*}: 5' CTGATTCTGGTGTGGCCAAGTCAGACTAAACTCTGTTCC TTCTC 3' (SEQ ID NO:108).

[0280] pENTR-*pre-miR-PDSb*^{169g} was produced by using the oligonucleotides:

[0281] *miR169*^{PDSb}: 5' GAGAATGAGGTTGATCTCTTCCAGTCTCAGGGTTTTTA CCAATG 3' (SEQ ID NO:109), and

[0282] *miR169*^{PDSb*}: 5' GATTCTGGTGTCCCTGAAGACTGGAAAGAGATCTGTTCCCTT CTCTTC 3' (SEQ ID NO:110).

[0283] The two mutagenized *miR-PDS*^{169g} precursors above were then transferred into plant 20 binary vectors pBADC and pB2GW7 to generate pBA-*pre-miR-PDSa*^{169g}, pB2-*pre-miR-PDSa*^{169g}; pBA-*pre-miR-PDSb*^{169g}, and pB2-*pre-miR-PDSb*^{169g}.

[0284] Precursors for artificial miRNAs that target *N. benthamiana rbcS* transcripts (pENTR-*pre-miR-rbcS*^{159a}-A) were produced using similar procedures as those described for pENTR-*miR-PDS*^{159a} using the following primers and cloned into pK2GW7:

[0285] MrbcSA-S: 5' TCTGACGATGGAAGTCCTCGCCCGACATTGAAAATGAGTT GA 3' (SEQ ID NO:111), and

[0286] MrbcSA-R: 5' AAACCCGGGATGTTCCCTCGCCCGGAATTGAAAGAGAGTAA AAG 3' (SEQ ID NO:112).

[0287] All cloned sequences were confirmed by DNA sequencing.

[0288] Precursor sequences used

[0289] miR159a precursor template sequence (276bp)

ACAGTTGCTTATGTCGGATCCATAATATATTGACAAGATACTTGTTCGATAG
ATCTTGATCTGACGATGGAAG**TAGAG****CTCCTTAAAG****TTCAAAC**ATGAGTTGAGCA
5 GGGTAAAGAAAAGCTGCTAAGCTATGGATCCATAAG**CCCTAATCCTGTAAAGTA**
AAAAAAGGATTGGTTATATGGATTGCATATCTCAGGAG**CTTAACTGCCCTTAAT**
GGCTTTACTCTT**GGATTGAAAGGGAGCTCTA**CATC**CCGGGTC** (SEQ ID NO:113)

(Sequence of the pre-miR159a cloned. Sequences of miR159a* and miR159a (italic) are shown in bold. Nucleotides changed in *miR-PDS^{159a}* are underlined.)

10 [0290] miR-159a mature template

5' TTTGGATTGAAGGGAGCTCTA 3' (SEQ ID NO:114)

[0291] miR-*PDS^{159a}* mature template

5' TTTGGA a a t A t GGGAt CTCT t 3' (SEQ ID NO:115)

[0292] miR169g precursor template sequence 0.3 kb (222bp)

15 AATGATGATTACGATGATGAGAGTCTCTAGTTGTATCA**GAGGGTCTGCATGGAAG**
AATAGAGAATGAGGTT**GAGCCAAGGATGACTTGCCGGG**TTTTTACCAATGAATCT
AATTAACTGATTCTGGT**CCGGCAAGTTGACCTTGG****CTCTGTTCCCTCTTCTT**
20 TTGGATGTCAGACTCCAAGATATCTATCATGAATC**GTGATCAAAC**TTG (SEQ
ID NO:116) (Sequence of the pre-miR169g fragment (0.3kb) cloned. Sequences of miR169g
(italic) and miR169g* are shown in bold. Nucleotides changed in miR-*PDS^{169g}* are underlined.)

[0293] miR169g mature template

5' GAGCCAAGGATGACTTGCCGG 3' (SEQ ID NO:117)

[0294] miR-*PDSa^{169g}* mature template

5' GAG t t t AG t c TGACTTG gC c a 3' (SEQ ID NO:118)

25 [0295] miR169g mature template

5' GAGCCAAGGATGACTTGCCGG 3' (SEQ ID NO:119)

[0296] miR-*PDSb^{169g}* mature template

5' GA tC t c t t c c a g t c T t C aGG 3' (SEQ ID NO:120)

[0297] miR169g precursor template sequence 2.0kb (2474bp)

30 AAGCTTGATCTTAGCTTTGCCAAAGCTTCTTGA**TTTTCTATTCTCTAATCT**
ATCCATTGACCATTGGGGTGATGATATTCTCAATT**ATGTTGTTGTTATTGCCA**
TCCACAGACCCACGTTGATTGTTAATCAA**AAAATATAAAACTGACAGTTGTGCCA**
CTAGTCACTTGCCAATTAA**GATTC****AAAGCTCCTCCTTACATTAGTATCAAGTG**
AGACTAGCACAAGCTTTAAGTCCAGATA**AAAAAGCCCCATGGAAGGGAAAGCTTCA**
35 AGAACGAGATTAA**ACCGTAAAACCCAATT**CGATTCCGCTAATAATTGGATCCAA
AAATCTAGACAAAATCTGATAAAATTAGACAAAGAAA**TGGATAAAACCCCCAAAAC**
CCATAATCGTCGTTCTGTTGCTCAATATCACTCTTCCCTCCAACGAGTTA
GTTAGAGTGACGTGGCAGCTGA**ACTAGATTGGAGTAACGGGATAGATTACCCATA**
AAGCCCCAATAATGATCATTACGTGAGACATAACTGCTTAGATAACCTCATTATG

GGCTTAGATGGGGCTCTAGTGTAGTCATAAGCTCTAAATACCATTCTAGT^{GA}AT
 ATATCAATCTTAGCTTGGATTGGATCGTGTCTATAGTAAAAAAACTTTACTA
 TTTATGTTAGCAATCCCACCTAACATTCAATATGTTAAAATGAAAGAGTTACCA
 AAAGGAAAGAAAAAAAGGTTGGTAATGAATTATCTAACGATACGATATT^{CA}
 5 AATCTAACGATGGTCTATCAATAAATAGAACAAAGTTAACGCTTACGCTT^{TGT}
 TACCTGTTCTTCTTAGCAATTAAATATTAAACGAGTTAGTAATATAAATA^{TGT}
 TTCCAGTTATACCAAACTTATGTAATATTCTAACGCTTGC^{AAA}ATTACA~~GA~~
 10 GTTTTGGAACGCGCACAAATTCTCATATATTCTACCCAAAAATAAATT^{TTT}
 TTTTTTACTTGT^{TT}TATAATCCTATATGAACATTGCTCATCTCCCCATTGATG-GTA
 ATTTCTATTCTATATGTAATTAAATCCTAACATGAAATTGAAAACATAA~~TTT~~
 GAAGATAATCAATCCTAATATCTCCGCTTAGATCTATTAAATGGTCTTATT^{GA}AAT
 15 TTCCTATATTGGCCTAATTATTGATATAGTGAATTATGGAAGCTTCAT^{TGT}
 TGATGGAATAAAACGGCTTATCCAATTAAATCGATCGGGAGCTATAACACAA~~ATC~~
 GAAACTCTAGTAGCTATAAAGAGTGT^{GA}ATAGCTTGGATCACATGTATTACTATT
 TATTACTAGCTCGT^{GA}ACAATTGGCTTGGAAAAAAATTATTACTAGTACT^{CC}
 CCCTCACAATGTGATGAGTCTCCAAATGATATATTCTCAACCCAAAGGACAAT^{CTG}
 AAATTTC^{CA}ATATATATTCCATT^{TT}TATCCGCAACATTGAAATTGTGGCAATGT^{TTT}
 TAAAAAGACTATTATAAAGAATCTTCTAAATTGTTCTACGACAATCGATAAC~~CAC~~
 20 CTTTGT^{GA}TCAACCCACACAAGACTATGATTCCAATCCTAACGAAACATACG-ACA
 CGTGGATT^{TT}TATGTCACACTAGTACGATGCGTCATGCCTCAGAGTACGAATT
 ATTACACATAAAATTCTATTGAATTGATAATATAAGGT^{CA}AGCCTTAAAG
 TAATTATATTCTCAATATACGGTTGTGGT^{AAA}ATTCCATT^{TT}TATTGTAGCTTGC
 ATGCACTACTAGTTAAAACC^{ATG}CATGGATTATTGCATATAAACATTATA^{TGA}
 25 ATTTC^{AA}ATTAAATTAATCCACACATTCCCATTCAATATGCCTATAAAC^{CT}TCA
 TCACGAGTATGACAAGATCACAAGACAAGAAAAAGAAAGGTAGAGAAAACATG^{ATA}
 ATGATGATTACGATGATGAGAGTCTAGTTGTATCAGAGGGCTTGCATGGA~~GA~~
 ATAGAGAATGAGGTT~~GAGCCAAGG~~^{GA}CTTGC^{CCGG}TTTTACCAATGAAT^{CTA}
 30 ATTA^{ACTG}ATTCTGGTGTCCGGCAAGT^{GT}ACCTGGCTCTGTTCTCTCTT
 TGGATGT^{CA}AGACTCCAAGATATCTATCATGAATCGT^{GA}AAACTTGTAA^{TT}
 CATTGAAATGT^{TTT}CTGATGCGAATT^{TTT}GGCTTACGGTTTCGATT^{GA}AT
 GATCAGATT^{TTT}GT^{TTT}GC^{ACT}CAA^{ACT}ATAGTTCACTTAGGTCTATT^{TT}TC^A
 GGTTATGAATGATAAAACAAGTAAGATT^{TT}TAGCTAGTTAGTCATT^{TT}CGATT
 35 CAAATTCAAACATCTGGTT^{TT}GGTTAGTTAAGTTGATT^{TT}CAAGTCAAAT^{GT}CTA
 TGTTTCTTGT (SEQ ID NO:121) (Sequence of the pre-miR169g fragment (2.0kb) cloned.
 Sequences of miR169g (italic) and miR169g* are shown in bold.)

[0298] Target gene sequences used:

[0299] *Nicotiana benthamiana* *PDS* sequences:

[0300] 5'end probe sequence (corresponding to Le-*PDS* pos.1-268, see Fig. 15A):

40 ATGCCTCAAATTGGACTTGT^{TT}CTGCTGTTAAC^{TT}GAGAGT^{CC}AAAGGTAGTTCA~~GCT~~
 TATCTTGGAGCTCGAGGT^{CGT}CTTCTTGGGA^{ACT}GAAAGTCGAGATGGTGC^{TTG}
 CAAAGGAATT^{CGT}TATGTTGCTGGTAGCGAATCAATGGTCATAAGTTAAAGATT
 CGTACTCCCCATGCCACGACCAGAAGATTGGTTAAGGACTGGGGC^{CTT}AAAGGT
 CGTATGCATTGATTATCCAAGACCAGAGCTGGACAA^{ACAG} (SEQ ID NO:122)

[0301] Partial+5'RACE fragment. Assembled sequence from partial *Nicotiana benthamiana* *PDS* sequence (Genbank AJ571700) and 5'RACE experiments (corresponding to Le-*PDS* pos. 858-1514, see Fig. 15A).

GGCACTCAACTTATAAACCCCTGACGAGCTTCGATGCAGTCATTGATTGCTTT
 5 GAACAGATTCTTCAGGAGAACATGGTTCAAAAATGGCCTTTAGATGGTAACC
 CTCCTGAGAGACTTGCATGCCGATTGTGGAACATATTGAGTCAAAAGGTGGCCAA
GTCAGACTAAACTCACGAATAAAAAAGATCGAGCTGAATGAGGATGGAAGTGTCA
 AATGTTTATACTGAATAATGGCAGTACAATTAAAGGAGATGCTTGTGTTGCCA
 10 CTCCAGTGGATATCTTGAAGCTTCTTGC*CTGAAGACTGGAAAGAGATCCC**ATTT*
CCAAAAGTTGGAGAAGCTAGTGGGAGTCCTGTGATAAAATGTCCATATGGTTG
 ACAGAAA*ACTGAAGAACACATCTGATAATCTGCTCTCAGCAGAAGCCC**GTGCTC*
 AGTGTGTACGCTGACATGTCTGTTACATGTAAGGAATTACAACCCCAATCAGTCT
 15 ATGTTGGAATTGGTATTGCACCCGCAGAAGAGTGGATAATCGTAGTGACTCAGA
 AATTATTGATGCTACAATGAAGGA*ACTAGCGAAGCTTCCCTGATGAAATT*
 AGATCAGAGCAA*AGCAAAATATTGAAGTACCATGT* (SEQ ID NO:123) (Sequences
 targeted by miR-*PDS*^a^{169g} (bold), miR-*PDS*^b^{169g} (bold and italic) and miR-*PDS*^{159a} (underlined)
 are indicated.)

[0302] *Nicotiana benthamiana rbcS* sequences (Bolded nucleotides in all six *rbcS* gene sequences correspond to the sequence targeted by *miR-rbcS*^{159a}-A.):

20 [0303] *rbcS1* (Genbank accessions: CN748904: 56-633bp, CN748069: 419-end)

GGAGAAAGAGAA*ACTTCTGTCTTAAGAGTAATTAGCAATGGCTCCTCAGTTCTT*
 CCTCAGCAGCAGTGC*CCACCCGCA**GCAATGTTGCTCAAGCTAACATGGTTGCACCTT*
 TCACAGGTCTTAAGTCTGCTGCCTCATTCCCTGTTCAAGAA*AGCAAAACCTTGACA*
 TCACTTCCATTGCCAGCAACGGCGGAAGAGTGCAATGCATGCAGGTGTGGCCACCA
 25 ATTAACATGAAGAAGTATGAGACTCTCTCATAACCTCCGATTGAGCCAGGAGCA
 ATTGCTCTCCGAAATTGAGTACCTTTGAAAA*ATGGATGGGTTCTGCTTGGAAAT*
TCGAGACTGAGAAAGGATTGTCTACCGTGAAACACCACAAGTCACCAGGAA
 GATGGCAGATACTGGACCATGTGGAAGCTACCTATGTCGGATGCACTGATGCCAC
 30 CCAAGTGTGGCTGAGGTGGAGAGAGCGAAGAAGGAATACCCACAGGCCTGGTC
 CGTATCATTGGATTGACAACGTGCGTCAAGTGCAGTCAGTTCATTGCCTCC
 AAGCCTGACGGCTACTGAGTTCATATTAGGACA*ACTTACCCATTGTCTGTCTTA*
 GGGGCAGTTGTTGAAATGTTACTTAGCTCTTTTCCCTCCATAAAA*ACTGT*
 TTATGTTCTCTTTATTGGTGTATGTTGGATTCCCTACCAAGTTATGAGACCT
 AATAATTATGATTGCTTGCTTGTAAAA*AAAAAAAAAAAAAAA* (SEQ ID NO:124)

35 [0304] *rbcS2* (Genbank accessions: CN748495: 3-552 b, CN748945: 364-575 b)

TCTTCTGTCTTAAGTGTAA*TTAACATGGCTCCTCAGTTCTTCCTCAGCAGCAGT*
 TGCCACCCGCAGCAATGTTGCTCAAGCTAACATGGTTGCACCTTC*ACTGGTCTTAA*
 GTCAGCTGCCTCGTTCCCTGTTCAAGGAAGCAAA*ACCTTGACATCACTCCATTGC*
 CAGCAACGGCGGAAGAGTGCAATGCATGCAGGTGTGGCCACCAATTAAACAAGAAG
 40 AAGTACGAGACTCTCTCATAACCTCCTGATCTGAGCGTGGAGCAATTGCTTAGCGAA
 ATTGAGTACCTCTGAAAA*ATGGATGGGTTCTGCTTGGAAATTCGAGACTGAGC*
 GCGGATTGTCTACCGTGAA*ACACCACAAGTCACCAGGGAA*
 TGGACCATGTGGAAGTTGCCTATGTTGGATGC*ACTGATGCCACCCAAAGTGTGGCC*
 GAGGTGGAAGAGGCAGAACAGGCATA*ACCCACAGGCCTGGATCCGTATTATTGGATT*
 45 CGACAACGTGCGTCAAGTGCAGTCAGTTCATTGCCTACAAAGCCAGAAGGCT

ACTAAGTTCATATTAGGACAACTTACCCATTGTCCACTTAGGGCAATTGTT
 TGAAATGTTACTTGGCTTCTTTTTAATTCCCACAAAAACTGTTATGTTCC
 TACTTCTATTGGTGTATGTTTGCACTCCTACCAAGTTATGAGACCTAATAACTA
 TGATTGGTGCTTGTTGTAAAT (SEQ ID NO:125)

5 [0305] *rbcS3* (Genbank accessions: CN746374: 22-108 b, CN748757: 156-175 b,
 CN748929: 158-309 b, CN748913: 319-489 b, CN748777: 485-603 b, CN748188: 453-529 b)

TAGCAATAGCTTAAGCTTAGAAATTATTCAGAAATGGCTCCTCAGTTATGTCC
 TCAGCAGCTGCTGCGACCGGCCAATGCTGCTCAAGCCAACATGGTGCACC
 10 CTTCACTGGCCTCAAGTCCGCCCTCCTCCCTGTTACCAAGGAAACAAAACCTTGA
 CATTACCTCCATTGCTAGCAATGGTGGAAAGAGTTCAATGCATGCAGGTGTGGCCAC
 CAATTAAACATGAAGAAGTACGAGACACTCTCATACCTCCTGATTGAGGCCAGGAG
 CAATTGCTTAGTGAAGTTGAGTACCTTGAAAAATGGATGGGTTCTGCTTGGGA
 15 **ATTCGAGACTGAGCGTGGATTGCTACCGTGAACACCAACTCACCAGGAACT**
 ACGATGGCAGATACTGGACCATGTGGAAGTTGCCATGTCGGGTGCACTGATGCC
 ACTCAGGTGTTGGCTGAGGTCGAGGAGGCAAAGAAGGCTACCCACAAGCCTGGGT
 TAGAATCATTGGATTGACAAACGTCGCAAGTGCAATGCATCAGTTATCGCCTC
 20 CAAGCCAGAAGGCTACTAAAATCTCCATTAAAGGCAACTATCGTATGTGTTCCC
 CGGAGAAACTGTTGGTTCTGCTCCTATATTATTCAATGTATGTTTGAAAT
 TCCAA (SEQ ID NO:126)

20 [0306] *rbcS4* (Genbank accessions CN748906: 9-607 b, CN747257: 629-709b)

AATGGCTCCTCAGTTATGTCCTCAGCTGCCGCTTGCCACCGGCCAATGCTGC
 TCAAGCCAGTATGGTTGCACCTTCACTGGCCTCAAGTCCGCAACCTCCTCCCTGT
 25 TTCCAGAAAACAAAACCTTGACATTACTCCATTGCTAGCAACGGCGGAAGAGTT
 AATGCATGCAGGTGTGGCCACCAATTAAACAAGAAGTACGAGACACTCTCATAC
 CTTCCGATTGAGCCAGGAGCAATTGCTTAGTGAAGTTGAGTACCTGTTGAAAAAT
 GGATGGGTTCTGCTTGGAAATTGAGACTGAGCGTGGATTGCTACCGTGAAC
 ACCACAGCTCACCAGGATATTATGATGGCAGATACTGGACCATGTGGAAGTTGCC
 30 ATGTTCGGGTGCAGTGATGCCACTCAGGTGTTGGCTGAGGTCGAGGAGGCAAAGAA
 GGCTTACCCACAAGCCTGGTTAGAATCATTGGATTGACAATGTCCGTCAAGTGC
 AATGCATCAGTTCATCGCCTACAAGCCAGAAGGCTACTAGAAATCTCCATTAAAG
 GCAACTATCGTATGTGTTCCCGGAGAAAATGTTGGTTCTGCTTCATTATA
 TTATTCAATGTATGTTTGAAATTCAATCAAGGTTATGAGAACTAATAATGACATT
 35 TAATTGTTCTTTCTATATA (SEQ ID NO:127)

[0307] *rbcS5* (Genbank accession: CN744712: 16-713 b)

35 TAAATAATTGCAACAATGGCTCCTCTGTGATTCTCAGCTGCCGTTGC
 CACCGCGCTAATGCTGCTCAAGCCAGCATGGTTGCACCCCTCACTGGCCTCAAATC
 TGCTCCTCCTCCCTGTTACAGAAAACAAAACCTTGACATTACATCCATTGCTAG
 CAATGGTGGAAAGAGTCCAATGCATGCAGGTGTGGCCACCAATTAAACATGAAGAAGT
 ACGAGACACTCTCATACCTCCTGATTGAGGCCAGGAGCAATTGCTTAGTGAAGTTG
 40 AGTATCTTGTAAAAATGGATGGGTTCTGCTTGGAAATTGAGACTGAGCGTGG
 ATTTGTCTACCGTGAACATCACAGCTCACCAGGATACTACGATGGCAGATACTGGA
 CCATGTGGAAAGTTGCCATGTTGGTGCAGTGATGCCACTCAGGTGTTGGCTGAGG
 TCGAGGAGGCAAAGAAGGCTTACCCACAAGCCTGGTTAGAATCATTGGATTGAC
 AACGTCCGTCAAGTGCAATGCATCAGTTATGCCCTCCAAGCCAGAAGGCTACTA
 45 AAATCTCCATTAAAGGCAACTTATCGTATGTTCCCCGGAGAAAATGTTGGT

TTTCCTGCTTCATTATATTCAATGTATGTTTGAATTCCAATCAAGGTTATG**A**
AACTAATAATGACATTAA (SEQ ID NO:128)

[0308] *rbcS6* (Genbank accessions: CN745030: 14-123 b, CN748077: 1-523 b)

GCACGAGGCTTCCTCAGTTATGTCCTCAGCTGCCGCTGTTCCACCGGCCAAT**G**
5 TGTTCAAGCCAGCATGGTCGCACCCTCACTGGCCTCAAGGCCGCCCTCCTCC
GGTTCCAGGAAACAAAACCTTGACATTACTCCATTGCTAGAAATGGTGGAAAG**A**
TCCAATGCATGCAGGTGTGGCCCAATTAAACAAGAAGTACGAGACACT**C**
TACCTTCCTGATTGAGCGTGGAGCAATTGCTTAGCGAAATTGAGTACCTTTGA**AA**
10 AATGGATGGGTT**C**CTTG**G**AAATT**C**GAGACTGAGCATGGATT**C**GT**T**ACCG**T**
AACACCACCACTCACCAGGATACTACGATGGCAGATACTGGACGATGTGGAAAGTTG
15 CCCATGTTGGGTGCACCGATGCCACTCAGGTCTGGCTGAGGTAGAGGAGGCC**AA**
GAAGGCTTACCCACAAGCCTGGGTAGAATCATTGGATT**C**ACAAACGTCCGT**C**
TGCAATGCATCAGTTCATCGCCTACAAGCCCAGGCTATTAAAATCTCCATT**TT**
AGGACAGCTTACCTATGTATT**C**AGGGAGTTGTTGAATT**C**CT**T**GGAGAAACT
15 GTTTGGTTTCCTTGTAAAT**C**TCT**T**CTATTAT**T**TTGGATT**T**ACT**C**AGT
TTATAAGAACTAATAATAATCATTGTT**C**TTACTAAAAAAAAAA (SEQ ID
NO:129)

[0309] Infiltration of *N. benthamiana* with *Agrobacterium tumefaciens*

20 [0310] Infiltration with *A. tumefaciens* carrying appropriate plasmids was carried out as follows. Cells were grown to exponential phase in the presence of appropriate antibiotics and 40 μ M acetosyringone. They were harvested by centrifugation, resuspended in 10 mM MgCl₂ containing 150 μ M acetosyringone and incubated at room temperature for 2 hrs without agitation. Infiltration was performed by using a syringe without needle applied to the abaxial side of leaves. After 1, 2, or 3 days leaf tissue was collected, frozen and ground in liquid nitrogen before RNA extraction.

[0311] Northern blot hybridizations

30 [0312] Leaves from *Nicotiana benthamiana* were used to extract total RNA using the Trizol reagent (Invitrogen). 10-20 μ g total RNA were resolved in a 15% polyacrylamide/ 1 \times TBE (8.9 mM Tris, 8.9 mM Boric Acid, 20 mM EDTA)/ 8 M urea gel and blotted to a Hybond-N+ membrane (Amersham). DNA oligonucleotides with the exact reverse-complementary sequence to miRNAs were end-labeled with ³²P- γ -ATP and T4 polynucleotide kinase (New England Biolabs) to generate high specific activity probes. Hybridization was carried out using the 35 ULTRAHyb-Oligo solution according to the manufacturer's directions (Ambion, TX), and signals were detected by autoradiography. In each case, the probe contained the exact antisense sequence of the expected miRNA to be detected.

[0313] Northern blot hybridizations to detect PDS mRNA abundance were performed according to standard procedures. The 5' end probe corresponded to a fragment of *N. benthamiana* *PDS* gene reported before (Guo *et al.* (2003) *Plant J* 34:383-392) equivalent to the tomato *PDS* gene sequence positions 1-268 (Genbank X59948, see above). The 3'end probe 5 corresponded to a fragment obtained by 5'RACE and equivalent to the tomato *PDS* gene sequence positions 1192-1514.

[0314] 5' RACE

[0315] To identify the products of miRNA-directed cleavage the First Choice RLM-RACE 10 Kit (Ambion) was used in 5' RACE experiments, except that total RNA (2 μ g) was used for direct ligation to the RNA adapter without further processing of the RNA sample. Subsequent steps were according to the manufacturer's directions. Oligonucleotide sequences for nested steps were according to the manufacturer's directions. Oligonucleotide sequences for nested PCR amplification of *PDS* cleavage fragment were:

3'Nb-PDS1 5' CCACTCTTCTGCAGGTGCAAAAACC 3' (SEQ ID NO:130)

15 3'Nb-PDS2 5' ACATGGTACTTCAATATTTTGCTTG 3' (SEQ ID NO:131)

3'Nb-PDS3 5' GATCTTGAAAGGCCGACAGGGTTCAC 3' (SEQ ID NO:132)

All three primers were designed based on available sequence information for the tomato *PDS* gene since the complete *N. benthamiana* *PDS* gene sequence has not been published.

[0316] PCR fragments obtained from 5'RACE experiments were cloned in the pCR4 vector 20 (Invitrogen) and analyzed by DNA sequencing of individual clones.

[0317] RT-PCR

[0318] First strand cDNA was synthesized form 5 μ g total RNA using an oligo-dT primer 25 (Sigma) and Ready-To-Go You-Prime First-strand beads (Amersham Biosciences). Amounts of first strand cDNA were normalized by PCR using primers for EF1 α (Nishihama *et al.* (2002) *Cell* 109:87-99). To amplify DNA fragments of *rbcS* cDNAs, the following primers were used.

NBrbcS5:1/2-F: 5' TTCCTCAGTTCTTCCTCAGCAGCAGTTG 3' (SEQ ID NO:133)

rbcS3-F: 5' CTCAGTTATGTCCTCAGCAGCTGC 3' (SEQ ID NO:134)

rbcS4/6-F: 5' TCCTCAGTTATGTCCTCAGCTGCC 3' (SEQ ID NO:135)

30 NBrbcS5-F: 5' TGTGATTTCCTCAGCTGCTGCC 3' (SEQ ID NO:136)

NBrbcS1 rev2: 5' AACTCAGTAGCCGTCAGGCTTGG 3' (SEQ ID NO:137)

NBrbcS2 rev2: 5' AATATGAAACTAGTAGCCTCTGGCTTGT 3' (SEQ ID NO:138)

NBrbcS3/4/5 rev1: 5' GTTTCTCCGGGGAACACATACGA 3' (SEQ ID NO:139)

NBrbcs6 rev1: 5' AAACAAACTTCCCCTGAATACATAGGG 3' (SEQ ID NO:140)

EXAMPLE 17

[0319] This example describes the design of an artificial microRNA to cleave the phytoene desaturase (*PDS*) mRNAs of *Nicotiana benthamiana*.

[0320] *Arabidopsis* miRNAs identified so far have been shown to target different mRNAs, and a significant number encodes transcription factors (Bartel (2004) *Cell* 116:281-297; Wang *et al.* (2004) *Genome Biol* 5:R65; Rhoades *et al.* (2002) *Cell* 110:513-520). Base-pairing of plant miRNAs to their target mRNAs is almost perfect and results in cleavage of the RNA molecule as has been shown for several examples (Jones-Rhoades and Bartel (2004) *Mol Cell* 14:787-799), resulting in silencing of gene expression. Alternatively, miRNA interaction with the target mRNA can result in inhibition of translation rather than mRNA cleavage as shown for miR172 of *Arabidopsis* (Aukerman and Sakai (2003) *Plant Cell* 15:2730-2741; Chen (2004) *Science* 303:2022-2025).

[0321] In an effort to design artificial miRNAs that can inhibit the expression of particular genes, we sought to modify the sequence of a known miRNA to target an mRNA of choice.

[0322] The *Arabidopsis* miR159 has been shown to target a set of MYB transcription factors. Base-pairing of miR159 to its target mRNAs is almost perfect and results in cleavage of the RNA molecule (Achard *et al.* (2004) *Development* 131:3357-3365; Palatnik *et al.* (2003) *Nature* 425:257-263). There are three genomic sequences (MIR159a, MIR159b, MIR159c) with the potential to encode miR159. The natural promoter and precise precursor sequence of miR159 are not known, nor is it known whether microRNA genes are transcribed by DNA polymerase II or III. We decided to use as precursor sequence a DNA fragment of 276 bp that contains the *Arabidopsis* miR159a. This precursor sequence, which is called pre-miR159a was placed downstream of a 35S promoter and flanked at the 3' end by a polyA addition sequence of the *nopaline synthase* gene (Fig. 11A). We decided to use the *N. benthamiana* phytoene desaturase (*PDS*) gene as a target to see whether we can design an artificial microRNA to cleave its mRNA and thereby compromise its expression. We compared the sequence of *At-miR159a* to that of *PDS* to find the best match between the two sequences. For one particular region of the *PDS* mRNA we found that only 6 base changes are sufficient to convert miR159a into a miRNA capable to perfectly base-pair to *PDS* mRNA (Fig. 11B). We called this sequence *miR-PDS*^{159a}.

[0323] To generate *pre-miR-PDS*^{159a}, PCR techniques were used to introduce point mutations in both miR159a and the miR159a* sequence (the RNA sequence located in the opposite arm to

the miRNA within the precursor sequence) in the context of the *Arabidopsis pre-miR159a*. The resulting precursor was placed under the control of the strong cauliflower mosaic virus (CaMV) 35S promoter and expressed in *N. benthamiana* by infiltration of *Agrobacterium tumefaciens* containing the appropriate constructs.

5 [0324] Expression of the *Arabidopsis pre-miR-PDS^{159a}* in *N. benthamiana* was first analyzed to confirm that the mutations introduced in its sequence did not affect its processing and maturation of *miR-PDS^{159a}*. Northern blot analysis showed that 2 to 3 days after infiltration *miR-PDS^{159a}* is clearly expressed (Fig. 11C), accumulating to levels comparable to endogenous miR159. Biogenesis of known miRNAs includes the generation of the almost complementary 10 miRNA* which is short-lived and accumulates to very low levels when compared to those of the actual miRNA. Consistently, the presence of *miR-PDS^{159a}** was detected but its abundance was significantly lower than that of *miR-PDS^{159a}* (Fig. 11C, middle panel). Expression of endogenous miR159 was unchanged under these conditions and served as both a loading and probe-specificity control (Fig. 11B, bottom panel). In addition, this result indicates that 15 expression of an artificial miRNA based on the *Arabidopsis* miRNA precursor does not affect expression of the endogenous *N. benthamiana* miR159. Finally, these findings imply that the enzymatic machinery for processing of natural microRNA precursors is not rate limiting and can process artificial precursors with great efficiency.

20 [0325] We next determined whether expression of *miR-PDS^{159a}* resulted in the expected cleavage of the endogenous *PDS* mRNA. Northern blot hybridization of the samples expressing *miR-PDS^{159a}* showed a clear reduction in *PDS* mRNA levels (Fig. 12A). To further establish the mechanism of *PDS* mRNA reduction we set to define: (1) whether the *PDS* mRNA is cleaved by 25 *miR-PDS^{159a}* and contains a diagnostic 5' phosphate, and (2) whether the cleavage point corresponds to the predicted site, based on the *PDS* mRNA:*miR-PDS^{159a}* base-pairing interaction. To this end, 5'RACE experiments were performed. We found that the 5'-end sequence of 5 out of 6 independent clones mapped the site of cleavage after the tenth nucleotide counting from the 5' end of *miR-PDS^{159a}*. The location of the cleavage site correlates perfectly with published work with other miRNA targets (Jones-Rhoades and Bartel (2004) *Mol Cell* 14:787-799).

30 [0326] The results demonstrate that the reduction of *PDS* mRNA levels was caused by accurate cleavage directed by *miR-PDS^{159a}*.

EXAMPLE 18

[0327] This example demonstrates that microRNA-directed cleavage of *PDS* mRNA can be produced from a different microRNA precursor.

[0328] To show that expression of artificial miRNAs is not restricted to the use of pre-

5 miR159a we have designed a different miR-*PDS* based on a putative precursor sequence containing the *Arabidopsis* miR169g to generate two different miR-*PDS*^{169g} (Fig. 13A). During the design of the expression vector for miR169g, we noticed that a construct containing only the stem-loop precursor of 222 bp resulted in higher accumulation of the mature miRNA than a construct containing the entire 2.0 kb intergenic region including the miR169g gene (Fig. 13B).

10 Based on this result we decided to continue our mutagenesis of miRNA sequences using exclusively short precursor vectors. Examination of the *PDS* mRNA with the miR169g sequence revealed a region in the mRNA sequence susceptible for miRNA cleavage, different from that found for miR-*PDS*^{159a}. Seven point mutations turn miR169g into a microRNA capable of base-pairing perfectly to the *PDS* mRNA (miR-*PDSa*^{169g}, Fig. 13A). As shown 15 before for the miR159a-based miR-*PDS*, transient expression of miR-*PDSa*^{169g} in *N. benthamiana* is easily detected (Fig. 13C). In addition, to test whether the entire miRNA can be changed independently of its original sequence, we have generated miR-*PDSb*^{169g} (Fig. 13A and Fig. 13C), which targets a different region in the *PDS* mRNA selected irrespective of its homology to the original miR169g. Using both miR-*PDSa*^{169g} and miR-*PDSb*^{169g} we could 20 detect cleavage of the *PDS* mRNA, as determined by 5'RACE analysis (Fig. 13D) and a reduction in *PDS* mRNA levels as determined by Northern blot analysis (Fig. 13E).

[0329] These results show that a different miRNA precursor can be used to target degradation of *PDS* mRNA and importantly, that the sequence of the original miRNA can be extensively changed to design an artificial one.

25

EXAMPLE 19

[0330] This example demonstrates microRNA-directed specific cleavage of *Nicotiana benthamiana rbcS* mRNAs.

[0331] To show that this approach can be used to target other genes different from *PDS*, we

30 have introduced point mutations in miR159a to target the different members of the Rubisco small subunit (*rbcS*) gene family of *N. benthamiana*. We searched for *rbcS* EST transcripts present in publicly available databases and found that at least 6 different *rbcS* transcripts are expressed in *N. benthamiana*. Nucleotide sequences of the coding region of these *rbcS*

transcripts were over 90% identical to each other, and allowed us to design miR-*rbsS*^{159a}-A, which targets all members of the gene family. Here, the sequence introduced in miR159a was not guided by the minimal number of changes that would target *rbsS* but reflected the need to target a specific region common to all *rbsS* mRNAs and thus included several changes. In this 5 way, we have generated one miRNA that targets all six *rbcS* mRNAs (miR-*rbcS*^{159a}-A, Fig. 14A).

[0332] As in the previous examples, we have detected efficient expression of the miR-*rbsS*^{159a}-A (Fig. 14B), but due to the high degree of homology among the members of this family, distinct *rbsS* mRNAs have been difficult to detect by Northern blot analysis. Instead, we 10 have used semi-quantitative RT-PCR to determine the levels of mRNAs in plants infiltrated with Agrobacterium strains containing the miR-*rbcS*^{159a}-A construct. Compared to leaves infiltrated with the empty binary vector (C in Fig. 14C), mRNA accumulation for *rbcS* genes 1, 2 and 3 was reduced while for *rbcS* genes 4, 5 and 6 it could not be detected in samples infiltrated with a 15 miR-*rbcS*^{159a}-A construct (A in Fig. 14C). These results indicate that the artificial miRNA targeted all the *rbcS* mRNAs it was intended for, although the efficiency in each case varied. Finally, the presence of the artificial miRNA did not interfere with expression of other plant genes such as EF1 α (Fig. 14C, bottom panel).

[0333] The artificial miRNAs presented here are distributed along three different locations in *PDS* mRNA (summarized in Fig. 15A), and have been used to target 2 different genes (*PDS* and *rbcS*, Fig. 15A and Fig. 15B). This range of use is also reflected in the flexibility of the miRNA sequences, as the artificial miRNAs show that almost every nucleotide position can be changed (Fig. 16). Changes in miR159a to create two artificial miRNAs retained only 8 positions unchanged (Fig. 16A). In the case of miR169g this number was reduced to only three positions (Fig. 16B). Moreover, when the mutations in both miRNAs are analyzed together, only the first 25 two nucleotide positions remain untouched. This suggests that every position along the miRNA sequence can be changed, adding to the advantages of using artificial miRNAs for gene silencing.

EXAMPLE 20

[0334] This example demonstrates that artificial *miRNACPC*^{159a} inhibits root hair development in *Arabidopsis*.

[0335] Root epidermal cells differentiate root-hair cells and hairless cells. Only root-hair epidermal cells are able to develop into root hair. In *Arabidopsis* roots, among a total of 16-22

cell files, 8 symmetrically positioned cell files are root-hair cells and all others are hairless cell files. *CAPRICE (CPC)*, a MYB like protein, positively regulates root hair development by negatively regulating *GLABRA2 (GL2)*, which promotes root epidermal cells differentiation into hairless cells. In *cpc* mutant, *GL2* causes most epidermal cells to differentiate into root hairless cells, and consequently, very few cells are able develop root hair. Roots of the *gl2* mutant or wild type transgenic plants over-expressing *CPC*, produce more root hairs compared to wild type roots (Fig. 17; Wada *et al.* (2002) *Development* 129:5409-5419).

[0336] *CPC* is a good candidate for investigations on the utility of artificial miRNAs to silence or suppress gene function because the loss-of-function phenotype of *CPC* appears at a very early stage during seedling development, does not cause lethality and is easy to observe. Using pre-miRNA159 as a backbone two artificial pre-miRNAs, *pre-miRCPC1^{159a}* and *pre-miRCPC3^{159a}* were designed to target different regions of the *CPC* mRNA. Mature *miRCPC1^{159a}* and *miRCPC3^{159a}* are complementary to the sequences located in nt 233-253 and nt 310-330, respectively, of the *CPC* messenger RNA. The nucleotide sequences for the precursor and mature miRNAs are as follows.

[0337] *miRCPC1^{159a}* precursor template:

5'acagttgcttatgtcgatccataatataattgacaagatactttcgatagatctgatctgacgatggaaagaagaggtagtaatgtgaaacatgagttgagcaggtaaagaaaagctgctaagctatggatcccataagccctaattctgtaaagtaaaaaaggattggttatggattgcataatctcaggagcttaacttgcccttaatggctttactcttcgtactactcacctctcatccgggtca 3' (SEQ ID NO:151).

[0338] *miRCPC1^{159a}* mature template: 5' ttgcataactcaccttt 3' (SEQ ID NO:152).

[0339] *miRCPC3^{159a}* precursor template:

5'acagttgcttatgtcgatccataatataattgacaagatactttcgatagatctgatctgacgatggaaagctcggtggcagagggtgggcatgagttgaggcaggtaaagaaaagctgctaagctatggatcccataagccctaattctgtaaagtaaaaaaggattggttatggattgcataatctcaggagcttaacttgcccttaatggctttactcttcgtactactcacctctcatccgggtca 3' (SEQ ID NO:153).

[0340] *miRCPC3^{159a}* mature template: 5' ctcccacctgacgccaacgag 3' (SEQ ID NO:154).

[0341] These two artificial pre-miRNAs were cloned into a vector which contains a constitutive 35S promoter for expression of these precursors. Northern blot analysis of *Nicotinana benthamiana* leaves infiltrated by *Agrobacteria* carrying 35S::*per-miRCPC1^{159a}* or 35S::*pre-miRCPC3^{159a}* constructs indicated successful production of mature *miRCPC1^{159a}* and *miRCPC3^{159a}*.

[0342] *Arabidopsis thaliana* plants were transformed by *Agrobacteria* carrying *XVE::pre-miRCPC1^{159a}* or 35S::*pre-miRCPC1^{159a}*, and many transgenic lines were obtained. T₁ seeds of *XVE::pre-miRCPC1^{159a}* plants were germinated on antibiotic selection medium containing

kanamycin and resistant transgenic seedlings were transferred to MS medium with or without β -estradiol, an inducer of the XVE system. T_1 transgenic lines carrying $XVE::pre-miR159$ were used as a control. Pre-miR159 is the backbone used to construct the artificial $pre-miRCPC1^{159a}$.

[0343] No difference in root hair development between $XVE::pre-miR159$ seedlings grown 5 on medium with or without inducer (Figure 18, panels c and d) was seen. By contrast, $XVE::pre-miRCPC1^{159a}$ seedlings grown on medium with β -estradiol clearly developed fewer root hairs (Figure 18, panel b) than those grown without inducer (Figure 18, panel a).

[0344] T_1 seedlings of transgenic *Arabidopsis* seedlings carrying $35S::pre-miRCPC1^{159a}$, 10 $35S::pre-miR159$ and $35S::pre-miRP69^{159a}$ were investigated and similar results were obtained as the XVE inducible lines. T_1 seeds of transgenic lines were germinated on a BASTA-selective medium and two-week old seedlings were transferred to MS medium plates placed vertically in a tissue culture room. In this experiment, two negative controls were used: transgenic lines carrying $35S::pre-miR159$ and those carrying $35S::pre-miRP69^{159a}$. The latter was designed 15 using *pre-miR159* as a backbone to produce an artificial $pre-miRP69^{159a}$ targeting nt 214-234 of the *P69* mRNA of turnip yellow mosaic virus (TYMV; Bozarth *et al.* (1992) *Virology* 187:124-130). The nucleotide sequences for the precursor and mature miRNAs are as follows.

[0345] $miRP69^{159a}$ precursor template:

20 5'acagttgcttatgtcgatccataatattgacaagatactttgtttcgata~~g~~atcttgatctgacgatggaaaggccacaagacaatcga
gactttcatgagttgagcaggtaaagaaaagctgctaagctatggatcccataa~~g~~ccctaattctgtaaagtaaaaaggattggatat
ggattgcatatctcaggagcttaacttgccttaatggctttactcttcaaagtct~~c~~gattgtctgtggatccgggtca 3' (SEQ ID
NO:155)

[0346] $miRP69^{159a}$ mature template: 5' aaagtctcgattgt~~c~~ttgtgg 3' (SEQ ID NO:156).

[0347] Seedlings of both types of transgenic plants developed abundant root hair as wild type 25 plants (Figure 19, panels a and c). By contrast, among 30 independent $35S::pre-miRCPC1^{159a}$ lines, 18 lines showed clearly fewer root hair (Figure 19, panel b) compared to negative control plants (Figure 19 panels a and c).

[0348] In negative control transgenic plants ($35S::pre-miR159$ and $pre-miRP69^{159a}$), all root-hair file cells in the epidermis of the root tip region were able to develop root hairs (Figure 20, panel a; see arrows). However, in transgenic lines carrying $35S::pre-miRCPC1^{159a}$ many cells in 30 root-hair files were unable to produce root hairs (Figure 20, panel b; see arrows). These results indicate that the artificial $miRCPC1^{159a}$ is able to induce cleavage of the endogenous *CPC* mRNA to cause a loss function of the *CPC* gene function and inhibit root hair development.

EXAMPLE 21

[0349] This example describes one embodiment of a process for the designing a polymeric pre-miRNA.

[0350] Step 1: Different pre-miRNAs are amplified by PCR to include an AvrII site in the 5' end and to include an SpeI site and an XhoI site in the 3' end. Each pre-miRNA is then cloned into a vector, such as pENTR/SD/D-TOPO (Invitrogen) to produce, for example, pENTR/pre-miRA, pENTR/pre-miRB and pENTR/pre-miRC (Fig. 21A).

[0351] Step 2: The pENTR/pre-miRA is digested with the restriction enzymes SpeI and XhoI. The restriction enzymes AvrII and XhoI are used to digest the pENTR/pre-miRB vector (Fig. 21B). Opened vector pENTR/pre-miRA and DNA fragment of pre-miRB are collected and purified for further steps.

[0352] Step 3: The opened vector pENTR/pre-miRA and DNA fragment of pre-miRB from step 2 are ligated to generate dimeric pre-miRA-B (Fig. 21C). Because of compatible cohesive ends of AvrII and SpeI, the pre-miRB fragment can be inserted into the opened pENTR/pre-miRA and both AvrII and SpeI sites will disappear after ligation (Fig. 21C).

[0353] Step 4: The pENTR/pre-miRA-B is digested by with the restriction enzymes SpeI and XhoI, and pENTR/pre-miRC is digested with the restriction enzymes AvrII and XhoI (Fig. 21D). Opened vector pENTR/pre-miRA-B and DNA fragment of pre-miRC are collected and purified for further steps.

[0354] Step 5: The opened vector pENTR/pre-miRA-B and DNA fragment of pre-miRC from step 4 are ligated to generated triple pre-miRNA-B-C (Fig. 21E).

[0355] In this manner, or using functionally equivalent restriction enzymes polymeric pre-miRNAs containing more pre-miRNA units can be prepared. As many pre-miRNAs as desired can be linked together in this fashion, with the only limitation being the ultimate size of the transcript. It is well known that transcripts of 8-10 kb can be produced in plants. Thus, it is possible to form a multimeric pre-miRNA molecule containing from 2-30 or more, for example from 3-40 or more, for example from 3-45 and more, and for further example, multimers of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or more pre-miRNAs.

30

EXAMPLE 22

[0356] This example demonstrates the successful processing of a dimeric pre-miRNA to two mature miRNAs.

[0357] Artificial *pre-miRPDS1*^{169g} and *pre-miRCPC3*^{159a} were linked to form dimeric precursor, *pre-miRPDS1*^{169g}-*CPC3*^{159a} as described in Example 21. This dimeric miRNA precursor was cloned into a vector in which 35S promoter drives expression of the *pre-miRPDS1*^{169g}-*CPC3*^{159a} (Fig. 22). The nucleotide sequences for the precursor and mature miRNAs are as follows.

5 [0358] *miRPDS1*^{169g} precursor template:

5'aatgatgattacgatgatgagagtctctagtttatcagaggcttgcatttgcataatgagaatgaggtagtttagtctgacttggcc
acttttttaccaatgaatctaattactgattctgggtggccaaagtcaactctgtttccctctttggatgtcagactccaagata
tctatcatcatgatcaaacttg 3' (SEQ ID NO:157).

10 [0359] *miRPDS1*^{169g} mature template: 5' gagtttagtctgacttggcc 3' (SEQ ID NO:158).

[0360] *miRPDS1*^{169g}-*CPC3*^{159a} precursor template:

5'caccttaggaatgattacgatgatgagagtctctagtttatcagaggcttgcatttgcataatgagaatgaggtagtttagtctg
acttggccagtttttaccaatgaatctaattactgattctgggtggccaaagtcaactctgtttccctctttggatgtcagact
ccaagatatactatcatcatgatcaaacttgaaagggtggcgactaggacagttgcttatgtcggatccataatataattgacaaga
tacttttttcgatagatctgatctgacgatgaaagctcggtggcgacagggtgggagcatgagttgagcaggtaaagaaaagctgctaa
gctatggatccataagccctaattctgtaaagtaaaaaaggattggatatggatcatatctcaggagcttaactgcccttaatggct
tttactttccctccacctgacgccaacgcatccgggtcaaagggtggcgactagtctagactcgagtatt 3' (SEQ ID
NO:159).

15 [0361] Northern blotting analysis of tobacco *Nicotiana benthamiana* leaves, infiltrated by *Agrobacterium* carrying different constructs of 35S::*pre-miRPDS1*^{169g}, 35S::*pre-miRCPC3*^{159a} and 35S::*pre-miRPDS1*^{169g}-*CPC3*^{159a}, indicates that mature *miRPDS1*^{169g} and *CPC3*^{159a} were successfully produced from the dimeric miRNA precursor (Figs. 23A and 23B). In this experiment, treatment 1 is 35S::*pre-miRPDS1*^{169g}, treatment 2 is 35S::*miRCPC3*^{159a} and treatment 3 is 35S:: *pre-miRPDS1*^{169g}-*CPC3*^{159a}. When *miRPDS1*^{169g} anti sense DNA oligo as probe, both 1 and 3 treatments showed signals that proved the dimeric precursor was able to produce matured *miRPDS1*^{169g}. When the probe is *miRCPC3*^{159a} anti sense DNA oligo, signal in treatment 3 confirmed the ability of *pre-miRPDS1*^{169g}-*CPC3*^{159a} to generate mature *miRCPC3*^{159a}.

EXAMPLE 23

30 Design of Anti-viral miRNAs

[0362] Since viral gene silencing suppressors are used to counteract host defense, we reasoned that compromising the production of these suppressors by the expression of specific miRNAs would be an effective mechanism to confer resistance or tolerance to plant viruses (Roth *et al.* (2004) *Virus Res* 102:97-108). This principle is demonstrated by using TuMV as an example.

[0363] HC-Pro and P69 are plant PTGS suppressors encoded by TuMV and TYMV, respectively (Anandalakshmi *et al.* (1998) *Proc Natl Acad Sci USA* 95:13079-13084; Chen *et al.* (2004) *Plant Cell* 16:1302-1313; Kasschau and Carrington (1998) *Cell* 95:461-470). Using these two viral suppressor genes as targets, artificial miRNAs were designed with sequence 5 complementarity to their coding sequences.

[0364] At-miR159a is strongly expressed in most *Arabidopsis* organs and at high levels. Similar high level expression was also found in other plants species such as corn and tobacco. For these reasons, the *miR159a* precursor (pre-miR159a) was used as a backbone to generate artificial miRNAs. Pre-miR159a, a 184nt stem-loop RNA, produces mature *miR159a* (5'-uuuggauugaaggggagcucua-3'; SEQ ID NO:160) from the base of its stem near the 3'end. This base stem sequence is the miR159a sequence and the complementary strand is called miR159a* sequence (Fig. 24; SEQ I DNO:161). To design artificial miRNA, the miR159a sequence was replaced by a sequence 5'-acuugcucacgcacucgacug-3' (SEQ ID NO:162), which is complementary to the viral sequence encoding HC-P from 2045 to 2065 of the TuMV genome 10 sequence. The miR159a* sequence was also altered to maintain the stem structure. For more 15 efficient miRNA processing and convenient manipulation of the artificial miRNA precursor, a 78bp sequence cloned from the genome sequence upstream of pre-miR159 was added to the 5'end of this artificial miRNA precursor. This primary miRNA-like artificial miRNA precursor was called pre-miRHC-P^{159a}. Its DNA sequence follows.

[0365] *Pre-miRHC-P^{159a}*

5'CAGTTGCTTATGTCGGATCCATAATATATTGACAAGATACTTGTTTCGATA
GATCTTGATCTGACGATGGAAGCAGTCGAGTGCCTGAGCAAGTCATGAGTTGAGCA
GGGTAAAGAAAAGCTGCTAACAGCTATGGATCCCATAAGCCCTAACCTGTAAAGTA
AAAAAGGATTGGTTATGGATTGCATATCTCAGGAGCTTAACTGCCCTTAAT
25 GGCTTTACTCTTCACTGCTCACGCACTCGACTGC 3' (SEQ ID NO:163)

[0366] Using the same method, *pre-miRP69^{159a}* was also constructed. *Pre- miRP69^{159a}* was predicted to generate mature artificial miRNA P69^{159a}, 5'-aaagucucgauugucuugugg-3' (SEQ ID NO:164), to target the *P69* gene of TYMV. Its DNA sequence follows.

[0367] *Pre-miR P69^{159a}*

30 5'CAGTTGCTTATGTCGGATCCATAATATATTGACAAGATACTTGTTTCGATA
GATCTTGATCTGACGATGGAAGCACAAGACAATCGAGACTTCATGAGTTGAGCA
GGGTAAAGAAAAGCTGCTAACAGCTATGGATCCCATAAGCCCTAACCTGTAAAGTA
AAAAAGGATTGGTTATGGATTGCATATCTCAGGAGCTTAACTGCCCTTAAT
GGCTTTACTCTCAAAGTCTCGATTGTCTGGC 3' (SEQ ID NO:165)

EXAMPLE 24

Expression of *pre-miRHC-Pro^{159a}* and *pre-miRP69^{159a}* in *Nicotiana benthamiana*

[0368] Replacement of the miR159 and miR159* sequences in the pre-miR159 may possibly effect RNA folding structure which is believed to be important for miRNA biosynthesis. A 5 tobacco transient expression system was used to check whether these two artificial miRNA precursors can produce the desired miRNAs. *Agrobacterial* cells containing plasmids with 35S::*pre-miR-HC-Pro^{159a}*, 35S::*pre-miR-P69^{159a}*, 35S::*HC-Pro*, 35S::*P69*, and *XVE::pre-miR-P69^{159a}* were used to infiltrate *N. benthamiana* leaves (Llave *et al.* (2000) *Proc Natl Acad Sci USA* 97:13401-13406; Voinnet *et al.* (2000) *Cell* 103:157-167).

10 [0369] One ml of stationary phase growth culture of *Agrobacterium tumefaciens* carrying different constructs were cultured overnight in 50 ml LB medium containing 100 mg/l spectinomycin and 50 mg/l kanamycin and cells were collected by centrifugation at 4,000 rpm for 10 minutes. Bacterial pellets were re-suspended in 50 ml 10 mM MgCl₂ solution with 75 µl of 100 mM acetosyringone. After incubation at room temperature for 3 hr without shaking, the 15 *Agrobacterial* suspensions were infiltrated into leaves of *N. benthamiana* by a syringe. Two days later, total RNA was extracted from the infiltrated leaves using the trizol reagent (Invitrogen) and analyzed by northern blot hybridizations (Guo *et al.* (2005) *Plant Cell* 17:1376-1386; Wang *et al.* (2004) *Genome Biol* 5:R65). Samples of 20 µg total RNA were analyzed by electrophoresis on a 15% polyacrylamide gel and blotted to a Hybond-N+ membrane (Amersham). DNA oligonucleotides with exact complementary sequence to *miR-HC-Pro^{159a}* or *pre-miR-P69^{159a}* were end-labeled with [γ -³²P]-ATP and T4 polynucleotide kinase to generate high specific activity probe. Hybridization was carried out using the ULTRA-Hyb Oligo solution according to the manufacturer's directions (Ambion) and signals were detected by autoradiography.

20 [0370] Northern blot analyses of *miR-HC-Pro^{159a}* were performed with three different treatments: (1) *Agrobacterial* cells with 35S::*pre-miR-HC-Pro^{159a}*, (2) *Agrobacterial* cells with 35S::*HC-Pro*, and (3) *Agrobacterial* cells with 35S::*pre-miR-HC-Pro^{159a}* and 35S::*HC-Pro*. The results are shown in Fig. 25.

25 [0371] Note that mature *miR-HC-Pro^{159a}* signals were detected in all treatments with 35S::*pre-miR-HC-Pro^{159a}* (column 1, 2, 5, 6 of Fig. 25). No signal was detected when leaves were infiltrated with the 35S::*HC-Pro* construct only (column 3 and 4 of Fig. 25). This result indicates that the artificial *pre-miR-HC-Pro^{159a}* can generate mature *miR-HC-Pro^{159a}* in the plant cell.

[0372] In the case of *miR-P69*, 4 different treatments were performed : (1) *Agrobacterial* cells carrying *35S::pre-miR-P69^{159a}*, (2) *Agrobacterial* cells carrying *XVE::pre-miR-P69^{159a}*, (3) *Agrobacterial* cells carrying *35S::P69*, and (4) *Agrobacterial* cells carrying *35S::pre-miR-P69^{159a}* and *35S::P-69*. Note that the XVE system is a transcriptional inducible system 5 responsive to β-estradiol (Zuo *et al.* (2001) *Nature Biotechnol* 19(2):157-61).

[0373] The Northern blot results (Fig. 26) showed that mature *miR-P69^{159a}* was detectable only in leaves infiltrated with *35S::pre-miR-P69^{159a}* and *XVE::pre-miR-P69^{159a}* plus inducer (column 1, 2, 4, 6, 8, and 9 of Fig. 26). Leaves infiltrated with *35S::P69* and *XVE::pre-miR-P69^{159a}* without inducer can not produce *miR-P69^{159a}* (column 3, 5, and 7 of Fig. 26). 10 Together, these results indicate that artificial *pre-miR-P69^{159a}* can be successfully used to generate mature *miR-P69^{159a}*.

EXAMPLE 25

Stable *Arabidopsis* Transgenic Lines with High Artificial miRNAs Expression Levels

[0374] Constructs containing *35S::pre-miR-HC-Pro^{159a}* or *35S::pre-miR-P69^{159a}* was transformed into *Arabidopsis* Col-0 ecotype mediated by *Agrobacteria* using the floral dip method (Clough and Bent (1998) *Plant J* 16:735-43).

[0375] Transgenic seedlings were selected on selection medium (MS salts 4.3 g/l + Sucrose 20 g/l + Basta 10 mg/l + Carbenicilin 200 mg/l + Agar 8 g/l). Twelve different *35S::pre-miR-HC-Pro^{159a}* or *35S::pre-miR-P69^{159a}* *T₂* transgenic lines were randomly picked and used to analyze mature artificial miRNA levels by northern blots. Among 12 transgenic *35S::pre-miRHC-Pro^{159a}* lines, 11 lines showed high levels of expression of *miRHC-Pro^{159a}* (Fig. 27). In *Arabidopsis* transgenic *35S::pre-miR-P69^{159a}* plants, all *T₂* lines tested showed *miR-P69^{159a}* 25 signals and 10 lines showed high expression levels (Fig. 28).

EXAMPLE 26

TuMV Virus Challenge of WT and Transgenic Plants

[0376] Inoculation of WT and transgenic *Arabidopsis* lines with the TuMV

[0377] *N. benthamiana* leaves were inoculated with *Turnip mosaic virus* (TuMV) (Chen *et al.* (2003) *Plant Dis* 87:901-905) and two weeks later tissues were extracted in 1:20 (wt/vol) dilution in 0.05 M potassium phosphate buffer (pH 7.0). This extract was used as a viral inoculum. *T₂* plants of *35S::miR-HC-Pro^{159a}* transgenic *Arabidopsis* lines were grown in a

greenhouse for 4 weeks (5 to 6 leaves stage) before inoculation. Plants were dusted with 600-mesh Carborundum on the first to fourth leaf and gently rubbed with 200 μ l inoculum. Wild type *Arabidopsis thaliana* (col-0) plants and transgenic plants expressing 35S::*miR-P69*^{159a} were used as controls. Inoculated plants were kept in a temperature-controlled greenhouse (23° C to 5 28° C) and symptom development was monitored daily for 2 weeks.

[0378] Enzyme-linked immunosorbent assay (ELISA)

[0379] Leaf disks (a total of 0.01 g) from different systemic leaves of each plant infected 10 with TuMV were taken 14 dpi (days post infection), and assayed by indirect enzyme-linked immunosorbent assay (ELISA) using a polyclonal antiserum to TuMV coat protein (CP) (Chen *et al.* (2003) *Plant Dis* 87:901-905) and goat anti-rabbit immunoglobulin G conjugated with alkaline phosphatase. The substrate p-nitrophenyl phosphate was used for color development. Results were recorded by measuring absorbance at 405 nm using Tunable Microplate Reader (VersaMax, Molecular Devices Co., CA).

[0380] Western blot analysis

[0381] 15 Western blot analysis was conducted using the rabbit antiserum to TuMV CP (Chen *et al.* (2003) *Plant Dis* 87:901-905) and goat anti-rabbit immunoglobulin G conjugated with alkaline phosphatase. Systemic leaves from *Arabidopsis* plants were homogenized in 20 volumes (wt/vol) of denaturation buffer (50 mM Tris-HCl, pH 6.8, 4% SDS, 2% 2-mercaptoethanol, 10% glycerol, and 0.001% bromophenol blue). Extracts were heated at 100° C 20 for 5 min and centrifuged at 8,000xg for 3 min to pellet plant debris. Total protein of each sample (15 μ l) was loaded on 12% polyacryamide gels, separated by SDS-polyacrylamide gel electrophoresis, and subsequently transferred onto PVDF membrane (immobilon-P, Millipore, Bedford, MA) using an electro transfer apparatus (BioRad). The membranes were incubated 25 with polyclonal rabbit antiserum to TuMV CP as primary antibodies and peroxidase-conjugated secondary antibodies (Amersham Biosciences) before visualization of immunoreactive proteins using ECL kits (Amersham Biosciences). Gels were stained with coomassie-blue R250 and levels of the large subunit of RUBISCO (55 kd) were used as loading controls.

[0382] 30 It was found that transgenic plants expressing *miR-HC-Pro*^{159a} artificial miRNA are resistant to TuMV infection (Fig. 29). Photographs were taken 2 weeks (14 days after infection) after inoculation. Plants expressing *miR-HC-Pro*^{159a} (line #11; Fig 33B) developed normal influorescences whereas WT plants and transgenic plants expressing *miR-P69*^{159a} (line #1; Fig 33B) showed viral infection symptoms.

[0383] Forteen days after TuMV infection, *miR-P69^{159a}* (line #1) and col-0 plants showed shorter internodes between flowers in inflorescences, whereas *miR-HC-Pro^{159a}* transgenic plant (line #11) displayed normal inflorescences development (Fig. 30, upper panel). Close-up views of inflorescences on TuMV-infected *Arabidopsis* plants. *miR-P69^{159a}* (line #1) and col-0 plants showed senescence and pollination defects whereas *miR-HC-Pro^{159a}* plants (line #11) showed normal flower and siliques development (Fig. 30, bottom panel). For mock-infection, plants were inoculated with buffer only.

[0384] In TuMV-infected *miR-P69^{159a}* (line #1) and WT (col-0) plants, siliques were small and mal-developed. *miR-HC-Pro^{159a}* plants (line #11) were resistant to TuMV infection and showed normal siliques development (Fig. 31). Buffer-inoculated plants (mock-inoculated) were used as controls.

[0385] Two independent experiments were performed to examine the resistance of various transgenic *miR-HC-Pro^{159a}* and WT plants to TuMV infection. Experiment 1: Sixteen individual plants of a T₂ transgenic line (line # 11 of *miR-HC-Pro^{159a}* plant and line #1 of *miR-P69^{159a}* plant) were used. Twelve individual plants were inoculated with virus whereas 4 individual plants were inoculated with buffer as control (MOCK). After 2 weeks system leaves were collected for western blot analyses using an antibody against TuMV CP. No TuMV CP was detected in *miR-HC-Pro^{159a}* transgenic plants, whereas, TuMV CP was highly expressed in *miR-P69^{159a}* and WT col-0 plants (Fig. 32). The large subunit (55kd) of RUBISCO was used as a loading control. Note that no CP was detected in lane 6 (top panel) and lane 4 (middle panel) likely due to failed virus inoculation. These plants had no symptoms. The results of the infectivity assay are shown in Table 7.

TABLE 7

25 Infectivity Assay of Transgenic *Arabidopsis* of the
miR-HC-Pro^{159a} and *miR-P69^{159a}* Challenged with TuMV Inocula

Transgenic line	Number of seedlings			Resistant rate (%)
	Resistant	Susceptible	Total	
<i>miR-HC-Pro^{159a}</i> #11	12	0	12	100
<i>miR-P69^{159a}</i> #1	1	11	12	8.3
col-0	1	11	12	8.3

[0386] Experiment 2: The following transgenic lines and WT plants were used. (1) 35S::*miR-HC-Pro^{159a}* plants: line #10 (12 plants inoculated with TuMV and 4 with buffer); line #11 (12

plants inoculated with TuMV and 4 with buffer); line #12 (9 plants inoculated with TuMV and 4 with buffer); line #13 (10 plants inoculated with TuMV and 4 with buffer). (2) *35S::miR-P69^{159a}* plants: line #1 (8 plants inoculated with TuMV and 4 with buffer); line #2 (7 plants inoculated with TuMV and 4 with buffer); line #3 (9 plants inoculated with TuMV and 4 with buffer); line 5 #7 (5 plants inoculated with TuMV and 4 with buffer).

[0387] Western blot results of a representative plant from each transgenic line are shown in Figure 33, panel A. Levels of the large subunit (55kd) of RUBISCO were used as loading controls. All plants expressing *35S::miR-HC-Pro^{159a}* were resistant to the virus and did not show any visible symptoms nor expressed any TuMV CP. All WT plants and *35S::miR-P69^{159a}* 10 plants showed TuMV infection symptoms and expressed high levels of TuMV CP. All mock-infected plants were normal and did not express any TuMV CP. Expression of artificial miRNA in *miR-HC-Pro^{159a}* and *miR-P69^{159a}* transgenic Arabidopsis is shown in Figure 33, panel B. The results of the infectivity assay are shown in Table 8.

15

TABLE 8

Infectivity Assay of Transgenic *Arabidopsis* of the
miR-HC-Pro^{159a} and *miR-P69^{159a}* Challenged with TuMV Inocula

Transgenic line	Number of seedlings			Resistant rate (%)
	Resistant	Susceptible	Total	
<i>miR-HC-Pro^{159a}</i> #10	12	0	12	100
<i>miR-HC-Pro^{159a}</i> #11	12	0	12	100
<i>miR-HC-Pro^{159a}</i> #12	9	0	9	100
<i>miR-HC-Pro^{159a}</i> #13	10	0	10	100
<i>miR-P69^{159a}</i> #1	0	8	8	0
col-0	1	11	12	8.3

[0388] Fourteen days after infection with TuMV, samples of systemic leaves were collected 20 and extracts assayed by ELISA. The results are means of ELISA readings of 9 or 12 plants from two different experiments. The results (Fig. 34) show that the *miR-HC-Pro^{159a}* plants were completely resistant to TuMV infection. The readings were taken after 30 min of substrate hydrolysis.

EXAMPLE 27

Production of More Than One Synthetic miRNAs
from Same Transcript Using Homo-Polymeric pre-miRNAs

[0389] Polymeric pre-miRNAs are artificial miRNA precursors consisting of more than one miRNA precursor units. They can either be hetero-polymeric with different miRNA precursors, or homo-polymeric containing several units of the same miRNA precursor. In previous Examples, it has been demonstrated that hetero-polymeric pre-miRNAs are able to produce different mature artificial miRNAs. For example, *pre-miR-PDS1^{169g}-CPC3^{159a}*, which is a dimer comprising of *pre-miR-CPC3^{159a}* and *pre-miR-PDS1^{169g}* can produce mature *miR-PDS1^{169g}* and *miR-CPC3^{159a}* when expressed in plant cells. Here, the use of homo-polymeric miRNA precursors to produce different mature artificial miRNAs is described.

[0390] *Pre-miR-P69^{159a}* and *pre-miR-HC-Pro^{159a}* were generated from the *pre-miR159a* backbone. They are derived from the same miRNA precursor. They were linked together to form a homo-dimeric pre-miRNA, *pre-miR-P69^{159a}-HC-Pro^{159a}*. The DNA sequence follows.

[0391] *Pre-miR^{159a}-HC-P^{159a}*

5'cagttgcttatgtcgatccataatataattgacaagatactttgtttcgatagatctgatctgacgatggaagccacaagacaatcgag
actttcatgagttgagcaggtaaagaaaagctgctaagctatggatcccataagccctaattcctgtaaagtaaaaaaggattggttatatg
gattgcatatctcaggagcttaacttgccttaatggctttactcttc**AAAGTCTCGATTGTCTTGTGGcATCCC**
GGGTCAAAGGGTGGCGACTAGGAcagttgcttatgtcgatccataatataattgacaagatactttgtttcgatag
atcttgatctgacgatggaaggcagtcgagtgcgtgagcaagtcatgagttgagcaggtaaagaaaagctgctaagctatggatcccataa
gccctaattcctgtaaagtaaaaaaggattggttatatggcatatctcaggagcttaacttgccttaatggctttactcttc**ACTTG**
CTCACGCACTCGACTGc 3' (SEQ ID NO:166)

[0392] The sequences in lower case text are At-miR159 backbone. The sequence in bold text is *miR-P69^{159a}*. The sequence in italic text is *miR-HC-Pro^{159a}*. The sequence in bold italic text is the linker sequence.

[0393] A tobacco transient expression system was used to check whether this homo-dimeric miRNA precursor can produce the desired mature *miR-P69^{159a}* and *miR-HC-Pro^{159a}*. In this experiment, three treatments were performed: (1) *Agrobacteria* with *35S::pre-miR-P69^{159a}*, (2) *Agrobacteria* with *35S::pre-miR-HC-Pro^{159a}*, and (3) *Agrobacteria* with *35S::pre-miR-P69^{159a}-HC-Pro^{159a}*. Northern analysis indicated that homo-dimeric miRNA precursor, *pre-miR-P69^{159a}-HC-Pro^{159a}*, can produce mature *miR-P69^{159a}* and *miR-HC-Pro^{159a}* (Fig. 35).

EXAMPLE 28

Expression of miRNAs from pre-miRNAs Inserted in Intronic Sequences

[0394] During RNA splicing, introns are released from primary RNA transcripts and therefore can potentially serve as precursors for miRNAs. In this example, the insertion of pre-
5 miRNAs into such intronic sequences to produce artificial miRNAs is described.

[0395] Most introns begin with the sequence 5'-GU-3' and end with the sequence 5'-AG-3'. These sequences are referred to as the splicing donor and splicing acceptor site, respectively. In addition to these sequences, the branch site which is located within introns is also important for intron maturation. Without the branch site, an intron can not be excised and released from the primary RNA transcript. A branch site is located 20-50 nt upstream of the splicing acceptor site. Distances between the splice donor site and the branch site are largely variable among different introns. For this reason, it was decided to insert artificial pre-miRNAs in between these two sites, i.e., the splice donor site and the branch site, of introns.

[0396] The *Arabidopsis* *CARPRICE* (*CPC*) gene contains three exons and two introns. 15 Following the consensus sequence of the branch site 5'-CU(A/G)A(C/U)-3', where A is conserved in all transcripts, two branch sites located in 128 to 132 nt (intron 1) and 722 to 726 nt (intron 2) downstream of the start codon are predicted. Sequences from 111 to 114 nt and from 272 to 697 nt, located in intron 1 and in intron 2, respectively, were replaced by artificial miRNA precursors containing the miR159a backbone. The DNA sequence follows.

20 [0397] *CPC* genome sequence

atgtttcggtcagacaaggcgaaaaatggataaacgacgacggagacagagcaaagccaaggcttgcgttccgaagGTCTGAT
TTCTCTTGTCTCTATATCTTTGATCGGTTGAGTCTGATTGTATGTTGT
TTCGCAAGgggtgagtagtatcgaatgggaagctgtgaagatgtcagaagaagaagaagatctcatttcggatgtataaactcgttg
gcgacagGTTAGAGACTCTTCTCTCGATCCATCTTGTGCTTCTTTTGG
25 TCTTTCATGTTGTCGAATCTGCTTAGATTGATCTCAAAAGTCGGTCTTIA
TTTATGCATTCTGGTTCTATTATATTATTGGGTCTAACTTACCGAGCTG
TCAATGACTGTGTTCAGCCTGATTGATCTTGTATTCTCTGTTCTTGT
TTTAGTTGTTCAAATAGCAAAACCTAATCAAGATTCTTCAGTTCTTCTTCTT
TATATATGATTCTTAGCAAAACATATTCTTAATTATGTCAGAACTCAGTTGG
30 CTAGTTGGTTCAATTGATTACAGCATGTTGTATGAAGTCAAAAGTGTAAAT
TACGATTCTGGTTCCATAGAATTAAACCGAATTACAAACTTTATGCGGG
TTTTATCGGAATAAAAGGTATTGGTTAAGTGTAAAGTTCCTCAACACTGACTGTT
AGCCTATCCTACGTGGCGCGTAGgtggagttgatcgccggacggacggaggataga
gagatattggcttatgaaacacggcgtcgcccccaacagacgaagagacttttaggaaatga (SEQ ID NO:167)

35 [0398] The sequences in lower case are exons. The sequences in bold italic text are branch
sites. The sequences in bold were replaced by artificial pre-miRNAs. Intron sequences include
sequences in normal text, bold text and bold italic text.

[0399] Constructs $35S::CPC-A$ and $35S::CPC-B$ were generated to check whether intron 1 or intron 2 of the unspliced *CPC* transcript can be used to insert artificial pre-miRNA for the production of artificial miRNAs. In the *CPC-A* construct, *pre-miR-HC-Pro*^{159a} was inserted into intron 1 with no change in intron 2. In *CPC-B*, *pre-miR-HC-Pro*^{159a} was inserted into intron 2 with no change in intron 1 (Fig. 36). *Agrobacterial* cells carrying $35S::CPC-A$, $35S::CPC-B$, $35S::pre-miR-HC-Pro$ ^{159a}, and $35S::pre-miR159a$ were infiltrated into *N. benthamiana* leaves for transient expression. Northern blot hybridizations using a probe complementary to *miR-HC-Pro*^{159a} showed that in 4 separate experiments leaf samples infiltrated with *CPC-A* and *CPC-B* expressed *miR-HC-Pro*^{159a} (Fig. 37). This result demonstrates that both intron 1 and intron 2 of the *CPC* transcript can be used to produce artificial miRNAs.

[0400] Constructs $35S::CPC-C$ and $35S::CPC-D$ were generated to determine the possibility of producing miRNAs in both introns. In *CPC-C*, *pre-miR-HC-Pro*^{159a} was inserted into intron 1 and *pre-miR-P69*^{159a} into intron 2. In *CPC-D*, *pre-miR-P69*^{159a} was inserted into intron 1 and *pre-miR-HC-Pro*^{159a} into intron 2 (Fig. 38). *Agrobacterial* cells carrying $35S::CPC-C$, $35S::CPC-D$, $35S::pre-miR-HC-P$ ^{159a}, and $35S::pre-miR-P69$ ^{159a} were infiltrated into *N. benthamiana* leaves for transient expression. Figure 39 shows northern blot results of four independent experiments. Note that all of the four samples show signals corresponding to *miR-HC-Pro*^{159a} miRNA and *miR-P69*^{159a}, although the signal in sample 1 is weak (Fig. 39, 1 of $35S::CPC-C$). This weak signal could be due to a lower transient expression efficiency in this particular sample. A similar situation was encountered in sample 4 of the $35S::CPC-D$ experiment. These results demonstrate that it is possible to use *CPC* introns to produce two different artificial miRNAs simultaneously in one transcript.

[0401] The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the Description as a whole. For example, in the Examples described above, *pre-miR159a* and *pre-miR169g* were used to generate artificial pre-miRNAs. However, other pre-miRNAs, such as described herein, could be used in place of *pre-miR159a* and *pre-miR169g*.

30 It will also be appreciated that in this specification and the appended claims, the singular forms of "a," "an" and "the" include plural reference unless the context clearly dictates otherwise. It will further be appreciated that in this specification and the

appended claims, The term “comprising” or “comprises” is intended to be open-ended, including not only the cited elements or steps, but further encompassing any additional elements or steps.

94/1
SEQUENCE LISTING

<110> The Rockefeller University

<120> MicroRNAs

<130> PCA18925

<150> PCT/US2004/033379

<151> 2004-10-12

<150> US 60/671,089

<151> 2005-04-14

<160> 174

<170> FastSEQ for Windows Version 4.0/Patent-In 3.3

<210> 1

<211> 1417

<212> DNA

<213> Arabidopsis thaliana

<400> 1

gcacctctca	ctccctttct	ctaaactagtc	ttgtgtgcac	ccatttatgt	gtacgtacta	60
ttatctcata	aataaatatt	tttaaaatata	gatgcattta	ttgatatgaa	aaagttacaa	120
gattagtttgc	ttgtgtgtga	gactttggat	cgacagatcg	aaaaattaac	taaccggtca	180
gtattgaata	tcaactatta	tatgctccat	gcattcgctt	atagttcac	acaatttgtt	240
ttcttcacgg	tctaaaatca	gaagattcca	tatattttct	tatgacgtaa	aaggaccact	300
tataagttga	cacgtcagcc	cttggattcg	tgaggtttt	ctctctactt	cacctatcta	360
ctttccctca	tatcccactg	ctttctcct	tcttgttctt	gtttttctcg	ttttttctt	420
cttcttctcc	aagaaaatag	agatcgaaaa	gattagatct	attttgcgtt	gcaagaaaatt	480
atcattttcg	tttcttcatt	catatattgt	tctattatgt	tgtacaataa	tagatactcg	540
atctcttgc	cgtgcgtaaa	ttttatacaa	gttgcggcg	gatccatgga	agaaagctca	600
tctgtcgttg	tttgcgttgc	cagcaccatt	aagattcaca	tggaaattga	taaataaccct	660
aaatttaggt	tttgcgtatgt	atatgagaat	cttgcgtatgt	ctgcataaac	aatcgacggc	720
tacaaatacc	taaagcttga	gaaagaaact	tgaagatatt	gattgaagtc	tggatcgatc	780
tttggtaat	ctctctcttgc	attagttta	agaatcactt	tttttttctt	gtgtttgaac	840
atgtttacat	atatcatcta	tgtctcaata	tatatatttt	cttaatctag	ggtcaatgac	900
ggatttagggc	gttaattaca	atgaatatgg	aaaaactatt	ttgccttga	tcttgacttg	960
agtgttgcgt	aacagatgta	taatgttgcgt	tagtatgtac	tgtattttt	ctagaatcat	1020
tctttgcgt	ccaaactctcc	attaatcaa	tgaggtcctt	ataggtatgc	ctatgatcaa	1080
gaacaacaag	atcgtgagca	cagatcgcc	agttcggtca	cttttaaaa	gagagatgtt	1140
atattgttaa	tttgcgttata	tcaaggatata	taaatacaga	atagttcgatc	cagagaccag	1200
acattttata	gtttcaattt	tatgacagtc	ttgtatataat	atttgcgtttaa	tagtgcgtca	1260
ccttctattt	ctgggttatt	acttgcgtccc	gaaattttct	tattgcgttca	atttgcgtat	1320
attagaaatt	ttgttttctt	gccaaatcaa	atcaaacatt	acgggtgcgtt	gtacattgtt	1380
ccagaacttt	tgtttcaag	tgctcaactt	gagaacc			1417

<210> 2

<211> 95

<212> DNA

<213> Arabidopsis thaliana

<400> 2

aggcgcgcga	ccattaagat	tcacatggaa	attgataat	accctaaatt	agggttttga	60
tatgtatatgc	agaatcttgc	tgtatgcgtca	tcaac			95

<210> 3

<211> 159

<212> DNA

<213> Artificial Sequence

<220>

<223> miRNA template cassette

<400> 3

ggatccatgg	aagaaagctc	atctgtcggt	gtttgttaggc	gcagcaccat	taagattcac	60
------------	------------	------------	-------------	------------	------------	----

94/2
atggaaattg ataaataaccc taaatttaggg ttttgatatg tatatgagaa tcttgatgtat 120
gctgcatcaa caatcgacgg ctacaaatac ctaaagctt 159

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> miRNA template to target At4g18960

<400> 4
taggttgtaa tgccgcgact t 21

<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> miRNA template to target At3g54340

<400> 5
ggtgttggaaatg aagagcgtaa g 21

<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> miRNA template to target At3g54340

<400> 6
agagcgtaag cacgtgaccc t 21

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> miRNA template to target maize phytoene desaturase

<400> 7
tgctggcaga agtccgattt c 21

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> miRNA template to target maize phytoene desaturase

<400> 8
agcttcctgg ataggactgc a 21

<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> miRNA template to target is maize IPPK2

<400> 9
aagttgttgtt taatcaccc a 21

94/3

<210> 10
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> miRNA template to target is maize ITPK5

<400> 10
 gaggacagtt tcgtatcctg g 21

<210> 11
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> miRNA template to target is maize Milps3

<400> 11
 gagcgtttac caccggtgtg c 21

<210> 12
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo1/4 for At4g18960 target

<400> 12
 gatccatgga agaaagctca tctgtcggtt tttgttaggca gtcgcggcac tacaacccaa 60
 tgaaaattga taaatac 77

<210> 13
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo2/4 for At4g18960 target

<400> 13
 tagggtattt atcaatttcc atttgggtgt agtgccgcga ctgcctacaa acaacgacag 60
 atgagcttcc ttccatg 77

<210> 14
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo3/4 for At4g18960 target

<400> 14
 cctaaatttag ggttttgata tgtatatttag gttgtaatgc cgcgactttc aacaatcgac 60
 ggctacaaat acctaa 76

<210> 15
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo4/4 for At4g18960 target

<400> 15

94/4		
agcttttagt attttagcc gtcgattgtt gaaagtcgat gcattacaac ctaatataca		60
tatcaaaacc ctaatt		76
<210> 16		
<211> 77		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic oligo1/4 for At3g54340 target		
<400> 16		
gatccatgga agaaagctca tctgtcggtt tttgttaggat tacgcccatttc attaccacca		60
tggaaattga taaatac		77
<210> 17		
<211> 77		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic oligo2/4 for At3g54340 target		
<400> 17		
taggttattt atcaatttcc atgggtggtaa tgaaggcgat aatcctacaa acaacgacag		60
atgagctttc ttccatg		77
<210> 18		
<211> 76		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic oligo3/4 for At3g54340 target		
<400> 18		
cctaaatttag gggtttgata tgtatatgtt ggaaatgaag agcgtaagtc aacaatcgac		60
ggctacaaat acctaa		76
<210> 19		
<211> 76		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic oligo4/4 for At3g54340 target		
<400> 19		
agcttttagt attttagcc gtcgattgtt gacttacgct cttcatttcc accatataca		60
tatcaaaacc ctaatt		76
<210> 20		
<211> 77		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Synthetic oligo1/4 for At3g54340 target		
<400> 20		
gatccatgga agaaagctca tctgtcggtt tttgttaggat gtcacgcgt tacgctcaca		60
tggaaattga taaatac		77
<210> 21		
<211> 77		
<212> DNA		
<213> Artificial Sequence		

94/5

<220>

<223> Synthetic oligo2/4 for At3g54340 target

<400> 21

tagggtattt atcaatttcc atgtgagcgt aagcgctgtga ccgcctacaa acaacgacag

60

77

<210> 22

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo3/4 for At3g54340 target

<400> 22

cctaaat tag ggtttgata tgtatatgag agcgtaagca cgtgaccctc aacaatcgac

60

76

<210> 23

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo4/4 for At3g54340 target

<400> 23

agcttaggt attttagcc gtcgattgtt gagggtcacg tgcttacgct ctcataataca

60

76

<210> 24

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo1/4 for phytoene desaturase target

<400> 24

gatccatgga agaaagctca tctgtcggtt tttgtaggca atcggacttc tgccagcaca

60

77

<210> 25

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo2/4 for phytoene desaturase target

<400> 25

tagggtattt atcaatttcc atgtgctggc agaagtccga ttgcctacaa acaacgacag

60

77

<210> 26

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo3/4 for phytoene desaturase target

<400> 26

cctaaat tag ggtttgata tgtatatgtt ctggcagaag tccgattgcc aacaatcgac

60

76

<210> 27

<211> 76

94/6

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo4/4 for phytoene desaturase target

<400> 27
 agcttttagt attttagcc gtcgattgtt ggcaatcgga cttctgccag cacatataca 60
 tatcaaaacc ctaatt 76

<210> 28
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo1/4 for phytoene desaturase target

<400> 28
 gatccatgga agaaagctca tctgtcggtt tttgttagtac agtcccatcc aggaagcaca 60
 tggaaattga taaatac 77

<210> 29
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo2/4 for phytoene desaturase target

<400> 29
 tagggtattt atcaatttcc atgtgcttcc tggatggac tgtactacaa acaacgacag 60
 atgagcttcc ttccatg 77

<210> 30
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo3/4 for phytoene desaturase target

<400> 30
 cctaaatttag ggttttgata tgtatatgag cttcctggat aggactgcac aacaatcgac 60
 ggctacaaat acctaa 76

<210> 31
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo4/4 for phytoene desaturase target

<400> 31
 agcttttagt attttagcc gtcgattgtt gtgcagtcct atccaggaag ctcataataca 60
 tatcaaaacc ctaatt 76

<210> 32
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo1/4 for IPPK2 target

<400> 32
 gatccatgga agaaagctca tctgtcggtt tttgttaggcg gggtgataaa ccacaacata 60

tggaaattga taaatac

<210> 33

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo2/4 for IPPK2 target

<400> 33

tagggtattt atcaatttcc atatgttggt gtttatcacc ccgcctacaa acaacgacag
atgagctttc ttccatg

60

77

<210> 34

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo3/4 for IPPK2 target

<400> 34

cctaaat tag gttttgata tgtatataag ttgtggtaa tcacccatc aacaatcgac
ggctacaaat acctaa

60

76

<210> 35

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo4/4 for IPPK2 target

<400> 35

agctttagt attttagcc gtcgattgtt gatgggtga ttaaccacaa cttatataca
tatcaaacc ctaatt

60

76

<210> 36

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo1/4 for ITPK5 target

<400> 36

gatccatgga agaaagctca tctgtcggtt tttgttaggac aggatacgtt actgtccaca
tggaaattga taaatac

60

77

<210> 37

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo2/4 for ITPK5 target

<400> 37

tagggtattt atcaatttcc atgtggacag ttacgtatcc tgtcctacaa acaacgacag
atgagctttc ttccatg

60

77

<210> 38

<211> 76

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic oligo3/4 for ITPK5 target

94/8

<400> 38
 cctaaat tag gttttgata tgtatatgag gacagttcg tatcctggc aacaatcgac 60
 ggctacaaat acctaa 76

<210> 39
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo4/4 for ITPK5 target

<400> 39
 agcttttagt attttagcc gtcgattgtt gaccaggata cgaaactgtc ctcatataca 60
 tatcaaaacc ctaatt 76

<210> 40
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo1/4 for milps target

<400> 40
 gatccatgga agaaagctca tctgtcggtt tttgttaggac acaccggcgg taaacgcaca 60
 tggaaattga taaatac 77

<210> 41
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo2/4 for milps target

<400> 41
 tagggtattt atcaatttcc atgtgcgtt accgcccgtg tgtcctacaa acaacgacag 60
 atgagcttcc ttccatg 77

<210> 42
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo3/4 for milps target

<400> 42
 cctaaat tag gttttgata tgtatatgag cgtttaccac cggtgtgctc aacaatcgac 60
 ggctacaaat acctaa 76

<210> 43
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligo4/4 for milps target

<400> 43
 agcttttagt attttagcc gtcgattgtt gagcacaccg gtggtaaacg ctcatataca 60
 tatcaaaacc ctaatt 76

<210> 44
 <211> 4426
 <212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 44

ctaaattgt	agcgtaata	ttttgttaaa	attcgctta	aattttgtt	aatcagctc	60
atttttaac	caataggccg	aatcgcaaa	aatccctat	aatcaaaag	aatagaccga	120
gatagggtt	agtgttgtt	cagtttggaa	caagagtcc	ctattaaaga	acgtggactc	180
caacgtcaa	gggcgaaaaaa	ccgtctatca	gggcgatggc	ccactacgt	aaccatcacc	240
ctaatcaag	ttttgggt	cgaggtgccc	taaagcacta	aatcgaaacc	ctaaaggag	300
cccccgatt	agagcttgac	ggggaaagcc	ggcgaacgt	gcgagaaagg	aagggaaagaa	360
agcgaagga	gcgggccc	gggcgctggc	aagtgttagc	gtcacgctgc	gcgttaaccac	420
cacaccgccc	gcgcttaat	cgccgctaca	gggcgcgtcc	cattcgccat	tcaggctgcg	480
caactgttgg	gaagggcgat	cggtgcgggc	ctcttcgcta	ttacgcccagc	tggcgaaagg	540
gggatgtgct	gcaaggcgat	taagttgggt	aacgcccagg	tttcccagt	cacgacgtt	600
taaaacgacg	gccagtgagc	gcccgtata	cgactcacta	tagggcgaat	tgggtaccgg	660
gccctctaga	tgcattgtcg	agcggccgccc	agtgtatgg	atatctgcag	aattcgccct	720
tgactactcg	agcacctctc	actcccttc	tctaactagt	cttgtgtgc	cccatttatg	780
tgtacgtact	attatctcat	aaataaatat	ttttaaaatt	agatgcattt	attgatatga	840
aaaagttaca	agattagttt	gttgtgtgt	agactttgg	tcgacagatc	aaaaaattaa	900
ctaaccgtc	agtattgaat	atcaactatt	atatgctcc	tgcattcgct	tatagttca	960
cacaatttgt	tttcttcacg	gtctaaaatc	agaagattcc	atatatttc	ttatgacgta	1020
aaaggaccac	ttataagtt	acacgtcagc	ccttggattc	gtgagggttt	tctctctact	1080
tcacctatct	acttttcctc	atatcccact	gctttctcc	ttcttgcgtt	tgttttctc	1140
gttttttct	tcttcttctc	caagaaaata	gagatcgaaa	agattagatc	tatTTTGT	1200
agcaagaaat	tatcattttc	gtttcttcat	tcatatattg	ttcttattatg	ttgtacaata	1260
atagatactc	gatctcttgc	gcgtgcgtaa	attttataca	agttgtcggc	ggatccatgg	1320
aagaaagctc	atctgtcggt	gtttgttaggc	gcagcaccat	taagattcac	atggaaattg	1380
ataaatacc	taaatttaggg	ttttgatatg	tatatgagaa	tcttgatgt	gctgcatcaa	1440
caatcgacgg	ctacaaatac	ctaaagctt	agaaagaaaac	ttgaagatat	tgattgaagt	1500
ctggatcgat	ctttggtaaa	tctctctt	gattagttt	aagaatcact	ttttttttc	1560
tgtgttggaa	catgtttaca	tatatcatct	atgtctcaat	atatatttt	tcttaatcta	1620
gggtcaatga	cggatttaggg	cgttaattac	aatgaatatg	aaaaaactat	tttgccttt	1680
atcttgactt	gagtgttgc	gaacagatgt	ataatgtt	gtagtgatgt	ctgtatTTT	1740
tctagaatca	ttcttttagtc	tccaaactctc	cattaatcaa	atgaggtcct	tataggtaat	1800
gctatgatca	agaacaacaa	gatcgtgagc	acagatcggc	cagttcggtc	actttttaaa	1860
agagagatgt	tatattgtt	atttgttatt	atcaggtata	ataaaatacag	aatagttcg	1920
ccagagacca	gacattttat	agtttcaatt	ttatgacagt	cttgcataaa	tatTTTGT	1980
atagtgttc	accttctatt	tctgggttat	tacttgcgtt	cgaaattttc	ttatttttct	2040
aattttgtaa	tattagaaat	ttggttttct	tgccaaatca	aatcaaacat	tacgggtgt	2100
tgtacattgt	accagaactt	ttgttttcaa	gtgctcaact	tgagaacctc	gagtagtcaa	2160
gggcgaattc	cagcacactg	gcggccgtt	ctagttctag	agcggccgccc	accgcgggtgg	2220
agctccagct	tttggccctt	ttagtgaggg	ttaattgcgc	gcttggcgta	atcatggtca	2280
tagctgttc	ctgtgtgaaa	ttgttatccg	ctcacaattc	cacacaacat	acgagccgga	2340
agcataaaatgt	gtaaagcctg	gggtgcctaa	tgagttagct	aactcacatt	aattgcgtt	2400
cgctcactgc	ccgctttcca	gtcgggaaac	ctgtcggtcc	agctgcatta	atgaatcggc	2460
caacgcgcgg	ggagaggcgg	tttgcgtatt	gggcgcctt	ccgcttccctc	gctcactgac	2520
tcgctgcgt	cggtcggtcg	gctgcggcga	gcccgtatcag	ctcactcaaa	ggcggtaata	2580
cgttatcca	cagaatcagg	ggataacgca	ggaaagaaca	tgtgagcaaa	aggccagcaa	2640
aaggccagga	accgtaaaaaa	ggccgcgtt	ctggcggttt	tccataggct	ccgccccct	2700
gacgagcatc	acaaaaatcg	acgctcaagt	cagagggtggc	gaaaccgcac	aggactataa	2760
agataccagg	cgtttcccc	tggaaagctcc	ctcgtcgct	ctcctgttcc	gaccctgccc	2820
cttaccggat	acctgtccgc	ctttctccct	tcgggaagcg	tggcgctt	tcatagctca	2880
cgtgttaggt	atctcagtt	ggtgttaggt	gttcgccttca	agctggctg	tgtgcacgaa	2940
ccccccgttc	agccccgaccg	ctgcgcctt	tccggtaact	atcgtcttgc	gtccaaaccg	3000
gtaagacacg	acttatcgcc	actggcagca	gccactggta	acaggattag	cagagcgagg	3060
tatgttaggc	gtgctacaga	gttcttgaag	tggtgccctt	actacggct	cactagaagg	3120
acagtatttg	gtatctgcgc	tctgctgttt	ccagtttac	tcggaaaaaa	agttggtagc	3180
tcttgcgtt	gcaaaacaaac	caccgcttgcgtt	agcgggtgg	tttttgcgtt	caagcagcag	3240
attacgcga	aaaaaaaagg	atctcaagaa	gatccttgc	tcttttctac	gggggtctgac	3300
gctcgttgg	acgaaaactc	acgttaaggg	attttggtca	tgagattatc	aaaaaggatc	3360
ttcacctaga	tcctttaaa	ttaaaaaatga	agttttaaat	caatctaaag	tatatatgag	3420
taaacttggt	ctgacaggtt	ccaatgcctt	atcgttgagg	cacctatctc	agcgatctgt	3480
ctatTTTGT	catccatagt	tgcctgactc	cccgtgtgt	agataactac	gatacgggag	3540
ggcttaccat	ctggccccag	tgctgcaatg	ataccgcgag	acccacgctc	accggctcca	3600
gatttatacg	caataaacc	gccagccgga	agggccgagc	gcagaagtgg	tcctgcaact	3660
ttatccgcct	ccatccagtc	tattaattgt	tgccggaaag	ctagagtaag	tagttcgcca	3720

94/10

gttaatagtt	tgcgcaacgt	tgttgcatt	gctacaggca	tcgtgggtc	acgctcgctg	3780
tttggtatgg	cttcatttcag	ctccggttcc	caacgatcaa	ggcgagttac	atgatcccc	3840
atgttgtgca	aaaaagcggt	tagctccttc	ggtcctccga	tcgttgcag	aagtaagttg	3900
gccgcagtgt	tatcactcat	ggttatggca	gcactgcata	attctcttac	tgtcatgcc	3960
tccgtaaat	gctttctgt	gactgggtgag	tactcaacca	agtcatctg	agaatagtgt	4020
atgcggcgac	cgagttgctc	ttgcccggcg	tcaatacggg	ataataccgc	gccacatagc	4080
agaactttaa	aagtgctcat	cattggaaaaa	cgttctcgg	ggcgaaaaact	ctcaaggatc	4140
ttaccgctgt	tgagatccag	ttcgatgtaa	cccactcg	cacccaactg	atcttcagca	4200
tcttttactt	tcaccagcg	ttctgggtga	gcaaaaacag	gaaggcaaaa	tgccgcaaaa	4260
aagggaaataa	gggcgacacg	gaaatgtga	atactcatac	tcttcctttt	tcaatattat	4320
tgaagcattt	atcagggtta	ttgtctcatg	agcggataca	tatttgaatg	tatttagaaa	4380
aataaaacaaa	taggggttcc	gcmcacattt	ccccgaaaaag	tgccac		4426

<210> 45

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> EAT 3' PCR primer

<400> 45

ctgtgctcac gatcttggtt ttcttgatc

29

<210> 46

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> EAT 5' PCR primer

<400> 46

gtcggcgat ccatggaaga aagctcatc

29

<210> 47

<211> 21

<212> RNA

<213> Arabidopsis thaliana

<220>

<223> AP2 RNA

<400> 47

cugcagcauc aucaggauuc u

21

<210> 48

<211> 21

<212> RNA

<213> Arabidopsis thaliana

<220>

<221> misc_feature

<222> (0)...(0)

<223> EAT miRNA

<400> 48

agaaucuuga ugaugcugca u

21

<210> 49

<211> 59

<212> DNA

<213> Arabidopsis thaliana

<400> 49

accaagtgtt gacaaatgct gcagcatcat caggattctc tcctcatcat cacaatcag

59

<210> 50

94/11

<211> 59
 <212> DNA
 <213> *Arabidopsis thaliana*

 <400> 50
 caccggccact gtttcaaattt gcagcatcat caggattctc actctcagct acacggccct 59

 <210> 51
 <211> 59
 <212> DNA
 <213> *Arabidopsis thaliana*

 <400> 51
 caccattgtt ctcagttgca gcagcatcat caggattctc acatttccgg ccacaacct 59

 <210> 52
 <211> 59
 <212> DNA
 <213> *Arabidopsis thaliana*

 <400> 52
 gaaatcgagt ggtggaaatg gcagcatcat caggattctc tcctcaacctt tccccttac 59

 <210> 53
 <211> 59
 <212> DNA
 <213> *Zea mays*

 <400> 53
 acgtgcccgtt gcaccactct gcagcatcat caggattctc taccggccgc ggggccaac 59

 <210> 54
 <211> 59
 <212> DNA
 <213> *Zea mays*

 <400> 54
 acgcccagcag cgccgcccgtt gcagcatcat caggattccc actgtggcag ctgggtgcg 59

 <210> 55
 <211> 35
 <212> DNA
 <213> *Artificial Sequence*

 <220>
 <223> *EAT PCR primer*

 <400> 55
 gactactcga gcacctctca ctccctttct ctaac 35

 <210> 56
 <211> 36
 <212> DNA
 <213> *Artificial Sequence*
 <220>
 <223> *EAT PCR primer*

 <400> 56
 gactactcga ggttctcaag ttgagcactt gaaaac 36

 <210> 57
 <211> 77
 <212> DNA
 <213> *Artificial Sequence*

 <220>
 <223> *EAT deletion oligonucleotide*

94/12

<400> 57
 gatccatgga agaaagctca tctgtcggtt tttgttaggcg cagcaccatt aagattcaca 60
 tggaaattga taaatac 77

<210> 58
 <211> 55
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EAT deletion oligonucleotide

<400> 58
 cctaaat tag ggtttgata tgtatattca acaatcgacg gctacaaata cctaa 55

<210> 59
 <211> 77
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EAT deletion oligonucleotide

<400> 59
 tagggtat tt atcaatttcc atgtgaatct taatggtgct gcgcctacaa acaacgacag 60
 atgagcttcc ttccatg 77

<210> 60
 <211> 55
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> EAT deletion oligonucleotide

<400> 60
 agcttttaggt attttagcc gtcgattgtt gaatatacat atcaaaaaccc taatt 55

<210> 61
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> S1 probe

<400> 61
 atgcagcatc atcaagattc tcatacat 30

<210> 62
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> mir172a-2 PCR primer

<400> 62
 gtcggcggat ccatggaaga aagctcatc 29

<210> 63
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> mir172a-2 PCR primer

94/13

<400> 63	
caaagatcga tccagacttc aatcaatatc	30
<210> 64	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> mir172a-1 PCR primer	
<400> 64	
taatttccgg agccacggtc gttgttg	27
<210> 65	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> mir172a-1 PCR primer	
<400> 65	
aatagtcgtt gattgccat gcagcatc	28
<210> 66	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Actin PCR primer	
<400> 66	
atggcagatg gtgaagacat tcag	24
<210> 67	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Actin PCR primer	
<400> 67	
gaagcacttc ctgtggacta ttgatg	26
<210> 68	
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> AP2 PCR primer	
<400> 68	
tttccgggca gcagcaacat tggtag	26
<210> 69	
<211> 29	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> AP2 PCR primer	
<400> 69	
gttcgcctaa gttaacaaga ggattnagg	29

94/14

<210> 70
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> ANT PCR primer

<400> 70
 gatcaacctc aatgactaac tctggtttc 30

<210> 71
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> ANT PCR primer

<400> 71
 gttatagaga gattcattct gtttcacatg 30

<210> 72
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> miRNA template to EAT

<400> 72
 agaatcttga ttagtgcgtca t 21

<210> 73
 <211> 175
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide 1 for EAT with attB sites

<400> 73
 ttaaacaagt ttgtacaaaa aagcaggctg tcgttgggg taggcgcagc accattaaga 60
 ttcacatgga aattgataaa taccctaaat tagggtttg atatgtatata gagaatcttgc 120
 atgtatgcgtc atcaacaatc gacggcaccc agtttcttg tacaaagtgg tttaa 175

<210> 74
 <211> 175
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic oligonucleotide 2 for EAT with attB sites

<400> 74
 ttaaaccact ttgtacaaga aagctgggtg ccgtcgattt ttgatgcagc atcatcaaga 60
 ttctcatata catatcaaaa ccctaatttta gggtattttt caatttccat gtgaatcttgc 120
 atggtgctgc gcctacaaac aacgacagcc tgctttttt tacaaacttg tttaa 175

<210> 75
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> miRNA template for FAD2

94/15

<400> 75
 agataagacc aactgtgtca t 21
 <210> 76
 <211> 175
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic oligonucleotide 1 for FAD2
 <400> 76
 ttaaacaagt ttgtacaaaa aaggcaggctg tcgttgtttg taggcgcac ac agctggctt 60
 atcacatgga aattgataaa taccctaaat taggggtttg atatgtatat gagataagac 120
 caactgtgtc atcaacaatc gacggcaccc agctttcttg tacaacttgg tttaa 175
 <210> 77
 <211> 175
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic oligonucleotide 2 for FAD2
 <400> 77
 ttaaaccact ttgtacaaga aagctgggtg ccgtcgattt ttgatgacac agttggctt 60
 atctcatata catatcaaaaa ccctaatttta gggattttt caatttccat gtgataagac 120
 cagctgtgtc gcctacaaac aacgacagcc tgctttttt tacaacttgg tttaa 175
 <210> 78
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> miRNA template for PDS
 <400> 78
 agaaaactctt aaccgtgcca t 21
 <210> 79
 <211> 175
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic oligonucleotide 1 to target PDS
 <400> 79
 ttaaacaagt ttgtacaaaa aaggcaggctg tcgttgtttg taggcggcac ggtcaagagt 60
 ttcacatgga aattgataaa taccctaaat taggggtttg atatgtatat gagaaactct 120
 taaccgtgcc atcaacaatc gacggcaccc agctttcttg tacaacttgg tttaa 175
 <210> 80
 <211> 175
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Synthetic oligonucleotide 2 to target PDS
 <400> 80
 ttaaaccact ttgtacaaga aagctgggtg ccgtcgattt ttgatggcac ggttaagagt 60
 ttctcatata catatcaaaaa ccctaatttta gggattttt caatttccat gtgaaactct 120
 tgaccgtgcc gcctacaaac aacgacagcc tgctttttt tacaacttgg tttaa 175
 <210> 81

<211> 907

<212> DNA

<213> Zea mays

<400> 81

ttaaaaaaaat	agcgatttgt	ttgaagaaaag	gatcatggcc	gagcatcatt	caacgtacct	60
ctgttagggcg	tatgaatcgt	tggatttagga	tcaaagtcgg	caacggttaa	attcaaggaa	120
gaaaacaacg	ggcgtggggt	cctgtccacg	tcatcaggtg	accaggcagg	caggcatgcg	180
cgccatgcgg	cattgcttct	gtccccgtgc	ccgggcagct	tttggcagcg	gatccggacg	240
gaacaccacg	cgcgcgcgcg	cgcggcaggc	acgcaccggc	caacttaatc	ttgcctccac	300
tctgcactag	tggggttatt	aacaatttga	ttaatccgac	actgacgtac	tgtgtcaacc	360
aatggcaccg	cctatatatt	aatcgaacca	ttcagctcgt	cttaattgcc	acccacccac	420
ccaccgccccat	tgccatggtt	cacctcattc	attctaagct	tagacgatgc	agtgatagaa	480
attaatactg	caaatacgtc	agtgtttgcg	ggcgtggcat	catcaagatt	cacaacccat	540
caatccgaac	cactgatttgc	aatgcattgt	atgagaatct	tgatgatgct	gcatccgcca	600
acaagcgcct	acgaacgttt	gtgtgctcat	cttcgccatc	aatcgagatt	ttgtatcttc	660
acgtttagct	aaggtgaaag	atcgtcatcc	catccgccta	aagctagctt	tgcaaatttt	720
tattcgaaac	aacgaccatt	tctatatatt	tcctttctct	gttatagtct	ctaattaacg	780
cctgtaaact	gttgcacccct	gcttctgcat	cttcttattt	attagtttg	tctcttatgg	840
atgctaaaca	gccatgacgt	ttcggacaat	gttcagctcg	tacttccttc	aatcgggagc	900
gcca	aaaa					907

<210> 82

<211> 1128

<212> DNA

<213> Zea mays

<400> 82

tcgtcgatct	gatttgccctg	ctttatttct	tcttcttctt	cacaccgagc	tagctagcta	60
tcttgcttta	atttgcctag	aacgaataga	tccaccgtac	tagcttcttgc	ctcgatctgc	120
agcttctcgc	ttgtgagcca	agagcccgcc	cagcagtgtc	ggccgtgcag	tggcactctc	180
tccatcaaca	atcaaccctc	tctccgtcga	catgtggaaa	ggtaggtaga	gatagatggt	240
gtgtgttaatc	cggttcccttgc	gttcttgcgt	ttccgatctc	ctctaattaa	tcgatctctc	300
tacctggcca	gctcaactca	cccattgttg	catctagctg	ttccaatctg	atgcatgata	360
tagatgatgc	ttgcggcctc	ttcttcttgc	ttcataggct	catcatctat	gcctctgtca	420
tgcacacact	cgtgtctttc	ttcttgatgg	atacacgtac	gggggggttgg	gttgttcaca	480
tatatagtat	tatagctatgt	ttatttagatg	caggtataca	gatcatgagg	aagcaagaaa	540
ttatgcaaaa	cagtcgggtgc	ttgcagggtgc	agcaccatca	agattcacat	ccccagctcg	600
atctgtgcatt	gatgagatga	gaatcttgat	gatgctgcat	cagcaaacac	tcacttacat	660
cgtatctcacc	cctggacaag	ctggacagtgc	aaaccggact	gagcaatcga	gtactactaa	720
aaacttgcctc	tcaagctctt	atgttttact	ttcaattacc	ttgcttatat	taattttctt	780
tcacttaatt	tagtttaattt	ctgctctctc	tctctctctc	tgtctctctc	tctctctctc	840
tggtttttc	atcttgcaaa	aaaaatgcag	aaattaat	gtatatgtgt	acctcatgat	900
tattaaggcc	gctgcaccat	gattttatgg	tatattatta	tcaagctaaa	acaggcttc	960
ccttttgcatt	atatttcaat	aattcgatcc	gcatcattag	tttctgcatt	tgccgatgat	1020
ctcgagggttc	tgtttgcaag	aagtggctgc	actgcagccc	tgcagctata	tatacacagg	1080
ttcaagttac	taattttgtgc	tttctacaat	aatcctatca	gtccgcag		1128

<210> 83

<211> 912

<212> DNA

<213> Zea mays

<400> 83

cactaatagc	tttcttatctg	atcgattcat	catcatccgg	gcatgcatga	gcatcatcg	60
ctccagatcg	ttgggctctc	gcagctacct	acattcaaca	ttcaagctcg	ctctacat	120
gcatgcaaat	ctgcaacact	cgctttggc	agggatacat	tcacgcccag	agagagagag	180
agagagagag	agagagagag	agagagagag	atgtgtgtgc	tgttagtcattc	agccagccgg	240
tgatttctgg	agtggcatca	tcaagattca	cacactgcat	gccaaacataa	tgcgcgtgtt	300
catgcattcca	tcggccgcgc	tgcattcatgc	atcatatata	atatatataat	atgtgtatgt	360
gtggaaatct	tgtatgtatgc	gcattggata	tcaaggctt	tatatatata	tggatcaagc	420
atatatataat	atatatataga	tcaccagtca	tatcgatctt	ttccttccag	gcttgctagg	480
taatttataaa	cttaaacctt	gttgcgttac	taactaattt	tacttagctt	gcttagctact	540
actataacttc	attgttagta	gtatgtatgc	agaaggaaag	taggcattccc	ggccgggtcg	600
taccttctt	ttttttgcac	agcaggatct	gaccttctgt	ataaaaatgc	tttttgcctt	660
gagttttttt	gtttttccac	agtaggaggt	agctgattct	gatctgtgt	ataaaaatgc	720
attttttcc	ttttcatttc	atggcagaag	gcaatatata	ataagaaaag	actgaaagga	780
aaaggcacca	ctgcccattat	ggatcgcatc	agtgcattcg	ttttgttctt	ctaaacgatt	840

94/17

caggtcatca ggtgagctag gtgggctaat aagtatata tagtattatcattttgcaca 900
 tgatttatat gg 912

<210> 84

<211> 1063

<212> DNA

<213> Zea mays

<400> 84

catgcatgct	gccttacacc	taagcttagct	agctgttcaa	tttgcattgc	gacgcattgc	60
ttcctccccc	tccgttgc	gtcggttgc	ttgtctcagt	aatccatcct	ctctcttttt	120
ttcttgctaa	tacataaaag	gggttcagat	ggtagctgc	agtggttatt	cttcttctta	180
gacgatgcaa	gtatatgtat	atggaccacc	aaattagctt	ctcgcttgc	cggccggaccg	240
ccatcatgca	ccttggagaa	gcaacagaac	gaagctcgct	gctatgctat	ctatggattta	300
ttgtatttta	tatgaatgaa	gcagcaagca	aacgttagtc	agtacagtcg	gtgcttgcag	360
gtgcagcacc	atcaagattc	acatcgcca	actcatgc	catgcata	tgcattttca	420
atgatgcgtg	cctcgcatgt	gtgtgtat	atatatgat	agatgagaat	tttgcattgt	480
ctgcattcgc	agacactcac	tagctcatgc	atcacccca	agtaataaga	gatgaattga	540
attaacgacc	atgcagctac	tagctctrgt	acgttaccat	tcgttccct	ctaatttctt	600
tttccattca	gtctaccc	tttgcttaatc	aacttgc	catataat	atggttccca	660
atgcgataag	ggttggcctg	caggcttagc	tctgcagcag	gtgcacccca	tgcattggccc	720
atgatacata	acatattgtat	ggatataatac	tagcataaaaa	acatgtatgt	gcagagcagc	780
agcatccatc	tcatagctag	cataaaaaaca	tgcattgact	agcagcggca	gttgcgtatg	840
actcttcgag	aggaaggaag	gaagcagcag	atcgatggac	gcaagacatg	agcagtgaca	900
gatgcataat	gtacgactac	atacagcatt	attgttattt	tttgcacccca	agcaaattaa	960
ggaaggggac	caaattgaaa	tataactatg	acattgcaga	cggcaccagc	agagtccaca	1020
gctcgtaac	ctgtgttagc	tgcctgccc	tggtacaatg	caa		1063

<210> 85

<211> 1738

<212> DNA

<213> Zea mays

<400> 85

ccatcagcaa	ctgctcgtag	ctccgtcc	atcacttaaa	ccttattatc	atcactctct	60
cttcctctct	cttctggccg	gccggcc	tcacccact	catcttctca	gttcattcca	120
tggagagcgt	cgttcctata	tatcatgc	catccacca	ggccctagct	aagctgtac	180
tacctgctag	gggttttatt	agttgctaa	cttcgctgg	ccggccctat	atatacctag	240
ctatagctgt	tttgcttgca	tagatcatcg	atccatgtt	ctagctagct	agctccctca	300
gttcagttca	gttcagttca	gctcagctag	ctagctact	cctcttctt	gtcgttgtgt	360
ccatcacaat	tttcttata	tcgatacagg	tgaggaggta	gctagacaga	tcaacaccaa	420
tcctctcaac	gacatccc	tgttcttgc	gagagatgg	gtgttaggtc	aaaggcagat	480
agatcatata	tagagggaga	gatgcata	ttgtgttaggg	tttcttcaatt	tggtttctatg	540
atcgattcat	tcgccc	gccccccctg	cgcattttagt	tatgttcttca	tccctcc	600
cttgttcc	atacatata	atatatgt	gtgtggctc	tgtatatacc	catgccc	660
ctctcaatct	catctatata	atataacc	atgttttgc	tctagctgtt	tcatttctt	720
tcactcg	tttgc	aaat	ctggtacat	ccggccctg	ttagtaagaa	780
aaatacacac	gtacgcgc	gaaccatgca	tcatcagct	gctcctct	ttccttctt	840
ttttgtt	tgcat	atata	ttcccatgaa	tgaatgttt	aagcatgagg	900
caagcaaaca	tcgac	atgtt	gtgc	gtcagcacc	accaagattc	960
ctcacgc	ttc	atgtt	catgc	tcgtatgtc	tcgcagc	1020
tgtgatgaga	tg	gaaatctt	gtatgt	catcagc	tatgcata	1080
gtaccccaac	aa	gggtgaga	gacgac	cggctgtgg	cactcact	1140
gtcg	attac	tttgc	tat	tatata	tcacacca	1200
gcaagggggc	tttgc	tttgc	tttgc	tgt	caactgagaa	1260
tgtgatgca	tat	atgt	gc	gat	tatata	1320
ttgcaaa	at	gac	at	at	atata	1380
tagc	atgt	gtt	at	at	at	1440
acgt	gtt	ttt	at	at	at	1500
acaccacaca	cc	cc	cc	cc	cc	1560
gcagcgt	ct	cc	cc	cc	cc	1620
gctgactt	ct	cc	cc	cc	cc	1680
tgtgtgt	ttt	ttt	ttt	ttt	ttt	1738

<210> 86

<211> 21

<212> DNA

<213> Arabidopsis thaliana

94/18

<400> 86		
agaatcttga tgatgctgca t	21	
<210> 87		
<211> 26		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Forward PCR primer for maize miR172a		
<400> 87		
ggatcctctg cactagtggg gttatt	26	
<210> 88		
<211> 26		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Reverse PCR primer for maize miR172a		
<400> 88		
gatatctgca acagtttaca ggcgtt	26	
<210> 89		
<211> 26		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Forward PCR primer for maize miR172b		
<400> 89		
ggatcccatg atatagatga tgcttg	26	
<210> 90		
<211> 26		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> Reverse PCR primer for maize miR172b		
<400> 90		
gatatcaaga gctgaggaca agtttt	26	
<210> 91		
<211> 170		
<212> DNA		
<213> Zea mays		
<400> 91		
tatacagatc atgaggaagc aagaaattat gcaaaacagt cggtgcttgc aggtgcagca	60	
ccatcaagat tcacatcccc agctcgatct gtgcattatg agatgagaat cttgatgtatg	120	
ctgcattcagc aaacactcac ttacatcgat ctcaccctg gacaagctgg	170	
<210> 92		
<211> 21		
<212> DNA		
<213> Zea mays		
<400> 92		
agaatcttga tgatgctgca t	21	
<210> 93		
<211> 21		

94/19

<212> DNA

<213> Zea mays

<400> 93

gtgcagcacc atcaagattc a

21

<210> 94

<211> 170

<212> DNA

<213> Artificial Sequence

<220>

<223> miRNA precursor template to target PDS

<400> 94

tatacagatc atgaggaagc aagaaattat gcaaaaacagt cggtgcttgc agatcctgcc
tcgcagggttgc tcacatcccc agctcgatct gtgcatgatg agatgagaca acctgcaagg
caggatcagc aaacactcac ttacatcgat ctcaccctg gacaagctgg

60

120

170

<210> 95

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> miRNA template to PDS target

<400> 95

agacaacctg caaggcagga t

21

<210> 96

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> miRNA template backside to PDS target

<400> 96

atcctgcctc gcaggttgc a

21

<210> 97

<211> 178

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide 1 for maize miR172b

<400> 97

gatctataca gatcatgagg aagcaagaaa ttatgcaaaa cagtcgggtgc ttgcagggtgc
agcaccatca agattcacat ccccagctcg atctgtgcat gatgagatga gaatcttgat
gatgctgcata cagcaaacac tcacttacat cgatctcacc cctggacaag ctgggtac

60

120

178

<210> 98

<211> 170

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide 2 for maize miR172b

<400> 98

ccagcttgc caggggtgag atcgatgtaa gtgagtgttt gctgatgcag catcatcaag
attctcatct catcatgcac agatcgagct ggggatgtga atcttgatgg tgctgcaccc
gcaaggcaccg actgtttgc ataatttctt gcttcctcat gatctgtata

60

120

170

<210> 99

94/20

<211> 178
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide 1 for maize PDS target

<400> 99
 gatctataca gatcatgagg aagcaagaaa ttatgcaaaa cagtcggtgc ttgcagatcc 60
 tgcctcgac gttgtcacat cccagctcg atctgtgcat gatgagatga gacaacctgc 120
 aaggcaggat cagcaaacac tcacttacat cgatctcacc cctggacaag ctgggtac 178

<210> 100
 <211> 170
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide 2 for maize PDS target

<400> 100
 ccagcttgtc caggggtgag atcgatgtaa gtgagtgttt gctgatcctg cttgcaggt 60
 tgtctcatct catcatgcac agatcgagct gggatgtga caacctgcga ggcaggatct 120
 gcaagcacccg actgtttgc ataatttctt gtttcctcat gatctgtata 170

<210> 101
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 101
 caccacagtt tgcttatgtc ggatcc 26

<210> 102
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 102
 tgaccggga tgttagagtc cttcaatcc 30

<210> 103
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 103
 atagatcttgc atctgacgat ggaagaagag atcctaactt ttcaaa 46

<210> 104
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 104
 tgaccggga tgaagagatc ccatatttcc aaa 33

94/21

<210> 105
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 105
 caccaatgat gattacgatg atgagagtc

29

<210> 106
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 106
 caaagtttga tcacgattca tga

23

<210> 107
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 107
 gagaatgagg ttgagtttag tctgacttgg ccagttttt taccaatg

48

<210> 108
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 108
 ctgattctgg tggccaa gtcagactaa actctgttcc cttctc

46

<210> 109
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 109
 gagaatgagg ttgatctctt tccagtcctc agggttttt taccaatg

48

<210> 110
 <211> 47
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 110
 gattctggtg tcctgaagac tggaaagaga tctgtttcct tctcttc

47

<210> 111

94/22

<211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 111
 tctgacgatg gaagttcctc gcccgacatt cgaaaatgag ttga 44

<210> 112
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 112
 aaacccggga tgttcctcgc ccggaattcg aaagaagagt aaaag 45

<210> 113
 <211> 272
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> miR159a precursor template

 <400> 113
 acagttgct tatgtcgat ccataatata tttgacaaga tactttgtt ttcgatagat 60
 cttgatctga cgatggaagt agagctcctt aaagttcaaa catgagttga gcagggtaaa 120
 gaaaagctgc taagctatgg atcccataag ccctaattcct tgtaaagtaa aaaaggattt 180
 ggttatatgg attgcatatc tcaggagctt taacttgcctt ttaatggct tttactcttc 240
 ttggattga agggagctct acatcccgaa tc 272

<210> 114
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> miR159a mature template

 <400> 114
 ttggattga agggagctct a 21

<210> 115
 <211> 21
 <212> DNA
 <213> miRPDS(159a) mature template

 <220>
 <223> oligonucleotide

 <400> 115
 ttggaaata tggatctct t 21

<210> 116
 <211> 222
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> miR169g precursor template

 <400> 116
 aatgatgatt acgatgatga gagtctctag ttgtatcaga gggcttgca tgaaagaata 60

94/23

gagaatgagg ttgagccaag gatgacttgc	cgggttttt taccaatgaa tctaattaac	120
tgattcttgt gtccggcaag ttgaccttgg	ctctgttcc ttctcttctt ttggatgtca	180
gactccaaga tatctatcat catgaatcgt	gatcaaactt tg	222
<210> 117		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> miR169 mature template		
<400> 117		
gagccaagga tgacttgcg g		21
<210> 118		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> miRPDSa(169g) mature template		
<400> 118		
gagtttagtc tgacttggcc a		21
<210> 119		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> miR169 mature template		
<400> 119		
gagccaagga tgacttgcg g		21
<210> 120		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> miRPDSb(169g) mature template		
<400> 120		
gatctcttcc cagtcttcag g		21
<210> 121		
<211> 2470		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> miR169 precursor template		
<400> 121		
aagctttgat cttagctct ttgccaagc ttctttgat ttttctattt ctctaattca		60
tccattgacc atttgggtg atgatattct tcaatttatg ttgttgttta ttgcccattcc		120
acagaccac gtttatttg ttaatcaa atatataaac tgacagttgt gccactagtc		180
acttgccaat taagcattcc aaagctcctt cctttacatt agtataatgt gagactagca		240
caagcttttta agtccagata aaaagccccca tggaaggaa gctttcaaga acgagattta		300
accgtaaaac ccaatttcga tttccgctaa taatttggat ccaaaaatct agacaaaatc		360
tgataaaaatt agacaaagaa atggataaaa ccccaaaacc cataatcgat gttgttcttg		420
tttgcttcaa tatcacttcc tcccttccaa cgagtttagtt agagtgcgt ggcagctgaa		480
ctagatttgg agtaacggga tagattaccc ataaagccccca ataatgatca ttacgtgaga		540
cataacttgc ttagataacc tcattttatg ggcttagatg gggctcttag tgtagtcat		600
aagcttttta ataccatttc tagttatata tcaatcttta gcttggatt ggatcggtt		660

94/24

cctataat	aaaaactttt	actat	ttt	gttagcaatc	ccacttaaca	ttcaat	atgt	720
ttaaaat	agagtttacc	aaaaggaaag	aaaaaaaggt	tggtaatgaa	tttatcta	780		
cggata	cgtat	at	ttt	ctaatgatgg	gatctatcaa	taaata	agaat	840
tttaacgc	ttgttac	cttcttct	tt	tagcaatta	atattaacg	aaagtt	900	
atataa	at	tttccagtt	atataccaaa	ctttagttaa	tattcataag	cttgcc	960	
tttaca	ttttggaa	gcgcacaaa	ttctcatata	tttcttaccc	aaaaataaa	1020		
tttttttt	tttttacttg	tttataatcc	tat	atgaaca	ttgctcatct	tccc	1080	
atggta	ttctattc	at	ttt	atgttaatt	aaatccta	taat	gaaatt	1140
tttga	atcaatc	at	at	ctcc	tcttagatct	at	ttaaatgg	1200
tttc	tttggc	tt	at	tttattt	gatatgt	at	ttatggaa	1260
gatgg	aaccgg	tc	cc	aaattt	tcgatcgg	gctata	acac	1320
tct	tagtag	ct	at	tttgcaca	tgtattact	tttattt	act	1380
agct	ctgt	ca	aa	tttggaaaa	atttatttac	tagtac	ccc	1440
gtgat	gagtc	tcc	aaat	gtat	cccaaaggac	aat	ctgaaat	1500
tattc	ccat	tat	cc	tttgc	tgtggcaat	ttt	ttttaaaa	1560
aaaga	aatctt	tct	aaattt	gt	tttgcata	ttt	tttgcata	1620
caca	agacta	tgat	ccat	tttgc	atcgataaca	cctt	tttgcata	1680
gtac	gatgc	tc	cgat	tttgc	atattattca	cata	aaaattt	1740
ttgata	aatgtc	ag	atctt	tttgc	tttgcata	ttt	tttgcata	1800
gtca	aaaattt	cat	ttt	tttgc	atgcactact	ag	tttgcata	1860
tttatt	attgc	at	at	tttgc	tttgcata	ttt	tttgcata	1920
ttca	atatgc	ct	ata	tttgc	tttgcata	ttt	tttgcata	1980
aagg	tagaga	aa	acat	tttgc	tttgcata	ttt	tttgcata	2040
ggtctt	gc	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2100
acca	atga	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2160
tctctt	tttgc	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2220
gtaattt	cat	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2280
tgaat	gtatc	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2340
tcagg	tttgc	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2400
tcaa	atttca	acat	tttgc	tttgc	tttgcata	ttt	tttgcata	2460
gttt	cgtt	tttgc	tttgc	tttgc	tttgcata	ttt	tttgcata	2470

<210> 122

<211> 268

<212> DNA

<213> Nicotiana benthamiana

<400> 122

atgc	cctaaa	ttggactt	gt	ttctgctt	aactt	gagag	tccaa	ggtag	ttcagctt	60
ctt	tttggag	ct	cg	tttgg	act	gaa	gtc	ggat	tttgc	120
aatt	cgtt	at	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	180
catg	ccac	cc	cc	cc	cc	cc	cc	cc	cc	240
tatc	caag	ca	ca	ca	ca	ca	ca	ca	ca	268

<210> 123

<211> 657

<212> DNA

<213> Nicotiana benthamiana

<400> 123

ggc	actca	tttataa	acc	ctgac	gg	ttc	gtat	gc	tgcattt	ttgctt	60
ca	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	120
gat	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	180
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	240
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	300
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	360
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	420
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	480
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	540
ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	ttt	600

<210> 124

<211> 781

<212> DNA

<213> Nicotiana benthamiana

<400> 124

94/25

ggagaaaagag	aaactttctg	tcttaagagt	aattagcaat	ggcttcctca	gttcttcct	60
cagcagcagt	tgccaccgc	agcaatgttgc	ctcaagctaa	catgggtgc	cctttcacag	120
gtcttaagtc	tgctgcctca	ttccctgttt	caagaaaagca	aaaccttgcac	atcacttcca	180
ttgccagcaa	cggcggaga	gtgcaatgca	tgcaagggtg	gccaccaatt	aacatgaaga	240
agtatgagac	tctctcatac	cttcccgtt	tgagccagga	gcaattgctc	tccgaaattt	300
agtaccttt	aaaaaatgga	tggttccctt	gcttggatt	cgagactgag	aaaggattt	360
tctaccgtga	acaccacaag	tcaccaggat	actatgatgg	cagatactgg	accatgtgga	420
agctacctat	gttcggatgc	actgatgcca	cccaagtgtt	ggctgaggtg	ggagaggcga	480
agaaggaata	cccacaggcc	tgggtccgt	tcattggatt	tgacaacgtg	cgtcaagtgc	540
agtgcacat	tttcatttgc	tccaaggctg	acggctactg	agtttcatat	taggacaact	600
taccctattt	tctgtctta	ggggcagttt	gtttgaaatg	ttacttagct	tctttttttt	660
ccttccata	aaaactgttt	atgttccttc	tttttattcg	gtgtatgtt	tggattccta	720
ccaagttatg	agacctaata	attatgattt	tgtgcttgt	ttgtaaaaaa	aaaaaaaaaa	780
					a	781

<210> 125

<211> 762

<212> DNA

<213> Nicotiana benthamiana

<400> 125

tctttctgtc	ttaagtgtaa	ttaacaatgg	cttcctcagt	tcttcctca	gcagcagttg	60
ccacccgcag	caatgttgc	caagctaaca	tgggtgcacc	tttcaacttgt	cttaagtgcag	120
ctgcctcggt	ccctgtttca	aggaagcaaa	accttgcacat	cacttccatt	gccagcaacg	180
gcgaaagagt	gcaatgcac	caggtgtggc	caccaattaa	caagaagaag	tacgagactc	240
tctcataacct	tcctgatctg	agcgtggagc	aattgcttag	cgaaattttag	taccttgcgt	300
aaaatggatg	ggttccttgc	ttgaaattcg	agactgagcg	cggatttgc	taccgtgaac	360
accacaagtc	accgggatac	tatgacggca	gatactggac	catgtggaa	ttgcctatgt	420
tcggatgcac	tgatgccacc	caagtgttgg	ccgaggtgga	agaggcgaag	aaggcataacc	480
cacaggcctg	gatccgtatt	attggattcg	acaacgtgcg	tcaagtgcag	tgcatcagtt	540
tcattgccta	caagccagaa	ggctactaag	tttcatatta	ggacaactta	cccttattgtc	600
cgactttagg	ggcaatttgc	ttgaaatgtt	acttggcttc	ttttttttt	aattttccca	660
caaaaactgt	ttatgttcc	tactttctat	tcgggtgtatg	ttttgcatt	cctaccaagt	720
tatgagacct	aataactatg	atttggtgct	ttgtttgtaa	at		762

<210> .126

<211> 683

<212> DNA

<213> Nicotiana benthamiana

<400> 126

tagcaatagc	tttaagctta	gaaattattt	tcagaaatgg	cttcctcagt	tatgtcctca	60
gcagctgctg	ttgcgaccgg	cgcctatgc	gctcaagcca	acatgggtgc	acccttcact	120
ggcctcaagt	ccgcctcctc	cttccctgtt	accagggaaac	aaaaccttga	cattacctcc	180
attgcttagca	atgggtggaa	agttcaatgc	atgcaggtgt	ggccaccaat	taacatgaag	240
aagtacgaga	cactctcata	ccttcctgtat	ttgagccagg	agcaatttgc	tagtgaagtt	300
gagtacctt	tgaaaaatgg	atgggttccct	tgcttggaaat	tcgagactga	gcgtggattc	360
gtctaccgtg	aacaccacaa	ctcaccagga	tactacgtat	gcagatactg	gaccatgtgg	420
aagttgccc	tgttcgggtg	cactgatgcc	actcaggtgt	tggctgaggt	cgaggaggca	480
aagaaggctt	acccacaagc	ctgggttaga	atcattggat	tcgacaaacgt	ccgtcaagt	540
caatgcacat	gttttatacg	ctccaaagcca	gaaggctact	aaaatctcca	tttttaaggc	600
aacttatctgt	atgtgttccc	cggagaaact	tttttgggtt	tcctgcttcc	ttatattatt	660
caatgtatgt	ttttgaattc	caa				683

<210> 127

<211> 700

<212> DNA

<213> Nicotiana benthamiana

<400> 127

aatggcttcc	tcaagttatgt	cctcagctgc	cgctgttgcc	accggcgcca	atgctgctca	60
agccagttatg	gttgcaccctt	tcactggcct	caagtccgca	acctccttcc	ctgtttccag	120
aaaacaaaac	cttgacattt	cttccattgc	tagcaacggc	ggaagagttc	aatgcacat	180
ggtgtggcca	ccaatttaca	agaagaagta	cgagacactc	tcataccctc	ccgatttgcgt	240
ccaggagcaa	ttgcttagtgc	aagttgagta	cctgttgaaa	aatggatggg	ttccttgctt	300
ggaattcggag	actgagcgtg	gattcgtcta	ccgtgaacac	cacagctcac	caggatatta	360
tgtatggcaga	tactggacca	tgttggaaat	gcccatgttc	gggtgcactg	atgcccactca	420
ggtgttggct	gaggtcgagg	aggcaaaagaa	ggcttaccca	caagcctggg	ttagaatcat	480

94/26

tggattcgac aatgtccgtc aagtgcata	catcagtttc atcgccata	agccagaagg	540
ctactagaat ctccatttt aaggcaactt	atcgatgtg ttccccggag	aaactgtttt	600
ggttttcct gcttcattat attattcaat	gtatgtttt gaattccat	caaggttatg	660
agaactaata atgacatttta atttgttct	tttctatata		700

<210> 128

<211> 698

<212> DNA

<213> Nicotiana benthamiana

<400> 128

taaataatta attgcaacaa tggcttcctc tttgatttcc ttagctgctg	ccgttgcac	60
cggcgctaat gctgctcaag ccagcatgg tgcacccttc actggcctca	aatctgcttc	120
ctccttcctt gttaccagaa aacaaaacct tgacattaca tccattgcta	gcaatggtgg	180
aagagtccaa tgcattgcagg tttggccacc aattaacatg aagaagtagc	agacactctc	240
atacccttcctt gattttagcc aggagcaatt gcttagtgaa gttgagtagt	ttttgaaaaaa	300
tggatgggtt ccttgcttgg aattcgagac tgagcgttgg	tttgcattacc	360
cagctcacca ggatactacg atggcagata ctggaccatg tggaaagg	ttgtgc ccatgttcgg	420
gtgcactgat gcccactcagg ttgtggctga ggtcgaggag gcaaagaagg	cttaccacaa	480
agcctgggtt agaatcattt gattcgacaa cgtccgtcaa gtgcaatgca	tcagtttat	540
cgcctccaaag ccagaaggct actaaaatct ccattttaa ggcaacttat	cgatgtgtt	600
ccccggagaa actgttttgg tttcctgct tcattatattt attcaatgta	tgttttgaa	660
ttccaatcaa ggttatgaga actaataatg acattaa		698

<210> 129

<211> 727

<212> DNA

<213> Nicotiana benthamiana

<400> 129

gcacgaggct tcctcagttt tttcctcagc tgccgctgtt tccaccggcg	ccaatgctgt	60
tcaagccagc atggtcgcac ctttcaactgg cttcaaggcc gcctccctt	tcccggtttc	120
caggaaacaa aaccttgaca ttacttccat tgcttagaaat ggttggaaagag	tccaatgcat	180
gcaggtgtgg ccccaatta acaagaagaa gtacgagaca ctctcatacc	ttcctgattt	240
gagcgtggag caatttgctt gcgaaattga gtacctttt aaaaatggat	gggttccctt	300
cttggaaattt gagactgagc atggattcgt ctaccgttggaa caccaccat	caccaggata	360
ctacgatggc agatactgga cttatgtggaa gttgcccattt ttcgggtgc	ccgatgccac	420
tcaggtctt gctgaggtag aggaggccaa gaaggcttac ccacaaggct	gggtcagaat	480
cattggattt gacaacgtcc gtcaagtgcata atgcatttgc ttcatgcct	acaagcccga	540
aggctattaa aatctccatt tttaggacag cttaccctat gtattcagg	gaagtttgg	600
tgaattctcc tggagaaact gttttgggtt tcctttgttt taatcttctt	tctattatat	660
tttggattt tactcaagtt tataagaact aataataatc atttgtttcg	ttactaaaaaa	720
aaaaaaaa		727

<210> 130

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 130

ccactttct gcaggtgcaa aaacc		25
----------------------------	--	----

<210> 131

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 131

acatggtaact tcaatatttt tgctttgc		28
---------------------------------	--	----

<210> 132

<211> 28

94/27

<212> DNA		
<213> Artificial Sequence		
<220>		
<223> oligonucleotide		
<400> 132		
gatctttgta aaggccgaca gggttcac		28
<210> 133		
<211> 29		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> oligonucleotide		
<400> 133		
ttcctcagtt ctttcctcag cagcagttg		29
<210> 134		
<211> 24		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> oligonucleotide		
<400> 134		
ctcagttatg tcctcagcag ctgc		24
<210> 135		
<211> 24		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> oligonucleotide		
<400> 135		
tcctcagtttga tgtcctcagc tgcc		24
<210> 136		
<211> 22		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> oligonucleotide		
<400> 136		
tgtgatttcc tcagctgctg cc		22
<210> 137		
<211> 23		
<212> DNA		
<213> Artificial Sequence		
<220>		
<223> oligonucleotide		
<400> 137		
aactcagtag ccgtcaggct tgg		23
<210> 138		
<211> 30		
<212> DNA		
<213> Artificial Sequence		

94/28

<220>
 <223> oligonucleotide

<400> 138
 aatatgaaac ttagtagcct tctggcttgt

30

<210> 139
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 139
 gtttctccgg ggaacacata cga

23

<210> 140
 <211> 27
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 140
 aaacaaactt cccctgaata cataggg

27

<210> 141
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 141
 uuuggauuga agggagcucu a

21

<210> 142
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 142
 uuuggaaaua uggaucucu u

21

<210> 143
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 143
 aagagauccc auauuuccaa a

21

<210> 144
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>

94/29

<223> oligonucleotide

<400> 144

gagccaagga ugacuugccg g

21

<210> 145

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 145

gaguuuaguc ugacuuggcc a

21

<210> 146

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 146

gaucucuuuc cagucuucag g

21

<210> 147

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 147

uggccaaguc agacuaaacu c

21

<210> 148

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 148

ccugaagacu ggaaagagau c

21

<210> 149

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 149

uuucgaauuc cgggcgagga a

21

<210> 150

<211> 21

<212> RNA

<213> Nicotiana benthamiana

<400> 150

uuccuugcua ggaauucgag a

21

94/30

<210> 151
 <211> 273
 <212> DNA
 <213> Artificial

<220>
 <223> miRCPC1(159) precursor template

<400> 151
 acagtttgct tatgtcgat ccataatata tttgacaaga tactttgttt ttcgatagat 60
 cttgatctga cgatggaaga agaggtgagt aatgttggaa catgagttga gcagggtaaa 120
 gaaaagctgc taagctatgg atcccataag ccctaattcct tgttaaagtaa aaaaggattt 180
 ggttatatgg attgcatatc tcaggagctt taacttgccc tttaatggct tttactcttc 240
 ttgcatact actcacctct tcacccggg tca 273

<210> 152
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> miRCPC1(159) mature template

<400> 152
 ttgcatact actcacctct t 21

<210> 153
 <211> 273
 <212> DNA
 <213> Artificial

<220>
 <223> miRCPC3(159) precursor template

<400> 153
 acagtttgct tatgtcgat ccataatata tttgacaaga tactttgttt ttcgatagat 60
 cttgatctga cgatggaagc tcgttggcga caggtgggag catgagttga gcagggtaaa 120
 gaaaagctgc taagctatgg atcccataag ccctaattcct tgttaaagtaa aaaaggattt 180
 ggttatatgg attgcatatc tcaggagctt taacttgccc tttaatggct tttactcttc 240
 ctcccacctg acgccaacga gcatccggg tca 273

<210> 154
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> miRCPC3(159) mature template

<400> 154
 ctcccacctg acgccaacga g 21

<210> 155
 <211> 273
 <212> DNA
 <213> Artificial

<220>
 <223> miRP69(159) precursor template

<400> 155
 acagtttgct tatgtcgat ccataatata tttgacaaga tactttgttt ttcgatagat 60
 cttgatctga cgatggaagc cacaagacaa tcgagacttt catgagttga gcagggtaaa 120
 gaaaagctgc taagctatgg atcccataag ccctaattcct tgttaaagtaa aaaaggattt 180
 ggttatatgg attgcatatc tcaggagctt taacttgccc tttaatggct tttactcttc 240
 aaagtctcga ttgtcttgc gcatccggg tca 273

<210> 156

94/31

<211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> miRP69(159) mature template

<400> 156
 aaagtctcg a ttgtcttgc g

21

<210> 157
 <211> 222
 <212> DNA
 <213> Artificial

<220>
 <223> miRPDS1(169) precursor template

<400> 157
 aatgatgatt acgatgatga gagtctctag ttgtatcaga gggcttgca tggaagaata 60
 gagaatgagg ttgagtttag tctgacttgg ccagttttt taccaatgaa tctaattaac 120
 tgattcttgtt gttggccaag tcagactaaa ctctgtttcc ttctcttctt ttggatgtca 180
 gactccaaga tatctatcat catgaatcgt gatcaaactt tg 222

<210> 158
 <211> 21
 <212> DNA
 <213> Artificial

<220>
 <223> miRPDS1(169) mature template

<400> 158
 gagtttagtc tgacttggcc a

21

<210> 159
 <211> 552
 <212> DNA
 <213> Artificial

<220>
 <223> miRPDS1(169)-CPC3(159) precursor template

<400> 159
 cacctaggaa ttagtattac gatgatgaga gtctcttagtt gtatcagagg gtcttgcatg 60
 gaagaataga gaatgagggtt gagtttagtc tgacttggcc agtttttta ccaatgaatc 120
 taattaactg attcttgtt tggccaagtc agactaaact ctgtttcctt ctcttctttt 180
 ggtatgtcaga ctccaagata tctatcatca tgaatcgtga tcaaacttt aagggtgggc 240
 gactaggaca gtttgcttat gtcggatcca taatatattt gacaagatac tttgtttttc 300
 gatagatctt gatctgacga tggaaagctcg ttggcgacag gtgggagcat gagttgagca 360
 gggtaaagaa aagctctaa gctatggatc ccataagccc taatccttgc aaagtaaaaa 420
 aggatttggt tatatggatt gcatatctca ggagctttaa cttgccttta aatggctttt 480
 actcttcctc ccacctgacg ccaacgagca tcccgggtca aagggtgggc gactagtcta 540
 gactcgagta tt 552

<210> 160
 <211> 21
 <212> RNA
 <213> Arabidopsis thaliana

<400> 160
 uuuggauuga agggagcucu a

21

<210> 161
 <211> 184
 <212> RNA
 <213> Arabidopsis thaliana

94/32

<400> 161
 guagagcucc uuuaaguuca aacaugaguu gagcagggua aagaaaagcu gcuaagcuau 60
 ggaucccaua agcccuuauc cuuguaaagu aaaaaaggau uugguuauau ggauugcaua 120
 ucucaggagc uuuuacuugc ccuuuuaugg cuuuuacucu ucuuuggauu gaagggagcu 180
 cuac 184

<210> 162
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> miRNA

<400> 162
 acuugcucac gcacucgacu g 21

<210> 163
 <211> 261
 <212> DNA
 <213> Artificial

<220>
 <223> miRNA precursor

<400> 163
 cagtttgctt atgtcggatc cataatataat ttgacaagat actttgttt tcgatagatc 60
 ttgatctgac gatggaagca gtcgagtgcg tgagcaagtc atgagttgag caggtaaag 120
 aaaagctgct aagctatgga tcccataagc cctaattcctt gttaaagtaaa aaaggatttg 180
 gttatatgga ttgcataatct caggagctt aacttgcctt ttaatggctt ttactcttca 240
 cttgctcactg cactcgactg c 261

<210> 164
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> miRNA

<400> 164
 aaagucucga uugucuugug g 21

<210> 165
 <211> 261
 <212> DNA
 <213> Artificial

<220>
 <223> miRNA precursor

<400> 165
 cagtttgctt atgtcggatc cataatataat ttgacaagat actttgttt tcgatagatc 60
 ttgatctgac gatggaagcc acaagacaat cgagactttc atgagttgag caggtaaag 120
 aaaagctgct aagctatgga tcccataagc cctaattcctt gttaaagtaaa aaaggatttg 180
 gttatatgga ttgcataatct caggagctt aacttgcctt ttaatggctt ttactcttca 240

94/33

aagtctcgat	tgtcttgtgg	c	261
<210> 166			
<211> 551			
<212> DNA			
<213> Artificial			
<220>			
<223> homo-polymeric pre-miRNA			
<400> 166			
cagtttgctt atgtcggatc cataatatat ttgacaagat actttgttt tcgatagatc			60
ttgatctgac gatggaagcc acaagacaat cgagacttc atgagttgag caggtaaag			120
aaaagctgct aagctatgga tcccataagc cctaattcctt gtaaagtaaa aaaggatttg			180
gttatatgga ttgcataatct caggagctt aacttgcctt ttaatggctt ttactcttca			240
aagtctcgat tgtcttgtgg catcccggtt caaagggtgg gcgacttagga cagttgctt			300
atgtcggatc cataatatat ttgacaagat actttgttt tcgatagatc ttgatctgac			360
gatggaagca gtcgagtgcg tgagcaagtc atgagttgag caggtaaag aaaagctgct			420
aagctatgga tcccataagc cctaattcctt gtaaagtaaa aaaggatttg gttatatgga			480
ttgcataatct caggagctt aacttgcctt ttaatggctt ttactcttca cttgctcacg			540
cactcgactg c			551
<210> 167			
<211> 23			
<212> DNA			
<213> Turnip mosaic virus			
<400> 167			
cgatttaggc ggcagataca gcg			23
<210> 168			
<211> 35			
<212> DNA			
<213> Turnip mosaic virus			
<400> 168			
attctcaatg gtttaatggc ctgggtgcatt gagaa			35
<210> 169			
<211> 26			
<212> DNA			
<213> Turnip mosaic virus			
<400> 169			
ataaaacggaa tgtgggtgat gatgga			26
<210> 170			
<211> 21			
<212> DNA			
<213> Turnip mosaic virus			
<400> 170			
gatcaggtgg aattcccgat c			21
<210> 171			
<211> 32			
<212> DNA			

94/34

<213> Turnip mosaic virus

<400> 171

cacgc当地
32

<210> 172

<211> 68

<212> DNA

<213> Turnip mosaic virus

<400> 172

gctgaagcgt acattgaaaa gcgtaaccaa gaccgaccat acatgccacg atatggtctt

60

cagc当地
68

<210> 173

<211> 80

<212> DNA

<213> Turnip mosaic virus

<400> 173

gaaatgactt ctagaactcc aatacgtgcg agagaagcac acatccagat gaaaggcagca

60

gcactgcgtg gcg当地
80

<210> 174

<211> 26

<212> DNA

<213> Turnip mosaic virus

<400> 174

acaacggtag agaacacgga gaggca

26

The embodiments of the present invention for which an exclusive property or privilege is claimed are defined as follows:

1. A method for down regulating a target sequence of a plant virus or plant viroid in a transgenic plant cell comprising:
 - (a) introducing into a plant cell a nucleic acid construct comprising a promoter functional in the plant cell operably linked to a polynucleotide, wherein the polynucleotide encodes one or more modified miRNA precursors, wherein each modified miRNA precursor comprises a fragment of a plant miRNA primary transcript that is modified in the miRNA sequence and the miRNA complementary sequence, wherein the plant primary transcript is a plant miR159 primary transcript, further wherein each modified miRNA precursor is capable of forming a double-stranded RNA or a hairpin, wherein each modified miRNA is a miRNA modified to be (i) fully complementary to a target sequence, (ii) fully complementary to a target sequence except for GU base pairing or (iii) fully complementary to a target sequence in the first ten nucleotides counting from the 5' end of the miRNA, wherein the target sequence of each modified miRNA is the same or different, and wherein at least one target sequence encodes a gene silencing suppressor of a plant virus or plant viroid and wherein the modified miRNA sequence targeting said gene silencing suppressor consists of (i) the nucleotide sequence of SEQ ID NO:162, (ii) a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO:162, (iii) the nucleotide sequence of SEQ ID NO:164 or (iv) a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO:164; and
 - (b) expressing the nucleic acid construct for a time sufficient to produce each modified miRNA, wherein each modified miRNA binds to its target sequence to form a second double-stranded RNA which is cleaved thereby down regulating the target sequence.
2. The method of claim 1, wherein the modified miRNA is a plant miRNA modified to be fully complementary to the target sequence.

3. The method of claim 1, wherein the modified miRNA is a plant miRNA modified to be fully complementary to the target sequence except for the use of GU base pairing.
4. The method of any one of claims 1 to 3, wherein the plant miRNA is from a plant selected from the group consisting of *Arabidopsis*, rice, and corn.
5. The method of any one of claims 1 to 4, wherein the promoter is a pathogen-inducible promoter.
6. The method of claim 5, wherein the nucleic acid construct encodes two or more modified miRNA precursor sequences.
7. The method of claim 6, wherein the nucleic acid construct is a hetero-polymeric precursor miRNA or a homo-polymeric precursor miRNA.
8. The method of claim 1, wherein the nucleic acid construct is inserted into an intron of a gene or transgene of the cell.
9. The method of any one of claims 1 to 8, wherein the plant cell is from a plant selected from the group consisting of corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.
10. An isolated nucleic acid comprising a promoter functional in the plant cell operably linked to a polynucleotide, wherein the polynucleotide encodes one or more modified miRNA precursors, wherein each modified miRNA precursor comprises a fragment of a plant miRNA primary transcript that is modified in the miRNA sequence and the miRNA complementary sequence, wherein the plant primary transcript is a plant miR159 primary transcript, further wherein each modified miRNA precursor is capable of forming a double-stranded RNA or a hairpin, wherein each modified miRNA is a miRNA modified to be (i) fully complementary to a target, (ii) fully complementary to a target sequence except for GU base pairing or (iii) fully complementary to a target sequence in the first ten nucleotides counting from the 5' end of the miRNA, wherein the target sequence of each modified miRNA is the

same or different, and wherein at least one target sequence encodes a gene silencing suppressor of a plant virus or plant viroid and wherein the modified miRNA sequence targeting said gene silencing suppressor consists of (i) the nucleotide sequence of SEQ ID NO:162, (ii) a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO:162, (iii) the nucleotide sequence of SEQ ID NO:164 or (iv) a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO:164.

11. The isolated nucleic acid of claim 10, wherein the modified miRNA is a plant miRNA modified to be fully complementary to the target sequence.

12. The isolated nucleic acid of claim 10, wherein the modified miRNA is a plant miRNA modified to be fully complementary to the target sequence except for the use of GU base pairing.

13. The isolated nucleic acid of any one of claims 10 to 12, wherein the plant miRNA is from a plant selected from the group consisting of *Arabidopsis*, rice, and corn.

14. The isolated nucleic acid of claim 13, wherein the promoter is a pathogen-inducible promoter.

15. The isolated nucleic acid of claim 14, wherein the nucleic acid construct encodes two or more modified miRNA precursor sequences.

16. The isolated nucleic acid of claim 15, wherein the nucleic acid construct is a heteropolymeric precursor miRNA or a homo-polymeric precursor miRNA.

17. A plant cell comprising the isolated nucleic acid of any one of claims 10 to 16.

18. The plant cell of claim 17, wherein the plant is selected from the group consisting of corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.

19. The plant cell of claim 17 or 18, wherein the isolated nucleic acid is inserted in an intron of a gene or transgene of the cell.

20. A method of obtaining a disease resistant transgenic plant by down regulating a target sequence of a plant virus or plant viroid in a plant comprising:

- (a) transforming a plant cell susceptible to infection by the plant virus or plant viroid with a nucleic acid construct comprising a promoter functional in a plant cell operably linked to a polynucleotide, wherein the polynucleotide encodes one or more modified miRNA precursors, wherein each modified miRNA precursor comprises a fragment of a plant miRNA primary transcript that is modified in the miRNA sequence and the miRNA complementary sequence, wherein the plant primary transcript is a plant miR159 primary transcript, further wherein each modified miRNA precursor is capable of forming a first double-stranded RNA or a hairpin, wherein each modified miRNA is a miRNA modified to be (i) fully complementary to a target sequence, (ii) fully complementary to a target sequence except for GU base pairing or (iii) fully complementary to a target sequence in the first ten nucleotides counting from the 5' end of the miRNA, wherein the target sequence of each modified miRNA is the same or different, and wherein at least one target sequence encodes a gene silencing suppressor of a plant virus or plant viroid and wherein the modified miRNA sequence targeting said gene silencing suppressor consists of (i) the nucleotide sequence of SEQ ID NO:162, (ii) a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO:162, (iii) the nucleotide sequence of SEQ ID NO:164 or (iv) a nucleotide sequence that is at least 90% identical to the nucleotide sequence of SEQ ID NO:164;
- (b) obtaining a transgenic plant from the transformed plant cell of (a);
- (c) expressing the nucleic acid construct in the transgenic plant of (b) for a time sufficient to produce each modified miRNA, wherein each modified miRNA binds to its target sequence to form a second double-stranded RNA which is cleaved thereby down regulating the target sequence; and
- (d) selecting a transgenic plant of (c) that is resistant to a plant virus or plant viroid, wherein the plant virus or plant viroid comprises the at least one target sequence

that encodes the gene silencing suppressor and wherein the disease resistant transgenic plant shows no symptoms of infection.

21. The method of claim 20, wherein the modified miRNA is modified to be fully complementary to the target sequence.

22. The method of claim 20, wherein the modified miRNA is modified to be fully complementary to the target sequence except for the use of GU base pairing.

23. The method of any one of claims 20 to 22, wherein the plant miRNA is from a plant selected from the group consisting of *Arabidopsis*, rice, and corn.

24. The method of any one of claims 20 to 23, wherein the promoter is a pathogen-inducible promoter.

25. The method of any one of claims 20 to 24, wherein the nucleic acid construct encodes two or more modified miRNA precursor sequences.

26. The method of claim 25, wherein the nucleic acid construct is a heteropolymeric precursor miRNA or a homo-polymeric precursor miRNA.

27. The method of any one of claims 20 to 26, wherein the isolated nucleic acid is inserted into an intron of a gene or transgene of the transgenic plant.

28. The method of any one of claims 20 to 27, wherein the plant is selected from the group consisting of corn, wheat, rice, barley, oats, sorghum, millet, sunflower, safflower, cotton, soy, canola, alfalfa, *Arabidopsis*, and tobacco.

A
A U
A U
U A
C G
C G
C G
A U
U
A U
A U
A U
U G
A
G A
U U
U A
A U
A G
A U
G A
G U
U A
A U
C G
A A
C G
U A
U A
A U
G C
A U
A U
U G
U A
A U
C G
C A
A U
C G
G C
A U
C G
G C
C A
G U
G C
A A
U A
G C
U A
U A
U U
G C
U G
U A
G C
C G
U G
G C

Figure 1


Figure 2


Figure 3


Figure 4



Figure 5

Figure 6

A

Col EAT



B

Col EAT





Figure 7

A



B





Figure 8


Figure 9



Figure 10**a****b**

FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 13A

miR169	GAGCCAAGGA <u>U</u> GACUUGCCGG
miR-PDS a^{169g}	GAG <u>UUUAGUC</u> <u>U</u> GACUUGGCC <u>A</u>
miR-PDS b^{169g}	GA <u>UCU</u> UUCC <u>AGUCU</u> UCAGG




FIG. 13B**FIG. 13C****FIG. 13D****FIG. 13E**

Fig. 14 A




FIG. 14B




FIG. 14C






FIG. 15A**FIG. 15B**

FIG. 16A

miR159a	5' UUUGGAUUGAAGGGAGCUCUA 3'
miR- <i>PDS</i> ^{159a}	5' UUUGG <u>AAAUA</u> <u>UGGGAUCUCUU</u> 3'
miR- <i>rbcS</i> ^{159a-A}	5' UU <u>C</u> GAA <u>UCCGGGCGAGGA</u> 3' *** * * ***

FIG. 16B

miR169g	5' GAGCCAAGGAUGACUUGCCGG 3'
miR- <i>PDSa</i> ^{169g}	5' GAG <u>UUUAG</u> <u>UCUGACUUGGCCA</u> 3'
miR- <i>PDSb</i> ^{169g}	5' GA <u>UCU</u> <u>UCCAGUCUUCAGG</u> 3' ** * * * *




Figure 17




Figure 18




Figure 19




Figure 20




FIG. 21A




FIG. 21B




FIG. 21C




FIG. 21D




FIG. 21E




Figure 22

ASmiRPDS1¹⁶⁹ASmiRCPC3¹⁵⁹

1 2 3

1 2 3

FIG. 23A

FIG. 23B




Figure 24




Figure 25

35s::pre-miRP69 ¹⁵⁹	+	+	-	-	-	-	-	+	+
XVE::pre-miRP69 ¹⁵⁹	-	-	+	+	+	+	-	-	-
35s::P69	-	-	-	-	-	-	+	+	+
β-estradiol	-	-	-	+	-	+	-	-	-
miRP69 ¹⁵⁹	-	+	+	+	+	+	+	+	+

Figure 26




Figure 27




Figure 28

TuMV (14dpi)

 $miR-HC-pro^{159}$ $miR-P69^{159}$ col-0

Mock


 $miR-HC-Pro^{159}$ $miR-P69^{159}$ col-0

Figure 29




A**B**

Figure 30



Expt. 1




Figure 32

Expt. 2



A**B**

Figure 33




Figure 34




Figure 35




Figure 36




Figure 37




Figure 38




Figure 39